<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1405-9940</journal-id>
<journal-title><![CDATA[Archivos de cardiología de México]]></journal-title>
<abbrev-journal-title><![CDATA[Arch. Cardiol. Méx.]]></abbrev-journal-title>
<issn>1405-9940</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Cardiología Ignacio Chávez]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1405-99402024000800001</article-id>
<article-id pub-id-type="doi">10.24875/acm.m25000098</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Guías mexicanas 2024 para el diagnóstico y tratamiento de la miocardiopatía hipertrófica]]></article-title>
<article-title xml:lang="en"><![CDATA[Mexican guidelines 2024 for the diagnosis and treatment of hypertrophic cardiomyopathy]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Llamas-Esperón]]></surname>
<given-names><![CDATA[Guillermo A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Berrios-Bárcenas]]></surname>
<given-names><![CDATA[Enrique A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cossío-Aranda]]></surname>
<given-names><![CDATA[Jorge E.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Guerra-López]]></surname>
<given-names><![CDATA[Arturo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Magaña-Serrano]]></surname>
<given-names><![CDATA[José A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Iturralde-Torres]]></surname>
<given-names><![CDATA[Pedro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lara-Vargas]]></surname>
<given-names><![CDATA[Jorge A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Meave-González]]></surname>
<given-names><![CDATA[Aloha]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alexanderson-Rosas]]></surname>
<given-names><![CDATA[Erick]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ilarraza-Lomelí]]></surname>
<given-names><![CDATA[Hermes]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Salazar-Mendiguchía]]></surname>
<given-names><![CDATA[Joel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García-Saldivia]]></surname>
<given-names><![CDATA[Marianna]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Barragán-García]]></surname>
<given-names><![CDATA[Rodolfo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Márquez-Murillo]]></surname>
<given-names><![CDATA[Manlio F.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sanchez]]></surname>
<given-names><![CDATA[Eduardo A. Arias]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ortiz-Ávalos]]></surname>
<given-names><![CDATA[Martín]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Buendía-Hernández]]></surname>
<given-names><![CDATA[Alfonso]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Molina-Fernández]]></surname>
<given-names><![CDATA[Luis G.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez-Diez]]></surname>
<given-names><![CDATA[Gerardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Aranda-Frausto]]></surname>
<given-names><![CDATA[Alberto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gaspar-Hernández]]></surname>
<given-names><![CDATA[Jorge]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Eid-Lidt]]></surname>
<given-names><![CDATA[Guering]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Virgen-Carrillo]]></surname>
<given-names><![CDATA[Luis R.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vásquez-Ortiz]]></surname>
<given-names><![CDATA[Zuilma Y.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ruiz-Esparza]]></surname>
<given-names><![CDATA[María E.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García-Cruz]]></surname>
<given-names><![CDATA[Edgar]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ávila-Vanzzini]]></surname>
<given-names><![CDATA[Nydia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vallejo-Venegas]]></surname>
<given-names><![CDATA[Enrique P.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vacío-Olguín]]></surname>
<given-names><![CDATA[Martha E.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Llamas-Delgado]]></surname>
<given-names><![CDATA[Guillermo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González-Hermosillo]]></surname>
<given-names><![CDATA[Jesús A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Marmolejo-Hernández]]></surname>
<given-names><![CDATA[Isadora]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sandoval-Rodríguez]]></surname>
<given-names><![CDATA[Eufracino]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Salgado-Loza]]></surname>
<given-names><![CDATA[Juan L.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Moreno-Salgado]]></surname>
<given-names><![CDATA[Rodrigo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Chávez-Mendoza]]></surname>
<given-names><![CDATA[Adolfo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez-Sánchez]]></surname>
<given-names><![CDATA[Carlos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ojeda-Delgado]]></surname>
<given-names><![CDATA[José L.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Laínez-Zelaya]]></surname>
<given-names><![CDATA[José S.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González-Romero]]></surname>
<given-names><![CDATA[Sergio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Luna-Calvo]]></surname>
<given-names><![CDATA[Miguel A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gaxiola-López]]></surname>
<given-names><![CDATA[Efraín]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mariona-Montero]]></surname>
<given-names><![CDATA[Vitelio A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Jerjes-Sánchez Díaz]]></surname>
<given-names><![CDATA[Carlos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Enciso-Muñoz]]></surname>
<given-names><![CDATA[José M.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pereira-López]]></surname>
<given-names><![CDATA[Gabriela I.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Patrón-Chi]]></surname>
<given-names><![CDATA[Sergio Alfonso]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Koretzky]]></surname>
<given-names><![CDATA[Solange G.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ramírez-Moreno]]></surname>
<given-names><![CDATA[Montserrat]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Cardiológica Aguascalientes Hospital Cardiológica Aguascalientes ]]></institution>
<addr-line><![CDATA[Aguascalientes ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Nacional de Cardiología Ignacio Chávez Instituto Nacional de Cardiología Ignacio Chávez ]]></institution>
<addr-line><![CDATA[ Ciudad de México]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Asociación Nacional de Cardiólogos de México Asociación Nacional de Cardiólogos de México ]]></institution>
<addr-line><![CDATA[ Ciudad de México]]></addr-line>
<country>México</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE) Centro Médico Nacional 20 de Noviembre ]]></institution>
<addr-line><![CDATA[ Ciudad de México]]></addr-line>
<country>México</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,L'Hospitalet de Llobregat Hospital Universitario de Bellvitge ]]></institution>
<addr-line><![CDATA[Barcelona ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af6">
<institution><![CDATA[,Hospital Medica Sur Hospital Medica Sur ]]></institution>
<addr-line><![CDATA[ Ciudad de México]]></addr-line>
<country>México</country>
</aff>
<aff id="Af7">
<institution><![CDATA[,Hospital General de México Dr. Eduardo Liceaga Hospital General de México Dr. Eduardo Liceaga ]]></institution>
<addr-line><![CDATA[ Ciudad de México]]></addr-line>
<country>México</country>
</aff>
<aff id="Af8">
<institution><![CDATA[,Hospital México Americano Virgen Cardiovascular Research ]]></institution>
<addr-line><![CDATA[Guadalajara Jalisco]]></addr-line>
<country>México</country>
</aff>
<aff id="Af9">
<institution><![CDATA[,Instituto Nacional de Nutrición Salvador Zubirán Instituto Nacional de Nutrición Salvador Zubirán ]]></institution>
<addr-line><![CDATA[ Ciudad de México]]></addr-line>
<country>México</country>
</aff>
<aff id="A10">
<institution><![CDATA[,Centro Médico ABC Centro Médico ABC ]]></institution>
<addr-line><![CDATA[ Ciudad de México]]></addr-line>
<country>México</country>
</aff>
<aff id="A11">
<institution><![CDATA[,Colegio de Medicina Interna de México Colegio de Medicina Interna de México ]]></institution>
<addr-line><![CDATA[ Ciudad de México]]></addr-line>
<country>México</country>
</aff>
<aff id="A12">
<institution><![CDATA[,Hospital Infantil de México Federico Gómez Hospital Infantil de México Federico Gómez ]]></institution>
<addr-line><![CDATA[ Ciudad de México]]></addr-line>
<country>México</country>
</aff>
<aff id="A13">
<institution><![CDATA[,Instituto Mexicano del Seguro Social (IMSS) Hospital de Cardiología Centro Médico Nacional Siglo XXI ]]></institution>
<addr-line><![CDATA[ Ciudad de México]]></addr-line>
<country>México</country>
</aff>
<aff id="A14">
<institution><![CDATA[,ISSSTE Hospital Regional de Alta Especialidad Centenario de la Revolución Mexicana ]]></institution>
<addr-line><![CDATA[ Ciudad de México]]></addr-line>
<country>México</country>
</aff>
<aff id="A15">
<institution><![CDATA[,Cardiológica Durango Cardiológica Durango ]]></institution>
<addr-line><![CDATA[Durango ]]></addr-line>
<country>México</country>
</aff>
<aff id="A16">
<institution><![CDATA[,Sociedad Mexicana de Cardiología Sociedad Mexicana de Cardiología ]]></institution>
<addr-line><![CDATA[Durango ]]></addr-line>
<country>México</country>
</aff>
<aff id="A17">
<institution><![CDATA[,IMSS Centro Médico Nacional de Occidente Hospital de Pediatría]]></institution>
<addr-line><![CDATA[Guadalajara Jal]]></addr-line>
<country>México</country>
</aff>
<aff id="A18">
<institution><![CDATA[,Tecnológico de Monterrey Escuela de Medicina y Ciencias de la Salud ]]></institution>
<addr-line><![CDATA[Monterrey NL ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<volume>94</volume>
<fpage>1</fpage>
<lpage>75</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1405-99402024000800001&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1405-99402024000800001&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1405-99402024000800001&amp;lng=en&amp;nrm=iso"></self-uri></article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Hellawell]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Lucove]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Occurrence of clinically diagnosed hypertrophic cardiomyopathy in the United States]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2016</year>
<volume>117</volume>
<page-range>1651-4</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ommen]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Mital]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Burke]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy:a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines]]></article-title>
<source><![CDATA[JACC]]></source>
<year>2020</year>
<volume>76</volume>
<page-range>e240</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arbelo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Protonotarios]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gimeno]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiomyopathies]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2023</year>
<volume>44</volume>
<page-range>3503-626</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Semsarian]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ingles]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New perspectives on the prevalence of hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2015</year>
<volume>65</volume>
<page-range>1249-54</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kampmann]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Wiethoff]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Wenzel]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Normal values of M mode echocardiographic measurements of more than 2000 healthy infants and children in central Europe]]></article-title>
<source><![CDATA[Heart]]></source>
<year>2000</year>
<volume>83</volume>
<page-range>667-72</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ho]]></surname>
<given-names><![CDATA[CY]]></given-names>
</name>
<name>
<surname><![CDATA[Day]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Ashley]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Genotype and lifetime burden of disease in hypertrophic cardiomyopathy:insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRE)]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2018</year>
<volume>138</volume>
<page-range>1387-98</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marian]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Braunwald]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertrophic cardiomyopathy:genetics, pathogenesis, clinical manifestation, diagnosis, and therapy]]></article-title>
<source><![CDATA[Circ Res]]></source>
<year>2017</year>
<volume>121</volume>
<page-range>749-70</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García-Giustiniani]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Arad]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ortiz-Genga]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phenotype and prognostic correlations of the converter region mutations affecting the ? myosin heavy chain]]></article-title>
<source><![CDATA[Heart]]></source>
<year>2015</year>
<volume>101</volume>
<page-range>1047-53</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maskatia]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertrophic cardiomyopathy:infants, children, and adolescents]]></article-title>
<source><![CDATA[Congenit Heart Dis]]></source>
<year>2012</year>
<volume>7</volume>
<page-range>84-92</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Epstein]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertrophic cardiomyopathy:a discussion of nomenclature]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>1979</year>
<volume>43</volume>
<page-range>1242-4</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Effat]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Goodwin]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Oakley]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Steiner]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertrophic obstructive cardiomyopathy]]></article-title>
<source><![CDATA[Br Heart J]]></source>
<year>1964</year>
<volume>26</volume>
<page-range>16-32</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Olivotto]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Zenovich]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2006</year>
<volume>114</volume>
<page-range>2232-9</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Olivotto]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Betocchi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2003</year>
<volume>348</volume>
<page-range>295-303</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Olivotto]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Cecchi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Poggesi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Yacoub]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patterns of disease progression in hypertrophic cardiomyopathy:an individualized approach to clinical staging]]></article-title>
<source><![CDATA[Circ Heart Fail]]></source>
<year>2012</year>
<volume>5</volume>
<page-range>535-46</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gottdiener]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Epstein]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. A wide angle, two dimensional echocardiographic study of 125 patients]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>1981</year>
<volume>48</volume>
<page-range>418-28</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Finley]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bos]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2008</year>
<volume>118</volume>
<page-range>1541-9</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lamas-Esperon]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[LLamas-Delgado]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Miocardiopatía hipertrófica. Propuesta de una nueva clasificación]]></article-title>
<source><![CDATA[Arch Cardiol Mex]]></source>
<year>2022</year>
<volume>92</volume>
<page-range>377-89</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kelly]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Semsarian]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multiple mutations in genetic cardiovascular disease:a marker of disease severity]]></article-title>
<source><![CDATA[Circ Cardiovasc Genet]]></source>
<year>2009</year>
<volume>2</volume>
<page-range>182-90</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Spirito]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2006</year>
<volume>114</volume>
<page-range>216-25</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Spirito]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Implications of left ventricular remodeling in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>1998</year>
<volume>81</volume>
<page-range>1339-44</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ho]]></surname>
<given-names><![CDATA[CY]]></given-names>
</name>
<name>
<surname><![CDATA[Mealiffe]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Bach]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[JACC]]></source>
<year>2020</year>
<volume>75</volume>
<page-range>2649-60</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garcia-Canadilla]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Cook]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Mohun]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Myoarchitectural disarray of hypertrophic cardiomyopathy begins pre birth]]></article-title>
<source><![CDATA[J Anat]]></source>
<year>2019</year>
<volume>235</volume>
<page-range>962-76</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Green]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Wakimoto]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice]]></article-title>
<source><![CDATA[Science]]></source>
<year>2016</year>
<volume>351</volume>
<page-range>617-21</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Dhillon]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Popovic]]></surname>
<given-names><![CDATA[ZB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy patients without severe septal hypertrophy:implications of mitral valve and papillary muscle abnormalities assessed using cardiac magnetic resonance and echocardiography]]></article-title>
<source><![CDATA[Rev Circ Cardiovasc Imaging]]></source>
<year>2015</year>
<volume>8</volume>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Harrigan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance]]></article-title>
<source><![CDATA[JACCC]]></source>
<year>2009</year>
<volume>54</volume>
<page-range>220-8</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kwon]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
<name>
<surname><![CDATA[Setser]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Thamilarasan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Abnormal papillary muscle morphology is independently associated with increased left ventricular outflow tract obstruction in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Heart]]></source>
<year>2008</year>
<volume>94</volume>
<page-range>1295-301</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sherrid]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Balaram]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Axel]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Swistel]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The mitral valve in obstructive hypertrophic cardiomyopathy:a test in context]]></article-title>
<source><![CDATA[JACC]]></source>
<year>2016</year>
<volume>67</volume>
<page-range>1846-58</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Klues]]></surname>
<given-names><![CDATA[HG]]></given-names>
</name>
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[WC]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Morphological determinants of echocardiographic patterns of mitral valve systolic anterior motion in obstructive hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1993</year>
<volume>87</volume>
<page-range>1570-9</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hopmeyer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lefebvre]]></surname>
<given-names><![CDATA[XP]]></given-names>
</name>
<name>
<surname><![CDATA[Schwammenthal]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Yoganathan]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Levine]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Importance of leaflet elongation in causing systolic anterior motion of the mitral valve]]></article-title>
<source><![CDATA[J Heart Valve Dis]]></source>
<year>1997</year>
<volume>6</volume>
<page-range>149-59</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Criley]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Siegel]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Has “obstruction”hindered our understanding of hypertrophic cardiomyopathy?]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1985</year>
<volume>72</volume>
<page-range>1148-5</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Östman-Smith]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Wettrell]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pathophysiology of hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2000</year>
<volume>11</volume>
<page-range>355</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Frenneaux]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Steeds]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Echocardiography in hypertrophic cardiomyopathy:diagnosis, prognosis, and role in management]]></article-title>
<source><![CDATA[Eur J Echocardiogr]]></source>
<year>2009</year>
<volume>10</volume>
<page-range>iii9-14</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dass]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cochlin]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Suttie]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Exacerbation of cardiac energetic impairment during exercise in hypertrophic cardiomyopathy:a potential mechanism for diastolic dysfunction]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2015</year>
<volume>36</volume>
<page-range>1547-54</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Varma]]></surname>
<given-names><![CDATA[PK]]></given-names>
</name>
<name>
<surname><![CDATA[Neema]]></surname>
<given-names><![CDATA[PK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertrophic cardiomyopathy:part 1 —introduction, pathology and pathophysiology]]></article-title>
<source><![CDATA[Ann Card Anaesth]]></source>
<year>2014</year>
<volume>17</volume>
<page-range>118-24</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Spirito]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Green]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Wesley]]></surname>
<given-names><![CDATA[YE]]></given-names>
</name>
<name>
<surname><![CDATA[Bonow]]></surname>
<given-names><![CDATA[RO]]></given-names>
</name>
<name>
<surname><![CDATA[Arce]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Noninvasive assessment of left ventricular diastolic function by pulsed Doppler echocardiography in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[JACC]]></source>
<year>1987</year>
<volume>10</volume>
<page-range>733-42</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Menon]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Eidem]]></surname>
<given-names><![CDATA[BW]]></given-names>
</name>
<name>
<surname><![CDATA[Dearani]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Ommen]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Ackerman]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diastolic dysfunction and its histopathological correlation in obstructive hypertrophic cardiomyopathy in children and adolescents]]></article-title>
<source><![CDATA[J Am Soc Echocardiogr]]></source>
<year>2009</year>
<volume>22</volume>
<page-range>1327-34</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ho]]></surname>
<given-names><![CDATA[CY]]></given-names>
</name>
<name>
<surname><![CDATA[Sweitzer]]></surname>
<given-names><![CDATA[NK]]></given-names>
</name>
<name>
<surname><![CDATA[McDonough]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2002</year>
<volume>105</volume>
<page-range>2992-7</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Michels]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Soliman]]></surname>
<given-names><![CDATA[OI]]></given-names>
</name>
<name>
<surname><![CDATA[Kofflard]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diastolic abnormalities as the first feature of hypertrophic cardiomyopathy in Dutch myosin-binding protein C founder mutations]]></article-title>
<source><![CDATA[JACC Cardiovasc Imaging]]></source>
<year>2009</year>
<volume>2</volume>
<page-range>58-64</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diastolic dysfunction of hypertrophic cardiomyopathy genotype-positive subjects without hypertrophy is detected by tissue Doppler imaging:a systematic review and meta-analysis]]></article-title>
<source><![CDATA[J Ultrasound Med]]></source>
<year>2017</year>
<volume>36</volume>
<page-range>2093-103</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sha]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Anastasakis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gramiak]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ultrasound localization of left ventricular outflow obstruction in hypertrophic obstructive cardiomyopathy]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1969</year>
<volume>40</volume>
<page-range>3-11</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Harding]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Spirito]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[WC]]></given-names>
</name>
<name>
<surname><![CDATA[Waller]]></surname>
<given-names><![CDATA[BF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systolic anterior motion of the posterior mitral leaflets:a previously unrecognized cause of dynamic subaortic obstruction in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1983</year>
<volume>68</volume>
<page-range>282-93</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Albert]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Patrick]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The mitral valve in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[J Cardiovasc Trans Res]]></source>
<year>2011</year>
<volume>4</volume>
<page-range>757-66</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Olivotto]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Harrigan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2011</year>
<volume>124</volume>
<page-range>40-7</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Levine]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[King]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An integrated mechanism for systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy based on echocardiographic observations]]></article-title>
<source><![CDATA[Am Heart J]]></source>
<year>1987</year>
<volume>113</volume>
<page-range>633-44</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Groarke]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Galazka]]></surname>
<given-names><![CDATA[PZ]]></given-names>
</name>
<name>
<surname><![CDATA[Cirino]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intrinsic mitral valve alterations in hypertrophic cardiomyopathy sarcomere mutation carriers]]></article-title>
<source><![CDATA[Eur Heart J Cardiovasc Imaging]]></source>
<year>2018</year>
<volume>19</volume>
<page-range>1109-16</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hang]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Schaff]]></surname>
<given-names><![CDATA[HV]]></given-names>
</name>
<name>
<surname><![CDATA[Nishimura]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Accuracy of jet direction on Doppler echocardiography in identifying the etiology of mitral regurgitation in obstructive hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[J Am Soc Echocardiogr]]></source>
<year>2019</year>
<volume>32</volume>
<page-range>333-40</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hong]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Schaff]]></surname>
<given-names><![CDATA[HV]]></given-names>
</name>
<name>
<surname><![CDATA[Nishimura]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mitral regurgitation in patients with hypertrophic obstructive cardiomyopathy:implications for concomitant valve procedures]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2016</year>
<volume>68</volume>
<page-range>1497-504</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Varnava]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Elliott]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[McKenna]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Davies]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertrophic cardiomyopathy:the interrelation of disarray, fibrosis, and small vessel disease]]></article-title>
<source><![CDATA[Heart]]></source>
<year>2000</year>
<volume>84</volume>
<page-range>476-82</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Olivotto]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The case for myocardial ischemia in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[JACC]]></source>
<year>2009</year>
<volume>54</volume>
<page-range>866-75</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cecchi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Olivotto]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Gistri]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2003</year>
<volume>349</volume>
<page-range>1027-35</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Olivotto]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Cecchi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Gistri]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[JACC]]></source>
<year>2006</year>
<volume>47</volume>
<page-range>1043-8</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Camici]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
<name>
<surname><![CDATA[Olivotto]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Rimoldi]]></surname>
<given-names><![CDATA[OE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The coronary circulation and blood flow in left ventricular hypertrophy]]></article-title>
<source><![CDATA[J Mol Cell Cardiol]]></source>
<year>2012</year>
<volume>52</volume>
<page-range>857-64</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Raphael]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Cooper]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Parker]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mechanisms of myocardial ischemia in hypertrophic cardiomyopathy insights from wave intensity analysis and magnetic resonance]]></article-title>
<source><![CDATA[JACC]]></source>
<year>2016</year>
<volume>68</volume>
<page-range>1651-60</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Navarro-López]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Soler]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Magriña]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systolic compression of coronary artery in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Int J Cardiol]]></source>
<year>1986</year>
<volume>12</volume>
<page-range>309-20</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yetman]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[McCrindle]]></surname>
<given-names><![CDATA[BW]]></given-names>
</name>
<name>
<surname><![CDATA[MacDonald]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Freedom]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Gow]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Myocardial bridging in children with hypertrophic cardiomyopathy —a risk factor for sudden death]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1998</year>
<volume>339</volume>
<page-range>1201-9</page-range></nlm-citation>
</ref>
<ref id="B56">
<label>56</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sorajja]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Ommen]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Nishimura]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Gersh]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Tajik]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Holmes]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Myocardial bridging in adult patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[JACC]]></source>
<year>2003</year>
<volume>42</volume>
<page-range>889-94</page-range></nlm-citation>
</ref>
<ref id="B57">
<label>57</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kitazume]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kramer]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Krauthamer]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[El Tobgi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Proudfit]]></surname>
<given-names><![CDATA[WL]]></given-names>
</name>
<name>
<surname><![CDATA[Sones]]></surname>
<given-names><![CDATA[FM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Myocardial bridges in obstructive hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Am Heart J]]></source>
<year>1983</year>
<volume>106</volume>
<page-range>131-5</page-range></nlm-citation>
</ref>
<ref id="B58">
<label>58</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mohiddin]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Begley]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Shih]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Fananapazir]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Myocardial bridging does not predict sudden death in children with hypertrophic cardiomyopathy but is associated with more severe cardiac disease]]></article-title>
<source><![CDATA[JACC]]></source>
<year>2000</year>
<volume>36</volume>
<page-range>2270-8</page-range></nlm-citation>
</ref>
<ref id="B59">
<label>59</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Llamas-Esperón]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cossio-Aranda]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Alexánderson-Rosas]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Miocardiopatía hipertrófica]]></article-title>
<source><![CDATA[Cómo tratarla y entenderla mejor]]></source>
<year>2021</year>
<publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[Planeación y desarrollo editorial SA de CV]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B60">
<label>60</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Binder]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Attenhofer Jost]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Klarich]]></surname>
<given-names><![CDATA[KW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Apical hypertrophic cardiomyopathy:prevalence and correlates of apical outpouching]]></article-title>
<source><![CDATA[J Am Soc Echocardiogr]]></source>
<year>2011</year>
<volume>24</volume>
<page-range>775-81</page-range></nlm-citation>
</ref>
<ref id="B61">
<label>61</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rowin]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Haas]]></surname>
<given-names><![CDATA[TS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertrophic cardiomyopathy with left ventricular apical aneurysm:implications for risk stratification and management]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2017</year>
<volume>69</volume>
<page-range>761-73</page-range></nlm-citation>
</ref>
<ref id="B62">
<label>62</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Rowin]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertrophic cardiomyopathy with left ventricular apical aneurysm:the newest high-risk phenotype]]></article-title>
<source><![CDATA[Eur Heart J Cardiovasc Imaging]]></source>
<year>2020</year>
<volume>21</volume>
<page-range>1351-2</page-range></nlm-citation>
</ref>
<ref id="B63">
<label>63</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Olivotto]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Montereggi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>1999</year>
<volume>33</volume>
<page-range>2044-51</page-range></nlm-citation>
</ref>
<ref id="B64">
<label>64</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Critoph]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Finlay]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Heart rate recovery in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2014</year>
<volume>113</volume>
<page-range>1011-7</page-range></nlm-citation>
</ref>
<ref id="B65">
<label>65</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Melacini]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Basso]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Angelini]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2010</year>
<volume>17</volume>
<page-range>2111-23</page-range></nlm-citation>
</ref>
<ref id="B66">
<label>66</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kubo]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Gimeno]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Bahl]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype]]></article-title>
<source><![CDATA[JACC]]></source>
<year>2007</year>
<volume>49</volume>
<page-range>2419-26</page-range></nlm-citation>
</ref>
<ref id="B67">
<label>67</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Choe]]></surname>
<given-names><![CDATA[YH]]></given-names>
</name>
<name>
<surname><![CDATA[Ota]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CMR assessment and clinical outcomes of hypertrophic cardiomyopathy with or without ventricular remodeling in the end-stage phase]]></article-title>
<source><![CDATA[Int J Cardiovasc Imaging]]></source>
<year>2018</year>
<volume>34</volume>
<page-range>597-605</page-range></nlm-citation>
</ref>
<ref id="B68">
<label>68</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guttmann]]></surname>
<given-names><![CDATA[OP]]></given-names>
</name>
<name>
<surname><![CDATA[Rahman]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[O'Mahony]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Anastasakis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Elliott]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy:systematic review]]></article-title>
<source><![CDATA[Heart]]></source>
<year>2014</year>
<volume>100</volume>
<page-range>465-72</page-range></nlm-citation>
</ref>
<ref id="B69">
<label>69</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sedaghat-Hamedani]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Kayvanpour]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Tugrul]]></surname>
<given-names><![CDATA[OF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy:a meta-analysis on 7675 individuals]]></article-title>
<source><![CDATA[Clin Res Cardiol]]></source>
<year>2018</year>
<volume>107</volume>
<page-range>30-41</page-range></nlm-citation>
</ref>
<ref id="B70">
<label>70</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mazzarotto]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Olivotto]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Boschi]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Contemporary insights into the genetics of hypertrophic cardiomyopathy:toward a new era in clinical testing?]]></article-title>
<source><![CDATA[J Am Heart Assoc]]></source>
<year>2020</year>
<volume>21</volume>
</nlm-citation>
</ref>
<ref id="B71">
<label>71</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1997</year>
<volume>350</volume>
<page-range>127-33</page-range></nlm-citation>
</ref>
<ref id="B72">
<label>72</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gaasch]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Levine]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Quinones]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Alexander]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Left ventricular compliance:mechanisms and clinical implications]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>1976</year>
<volume>38</volume>
<page-range>645-53</page-range></nlm-citation>
</ref>
<ref id="B73">
<label>73</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Elliott]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Anastasakis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Borger]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy:the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2014</year>
<volume>35</volume>
<page-range>2733-79</page-range></nlm-citation>
</ref>
<ref id="B74">
<label>74</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Elliott]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Kaski]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Prasad]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chest pain during daily life in patients with hypertrophic cardiomyopathy:an ambulatory electrocardiographic study]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>1996</year>
<volume>17</volume>
<page-range>1056-64</page-range></nlm-citation>
</ref>
<ref id="B75">
<label>75</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Antunes]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Scudeler]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[IJC Heart Vasc]]></source>
<year>2020</year>
<volume>27</volume>
<page-range>100503</page-range></nlm-citation>
</ref>
<ref id="B76">
<label>76</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saberi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cardim]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Yamani]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy:EXPLORER-HCM cardiac magnetic resonance sub study analysis]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2021</year>
<volume>143</volume>
<page-range>606-8</page-range></nlm-citation>
</ref>
<ref id="B77">
<label>77</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kubo]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kitaoka]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Okawa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Combined measurements of cardiac troponin I and brain natriuretic peptide are useful for predicting adverse outcomes in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circ J]]></source>
<year>2011</year>
<volume>75</volume>
<page-range>919-26</page-range></nlm-citation>
</ref>
<ref id="B78">
<label>78</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Minami]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Haruki]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kanbayashi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Maeda]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Itani]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hagiwara]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[B-type natriuretic peptide and risk of sudden death in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Heart Rhythm]]></source>
<year>2018</year>
<volume>15</volume>
<page-range>1484-90</page-range></nlm-citation>
</ref>
<ref id="B79">
<label>79</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kawasaki]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Sakai]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Harimoto]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Yamano]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Miki]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kamitani]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Usefulness of high-sensitivity cardiac troponin T and brain natriuretic peptide as biomarkers of myocardial fibrosis in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2013</year>
<volume>112</volume>
<page-range>867-72</page-range></nlm-citation>
</ref>
<ref id="B80">
<label>80</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hari]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[TP]]></given-names>
</name>
<name>
<surname><![CDATA[Soliman]]></surname>
<given-names><![CDATA[EZ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relationship between P-wave duration and the risk of auricular fibrillation. Expert Rev Cardiovasc Ther]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2018</year>
<volume>16</volume>
<page-range>837-43</page-range></nlm-citation>
</ref>
<ref id="B81">
<label>81</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Koga]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Yamaga]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hiyamuta]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Ikeda]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Toshima]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mechanisms of abnormal Q waves in hypertrophic cardiomyopathy assessed by intracoronary electrocardiography]]></article-title>
<source><![CDATA[J Cardiovasc Electrophysiol]]></source>
<year>2004</year>
<volume>15</volume>
<page-range>1402-8</page-range></nlm-citation>
</ref>
<ref id="B82">
<label>82</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Monzo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Martino]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lanzillo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Electrocardiographic voltage criteria in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[J Cardiovasc Med (Hagerstown)]]></source>
<year>2020</year>
<volume>21</volume>
<page-range>696-703</page-range></nlm-citation>
</ref>
<ref id="B83">
<label>83</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Finocchiaro]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Sheikh]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Biagini]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The electrocardiogram in the diagnosis and management of patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Heart Rhythm]]></source>
<year>2020</year>
<volume>17</volume>
<page-range>142-51</page-range></nlm-citation>
</ref>
<ref id="B84">
<label>84</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McLeod]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ackerman]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Nishimura]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Tajik]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gersh]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[-Ommen]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Outcome of patients with hypertrophic cardiomyopathy and a normal electrocardiogram]]></article-title>
<source><![CDATA[JACC]]></source>
<year>2009</year>
<volume>54</volume>
<page-range>229-33</page-range></nlm-citation>
</ref>
<ref id="B85">
<label>85</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Klues]]></surname>
<given-names><![CDATA[HG]]></given-names>
</name>
<name>
<surname><![CDATA[Schiffers]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy:morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>1995</year>
<volume>26</volume>
<page-range>1699-708</page-range></nlm-citation>
</ref>
<ref id="B86">
<label>86</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moro]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[D'Angelo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Nicolosi]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
<name>
<surname><![CDATA[Mimo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Zanuttini]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term evaluation of patients with apical hypertrophic cardiomyopathy. Correlation between quantitative echocardiographic assessment of apical hypertrophy and clinical-electrocardiographic findings]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>1995</year>
<volume>16</volume>
<page-range>210-7</page-range></nlm-citation>
</ref>
<ref id="B87">
<label>87</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Delcrè]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Di Donna]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Leuzzi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relationship of ECG findings to phenotypic expression in patients with hypertrophic cardiomyopathy:a cardiac magnetic resonance study]]></article-title>
<source><![CDATA[Int J Cardiol]]></source>
<year>2013</year>
<volume>167</volume>
<page-range>1038-45</page-range></nlm-citation>
</ref>
<ref id="B88">
<label>88</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cui]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Schaff]]></surname>
<given-names><![CDATA[HV]]></given-names>
</name>
<name>
<surname><![CDATA[Nishimura]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Conduction abnormalities and long-term mortality following septal myectomy in patients with obstructive hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[JACC]]></source>
<year>2019</year>
<volume>74</volume>
<page-range>645-55</page-range></nlm-citation>
</ref>
<ref id="B89">
<label>89</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kang]]></surname>
<given-names><![CDATA[KW]]></given-names>
</name>
<name>
<surname><![CDATA[Janardhan]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Jung]]></surname>
<given-names><![CDATA[KT]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Hwang]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fragmented QRS as a candidate marker for high-risk assessment in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Heart Rhythm]]></source>
<year>2014</year>
<volume>11</volume>
<page-range>1433-40</page-range></nlm-citation>
</ref>
<ref id="B90">
<label>90</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rattanawong]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Riangwiwat]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kanitsoraphan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Baseline fragmented QRS increases the risk of major arrhythmic events in hypertrophic cardiomyopathy:systematic review and meta-analysis]]></article-title>
<source><![CDATA[Ann Noninvasive Electrocardiol]]></source>
<year>2018</year>
<volume>23</volume>
</nlm-citation>
</ref>
<ref id="B91">
<label>91</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yamaguchi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ishimura]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Nishiyama]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertrophic nonobstructive cardiomyopathy with giant negative T waves (apical hypertrophy):ventriculographic and echocardiographic features in 30 patients]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>1979</year>
<volume>44</volume>
<page-range>401-12</page-range></nlm-citation>
</ref>
<ref id="B92">
<label>92</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Haghjoo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mohammadzadeh]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Taherpour]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ST-segment depression as a risk factor in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Europace]]></source>
<year>2009</year>
<volume>11</volume>
<page-range>643-9</page-range></nlm-citation>
</ref>
<ref id="B93">
<label>93</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ozeke]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Ertan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Keskin]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association of ST elevation with apical aneurysm in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Indian Heart J]]></source>
<year>2015</year>
<volume>67</volume>
<page-range>434-9</page-range></nlm-citation>
</ref>
<ref id="B94">
<label>94</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[JN]]></given-names>
</name>
<name>
<surname><![CDATA[Grifoni]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bos]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence and clinical correlates of QT prolongation in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2011</year>
<volume>32</volume>
<page-range>1114-20</page-range></nlm-citation>
</ref>
<ref id="B95">
<label>95</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The electrocardiogram as a diagnostic tool for hypertrophic cardiomyopathy:revisited]]></article-title>
<source><![CDATA[Ann Noninvasive Electrocardiol]]></source>
<year>2001</year>
<volume>6</volume>
<page-range>277-9</page-range></nlm-citation>
</ref>
<ref id="B96">
<label>96</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Panza]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relation of electrocardiographic abnormalities to evolving left ventricular hypertrophy in hypertrophic cardiomyopathy during childhood]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>1989</year>
<volume>63</volume>
<page-range>1258-65</page-range></nlm-citation>
</ref>
<ref id="B97">
<label>97</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Savage]]></surname>
<given-names><![CDATA[DD]]></given-names>
</name>
<name>
<surname><![CDATA[Wolfson]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy:a prospective study]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>1981</year>
<volume>48</volume>
<page-range>252-7</page-range></nlm-citation>
</ref>
<ref id="B98">
<label>98</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kawasaki]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Sakai]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Harimoto]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Holter monitoring and long-term prognosis in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Cardiology]]></source>
<year>2012</year>
<volume>122</volume>
<page-range>44-54</page-range></nlm-citation>
</ref>
<ref id="B99">
<label>99</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weissler-Snir]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Adler]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Usefulness of 14-day Holter for detection of nonsustained ventricular tachycardia in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2016</year>
<volume>118</volume>
<page-range>1258-63</page-range></nlm-citation>
</ref>
<ref id="B100">
<label>100</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Lian]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Rowin]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Link]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic implications of nonsustained ventricular tachycardia in high-risk patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circ Arrhythm Electrophysiol]]></source>
<year>2017</year>
<volume>10</volume>
</nlm-citation>
</ref>
<ref id="B101">
<label>101</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Adabag]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Casey]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Kuskowski]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Zenovich]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[JACC]]></source>
<year>2005</year>
<volume>45</volume>
<page-range>697-704</page-range></nlm-citation>
</ref>
<ref id="B102">
<label>102</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McKenna]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[England]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Doi]]></surname>
<given-names><![CDATA[YL]]></given-names>
</name>
<name>
<surname><![CDATA[Deanfield]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Oakley]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Goodwin]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Arrhythmia in hypertrophic cardiomyopathy I:influence on prognosis]]></article-title>
<source><![CDATA[Br Heart J]]></source>
<year>1981</year>
<volume>46</volume>
<page-range>168-72</page-range></nlm-citation>
</ref>
<ref id="B103">
<label>103</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Borne]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Varosy]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Masoud]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Implantable cardioverter-defibrillator shocks. Epidemiology, outcomes, and therapeutic approaches]]></article-title>
<source><![CDATA[JAMA Intern Med]]></source>
<year>2013</year>
<volume>173</volume>
<page-range>859-65</page-range></nlm-citation>
</ref>
<ref id="B104">
<label>104</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[O'Hanlon]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Grasso]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Roughton]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[JACC]]></source>
<year>2010</year>
<volume>56</volume>
<page-range>867-74</page-range></nlm-citation>
</ref>
<ref id="B105">
<label>105</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Santangeli]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Di Biase]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Lakkireddy]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Radiofrequency catheter ablation of ventricular arrhythmias in patients with hypertrophic cardiomyopathy:safety and feasibility]]></article-title>
<source><![CDATA[Heart Rhythm]]></source>
<year>2010</year>
<volume>7</volume>
<page-range>1036-42</page-range></nlm-citation>
</ref>
<ref id="B106">
<label>106</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dukkipati]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[d'Avila]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Soejima]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term outcomes of combined epicardial and endocardial ablation of monomorphic ventricular tachycardia related to hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circ Arrhythm Electrophysiol]]></source>
<year>2011</year>
<volume>4</volume>
<page-range>185-94</page-range></nlm-citation>
</ref>
<ref id="B107">
<label>107</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pitcher]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Wainwright]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Maisey]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Curry]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Sowton]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessment of chest pain in hypertrophic cardiomyopathy using exercise thallium 201 myocardial scintigraphy]]></article-title>
<source><![CDATA[Br Heart J]]></source>
<year>1980</year>
<volume>44</volume>
<page-range>650-6</page-range></nlm-citation>
</ref>
<ref id="B108">
<label>108</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Özy&#305;lmaz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pü&#351;üro&#287;lu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessment of the relationship between the ambulatory electrocardiography-based micro T-wave alternans and the predicted risk score of sudden cardiac death at 5 years in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Anatol J Cardiol]]></source>
<year>2018</year>
<volume>20</volume>
<page-range>165-73</page-range></nlm-citation>
</ref>
<ref id="B109">
<label>109</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nistri]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Olivotto]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Betocchi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic significance of left auricular size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy)]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2006</year>
<volume>98</volume>
<page-range>960-5</page-range></nlm-citation>
</ref>
<ref id="B110">
<label>110</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Epstein]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertrophic cardiomyopathy. Recent observations regarding the specificity of three hallmarks of the disease:asymmetric septal hypertrophy, septal disorganization and systolic anterior motion of the anterior mitral leaflet]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>1980</year>
<volume>45</volume>
<page-range>141-54</page-range></nlm-citation>
</ref>
<ref id="B111">
<label>111</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic value of global longitudinal strain in hypertrophic cardiomyopathy:a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Clin Cardiol]]></source>
<year>2022</year>
<volume>45</volume>
<page-range>1184-91</page-range></nlm-citation>
</ref>
<ref id="B112">
<label>112</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Echocardiographic assessment of left ventricular hypertrophy in patients with obstructive or nonobstructive hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>1983</year>
<volume>4</volume>
<numero>Suppl F</numero>
<issue>Suppl F</issue>
<page-range>73-91</page-range></nlm-citation>
</ref>
<ref id="B113">
<label>113</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wigle]]></surname>
<given-names><![CDATA[ED]]></given-names>
</name>
<name>
<surname><![CDATA[Sasson]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Henderson]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review]]></article-title>
<source><![CDATA[Prog Cardiovasc Dis]]></source>
<year>1985</year>
<volume>28</volume>
<page-range>1-83</page-range></nlm-citation>
</ref>
<ref id="B114">
<label>114</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chelliah]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
<name>
<surname><![CDATA[Senior]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pathological and physiological left ventricular hypertrophy:echocardiography for differentiation]]></article-title>
<source><![CDATA[Future Cardiol]]></source>
<year>2009</year>
<volume>5</volume>
<page-range>495-502</page-range></nlm-citation>
</ref>
<ref id="B115">
<label>115</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nagueh]]></surname>
<given-names><![CDATA[SF]]></given-names>
</name>
<name>
<surname><![CDATA[Bierig]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Budoff]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[J Am Soc Echocardiogr]]></source>
<year>2011</year>
<volume>24</volume>
<page-range>473-98</page-range></nlm-citation>
</ref>
<ref id="B116">
<label>116</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cianciulli]]></surname>
<given-names><![CDATA[TF]]></given-names>
</name>
<name>
<surname><![CDATA[Saccheri]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Bermann]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Solitary papillary muscle hypertrophy can be a precursor of hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2008</year>
<volume>117</volume>
<page-range>121</page-range></nlm-citation>
</ref>
<ref id="B117">
<label>117</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kobashi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Suwa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ito]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Otake]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Hirota]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Kawamura]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Solitary papillary muscle hypertrophy as a possible form of hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Jpn Circ J]]></source>
<year>1990</year>
<volume>62</volume>
<page-range>811-6</page-range></nlm-citation>
</ref>
<ref id="B118">
<label>118</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Serri]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Reant]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Lafitte]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global and regional myocardial function quantification by two-dimensional strain:application in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[JACC]]></source>
<year>2006</year>
<volume>47</volume>
<page-range>1175-81</page-range></nlm-citation>
</ref>
<ref id="B119">
<label>119</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nagueh]]></surname>
<given-names><![CDATA[SF]]></given-names>
</name>
<name>
<surname><![CDATA[Bachinski]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
<name>
<surname><![CDATA[Meyer]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2001</year>
<volume>104</volume>
<page-range>128-30</page-range></nlm-citation>
</ref>
<ref id="B120">
<label>120</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fujiwara]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Onodera]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Tanaka]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Progression from hypertrophic obstructive cardiomyopathy to typical dilated cardiomyopathy-like features in the end stage]]></article-title>
<source><![CDATA[Jpn Circ J]]></source>
<year>1984</year>
<volume>48</volume>
<page-range>1210-4</page-range></nlm-citation>
</ref>
<ref id="B121">
<label>121</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Inada]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Seiler]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Roberts-Thomson]]></surname>
<given-names><![CDATA[KC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Substrate characterization and catheter ablation for monomorphic ventricular tachycardia in patients with apical hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[J Cardiovasc Electrophysiol]]></source>
<year>2011</year>
<volume>22</volume>
<page-range>41-8</page-range></nlm-citation>
</ref>
<ref id="B122">
<label>122</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sachdev]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Shizukuda]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Brenneman]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Left auricular volumetric remodeling is predictive of functional capacity in nonobstructive hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Am Heart J]]></source>
<year>2005</year>
<volume>149</volume>
<page-range>730-6</page-range></nlm-citation>
</ref>
<ref id="B123">
<label>123</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Woo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Monakier]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enlarged left auricular volume in hypertrophic cardiomyopathy:a marker for disease severity]]></article-title>
<source><![CDATA[J Am Soc Echocardiogr]]></source>
<year>2005</year>
<volume>18</volume>
<page-range>1074-82</page-range></nlm-citation>
</ref>
<ref id="B124">
<label>124</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sherrid]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Balaram]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The mitral valve in obstructive hypertrophic cardiomyopathy:a test in context]]></article-title>
<source><![CDATA[JACC]]></source>
<year>2016</year>
<volume>67</volume>
<page-range>1846-58</page-range></nlm-citation>
</ref>
<ref id="B125">
<label>125</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silbiger]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Abnormalities of the mitral apparatus in hypertrophic cardiomyopathy:echocardiographic, pathophysiologic, and surgical insights]]></article-title>
<source><![CDATA[J Am Soc Echocardiogr]]></source>
<year>2016</year>
<volume>29</volume>
<page-range>622-39</page-range></nlm-citation>
</ref>
<ref id="B126">
<label>126</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Faber]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Seggewiss]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ziemssen]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intraprocedural myocardial contrast echocardiography as a routine procedure in percutaneous transluminal septal myocardial ablation:detection of threatening myocardial necrosis distant from the septal target area]]></article-title>
<source><![CDATA[Catheter Cardiovasc Interv]]></source>
<year>1999</year>
<volume>47</volume>
<page-range>462-6</page-range></nlm-citation>
</ref>
<ref id="B127">
<label>127</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Faber]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ziemssen]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Seggewiss]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Targeting percutaneous transluminal septal ablation for hypertrophic obstructive cardiomyopathy by intraprocedural echocardiographic monitoring]]></article-title>
<source><![CDATA[J Am Soc Echocardiogr]]></source>
<year>2000</year>
<volume>13</volume>
<page-range>1074-9</page-range></nlm-citation>
</ref>
<ref id="B128">
<label>128</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Faber]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Seggewiss]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Welge]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Echo-guided percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy:7 years of experience]]></article-title>
<source><![CDATA[Eur J Echocardiogr]]></source>
<year>2004</year>
<volume>5</volume>
<page-range>347-55</page-range></nlm-citation>
</ref>
<ref id="B129">
<label>129</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kuhn]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Gietzen]]></surname>
<given-names><![CDATA[FH]]></given-names>
</name>
<name>
<surname><![CDATA[Schäfers]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Changes in the left ventricular outflow tract after trans coronary ablation of septal hypertrophy (TASH) for hypertrophic obstructive cardiomyopathy as assessed by transesophageal echocardiography and by measuring myocardial glucose utilization and perfusion]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>1999</year>
<volume>20</volume>
<page-range>1808-17</page-range></nlm-citation>
</ref>
<ref id="B130">
<label>130</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nagueh]]></surname>
<given-names><![CDATA[SF]]></given-names>
</name>
<name>
<surname><![CDATA[Zoghbi]]></surname>
<given-names><![CDATA[WA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of imaging in the evaluation of patients at risk for sudden cardiac death:genotype-phenotype intersection]]></article-title>
<source><![CDATA[J Am Coll Cardiol Imaging]]></source>
<year>2015</year>
<volume>8</volume>
<page-range>828-45</page-range></nlm-citation>
</ref>
<ref id="B131">
<label>131</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arias]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Peña-Duque]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Ríos]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bubble contrast echocardiography for alcohol septal ablation]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2019</year>
<volume>72</volume>
<page-range>416</page-range></nlm-citation>
</ref>
<ref id="B132">
<label>132</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spaziano]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sawaya]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lefévre]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alcohol septal ablation for hypertrophic obstructive cardiomyopathy:indications, technical aspects, and clinical outcomes]]></article-title>
<source><![CDATA[J Invasive Cardiol]]></source>
<year>2017</year>
<volume>29</volume>
<page-range>404-10</page-range></nlm-citation>
</ref>
<ref id="B133">
<label>133</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Concha]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mertz]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systolic anterior motion:a report of two cases]]></article-title>
<source><![CDATA[Rev Med Chil]]></source>
<year>2012</year>
<volume>140</volume>
<page-range>1046-9</page-range></nlm-citation>
</ref>
<ref id="B134">
<label>134</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Izgi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Akgun]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Men]]></surname>
<given-names><![CDATA[EE]]></given-names>
</name>
<name>
<surname><![CDATA[Feray]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systolic anterior motion of the mitral valve in the absence of left ventricular hypertrophy:role of mitral leaflet elongation and papillary muscle displacement]]></article-title>
<source><![CDATA[Echocardiography]]></source>
<year>2010</year>
<volume>27</volume>
<page-range>8</page-range></nlm-citation>
</ref>
<ref id="B135">
<label>135</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Levine]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Vlahakes]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lefebvre]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Papillary muscle displacement causes systolic anterior motion of the mitral valve. Experimental validation and insights into the mechanism of subaortic obstruction]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1995</year>
<volume>91</volume>
<page-range>1189-95</page-range></nlm-citation>
</ref>
<ref id="B136">
<label>136</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sherrid]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Gunsburg]]></surname>
<given-names><![CDATA[DZ]]></given-names>
</name>
<name>
<surname><![CDATA[Moldenhauer]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pearle]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systolic anterior motion begins at low left ventricular outflow tract velocity in obstructive hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[JACC]]></source>
<year>2000</year>
<volume>36</volume>
<page-range>1344-54</page-range></nlm-citation>
</ref>
<ref id="B137">
<label>137</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gottdiener]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Arce]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dynamic subaortic obstruction in hypertrophic cardiomyopathy:analysis by pulsed Doppler echocardiography]]></article-title>
<source><![CDATA[JACC]]></source>
<year>1985</year>
<volume>6</volume>
<page-range>1-18</page-range></nlm-citation>
</ref>
<ref id="B138">
<label>138</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[EH]]></given-names>
</name>
<name>
<surname><![CDATA[Omran]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Wigle]]></surname>
<given-names><![CDATA[ED]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[WG]]></given-names>
</name>
<name>
<surname><![CDATA[Siu]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Rakowski]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mitral regurgitation in hypertrophic obstructive cardiomyopathy:relationship to obstruction and relief with myectomy]]></article-title>
<source><![CDATA[JACC]]></source>
<year>2000</year>
<volume>36</volume>
<page-range>2219-25</page-range></nlm-citation>
</ref>
<ref id="B139">
<label>139</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Klues]]></surname>
<given-names><![CDATA[HG]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Dollar]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[WC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1992</year>
<volume>85</volume>
<page-range>1651-60</page-range></nlm-citation>
</ref>
<ref id="B140">
<label>140</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nagueh]]></surname>
<given-names><![CDATA[SF]]></given-names>
</name>
<name>
<surname><![CDATA[Lakkis]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
<name>
<surname><![CDATA[Middleton]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Spencer III]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
<name>
<surname><![CDATA[Zoghbi]]></surname>
<given-names><![CDATA[WA]]></given-names>
</name>
<name>
<surname><![CDATA[Quinones]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Doppler estimation of left ventricular filling pressures in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1999</year>
<volume>99</volume>
<page-range>254-61</page-range></nlm-citation>
</ref>
<ref id="B141">
<label>141</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Olivotto]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Girolami]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Nistri]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The many faces of hypertrophic cardiomyopathy:from developmental biology to clinical practice]]></article-title>
<source><![CDATA[J Cardiovasc Transl Res]]></source>
<year>2009</year>
<volume>2</volume>
<page-range>349-67</page-range></nlm-citation>
</ref>
<ref id="B142">
<label>142</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Panza]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Petrone]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
<name>
<surname><![CDATA[Fananapazir]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Utility of continuous wave Doppler echocardiography in the noninvasive assessment of left ventricular outflow tract pressure gradient in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[JACC]]></source>
<year>1992</year>
<volume>19</volume>
<page-range>91-9</page-range></nlm-citation>
</ref>
<ref id="B143">
<label>143</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Esteban]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Thaman]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Heart]]></source>
<year>2008</year>
<volume>94</volume>
<page-range>1288-94</page-range></nlm-citation>
</ref>
<ref id="B144">
<label>144</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ho]]></surname>
<given-names><![CDATA[CY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertrophic cardiomyopathy:preclinical and early phenotype]]></article-title>
<source><![CDATA[J Cardiovasc Transl Res]]></source>
<year>2009</year>
<volume>2</volume>
<page-range>462-70</page-range></nlm-citation>
</ref>
<ref id="B145">
<label>145</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Canciello]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Lombardi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Borrelli]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Echocardiographic strain abnormalities precede left ventricular hypertrophy development in hypertrophic cardiomyopathy mutation carriers]]></article-title>
<source><![CDATA[Int J Mol Sci]]></source>
<year>2024</year>
<volume>25</volume>
<page-range>8128</page-range></nlm-citation>
</ref>
<ref id="B146">
<label>146</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kauer]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[van Dalen]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
<name>
<surname><![CDATA[Michels]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diastolic abnormalities in normal phenotype hypertrophic cardiomyopathy gene carriers:a study using speckle tracking echocardiography]]></article-title>
<source><![CDATA[Echocardiography]]></source>
<year>2013</year>
<volume>30</volume>
<page-range>558-63</page-range></nlm-citation>
</ref>
<ref id="B147">
<label>147</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cao]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[XY]]></given-names>
</name>
<name>
<surname><![CDATA[Zhong]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of hemodynamics in patients with hypertrophic cardiomyopathy by vector flow mapping:comparison with healthy subjects]]></article-title>
<source><![CDATA[Exp Ther Med]]></source>
<year>2019</year>
<volume>17</volume>
<page-range>4379-88</page-range></nlm-citation>
</ref>
<ref id="B148">
<label>148</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nagueh]]></surname>
<given-names><![CDATA[SF]]></given-names>
</name>
<name>
<surname><![CDATA[Smiseth]]></surname>
<given-names><![CDATA[OA]]></given-names>
</name>
<name>
<surname><![CDATA[Appleton]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recommendations for the evaluation of left ventricular diastolic function by echocardiography:an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging]]></article-title>
<source><![CDATA[J Am Soc Echocardiogr]]></source>
<year>2016</year>
<volume>29</volume>
<page-range>277-314</page-range></nlm-citation>
</ref>
<ref id="B149">
<label>149</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vinereanu]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Florescu]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Sculthorpe]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Tweddel]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Stephens]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Fraser]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Differentiation between pathologic and physiologic left ventricular hypertrophy by tissue Doppler assessment of long-axis function in patients with hypertrophic cardiomyopathy or systemic hypertension and in athletes]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2001</year>
<volume>88</volume>
<page-range>53-8</page-range></nlm-citation>
</ref>
<ref id="B150">
<label>150</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chejtman]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Baratta]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Marani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ferroni]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Bilbao]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Valor clínico del análisis de la fase sistólica de la contracción ventricular con Doppler tisular en la discriminación de hipertrofia fisiológica de formas patológicas]]></article-title>
<source><![CDATA[Rev Argent Cardiol]]></source>
<year>2006</year>
<volume>74</volume>
<page-range>129-35</page-range></nlm-citation>
</ref>
<ref id="B151">
<label>151</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bayrak]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Kahveci]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Mutlu]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Sonmez]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Degertekin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tissue Doppler imaging to predict clinical course of patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Eur J Echocardiogr]]></source>
<year>2008</year>
<volume>9</volume>
<page-range>278-83</page-range></nlm-citation>
</ref>
<ref id="B152">
<label>152</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Lever]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of strain imaging in detecting segmental dysfunction in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[J Am Soc Echocardiogr]]></source>
<year>2003</year>
<volume>16</volume>
<page-range>233-9</page-range></nlm-citation>
</ref>
<ref id="B153">
<label>153</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baratta]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chejtman]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Valor clínico de la utilización del strain rate sistólico en el estudio de distintas formas de hipertrofia ventricular izquierda]]></article-title>
<source><![CDATA[Rev Argent Cardiol]]></source>
<year>2007</year>
<volume>75</volume>
<page-range>367-73</page-range></nlm-citation>
</ref>
<ref id="B154">
<label>154</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kato]]></surname>
<given-names><![CDATA[TS]]></given-names>
</name>
<name>
<surname><![CDATA[Noda]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Izawa]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Discrimination of nonobstructive hypertrophic cardiomyopathy from hypertensive left ventricular hypertrophy on the basis of strain rate imaging by tissue Doppler ultrasonography]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2004</year>
<volume>110</volume>
<page-range>3808-14</page-range></nlm-citation>
</ref>
<ref id="B155">
<label>155</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Urbano Moral]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Arias-Godínez]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Left ventricular twist mechanics in hypertrophic cardiomyopathy assessed by three-dimensional speckle tracking echocardiography]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2011</year>
<volume>108</volume>
<page-range>1788-95</page-range></nlm-citation>
</ref>
<ref id="B156">
<label>156</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zegkos]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Parcharidou]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ntelos]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Efthimiadis]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Karvounis]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The prognostic implications of two-dimensional speckle tracking echocardiography in hypertrophic cardiomyopathy:current and future perspectives]]></article-title>
<source><![CDATA[Cardiol Rev]]></source>
<year>2018</year>
<volume>26</volume>
<page-range>130-6</page-range></nlm-citation>
</ref>
<ref id="B157">
<label>157</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Domínguez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[González-López]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Padrón-Barthe]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Cavero]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[García-Pavía]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of echocardiography in the diagnosis and management of hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Heart]]></source>
<year>2018</year>
<volume>104</volume>
<page-range>261-73</page-range></nlm-citation>
</ref>
<ref id="B158">
<label>158</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Okeie]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Shimizu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Yoshio]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Left ventricular systolic dysfunction during exercise and dobutamine stress in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[JACC]]></source>
<year>2000</year>
<volume>36</volume>
<page-range>856-63</page-range></nlm-citation>
</ref>
<ref id="B159">
<label>159</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pellikka]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Oh]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[Bailey]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
<name>
<surname><![CDATA[Nichols]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Monahan]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
<name>
<surname><![CDATA[Tajik]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dynamic intraventricular obstruction during dobutamine stress echocardiography. A new observation]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1992</year>
<volume>86</volume>
<page-range>1429-32</page-range></nlm-citation>
</ref>
<ref id="B160">
<label>160</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kawano]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Iida]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Fujieda]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Response to isoproterenol as a prognostic indicator of evolution from hypertrophic cardiomyopathy to a phase resembling dilated cardiomyopathy]]></article-title>
<source><![CDATA[JACC]]></source>
<year>1995</year>
<volume>25</volume>
<page-range>687-92</page-range></nlm-citation>
</ref>
<ref id="B161">
<label>161</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marwick]]></surname>
<given-names><![CDATA[TH]]></given-names>
</name>
<name>
<surname><![CDATA[Nakatani]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Haluska]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Lever]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Provocation of latent left ventricular outflow tract gradients with amyl nitrite and exercise in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>1995</year>
<volume>75</volume>
<page-range>805-9</page-range></nlm-citation>
</ref>
<ref id="B162">
<label>162</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schwammenthal]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Schwartzkopff]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Block]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Doppler echocardiographic assessment of the pressure gradient during bicycle ergometry in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>1992</year>
<volume>69</volume>
<page-range>1623-8</page-range></nlm-citation>
</ref>
<ref id="B163">
<label>163</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De la Morena]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Car]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Saura]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eco-Doppler de ejercicio en pacientes con miocardiopatía hipertrófica. Factores determinantes de la limitación funcional]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2013</year>
<volume>66</volume>
<page-range>98-103</page-range></nlm-citation>
</ref>
<ref id="B164">
<label>164</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grigg]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Wigle]]></surname>
<given-names><![CDATA[ED]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[WG]]></given-names>
</name>
<name>
<surname><![CDATA[Daniel]]></surname>
<given-names><![CDATA[LB]]></given-names>
</name>
<name>
<surname><![CDATA[Rakowski]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy:clarification of pathophysiology and importance in intraoperative decision making]]></article-title>
<source><![CDATA[JACC]]></source>
<year>1992</year>
<volume>20</volume>
<page-range>42-52</page-range></nlm-citation>
</ref>
<ref id="B165">
<label>165</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cardim]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Galderisi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Edvardsen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy:an expert consensus of the European Association of Cardiovascular Imaging endorsed by the Saudi Heart Association]]></article-title>
<source><![CDATA[Eur Heart J Cardiovasc Imaging]]></source>
<year>2015</year>
<volume>16</volume>
<page-range>280</page-range></nlm-citation>
</ref>
<ref id="B166">
<label>166</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Shen]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Song]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The use of cardiac magnetic resonance in hypertrophic cardiomyopathy over the past 10 years [2013-2023]:a CiteSpace-based bibliometric analysis]]></article-title>
<source><![CDATA[Quant Imaging Med Surg]]></source>
<year>2024</year>
<volume>14</volume>
<page-range>566-78</page-range></nlm-citation>
</ref>
<ref id="B167">
<label>167</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chun]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[SI]]></given-names>
</name>
<name>
<surname><![CDATA[Jin]]></surname>
<given-names><![CDATA[KN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertrophic cardiomyopathy:assessment with MR imaging and multidetector CT]]></article-title>
<source><![CDATA[Radiographics]]></source>
<year>2010</year>
<volume>30</volume>
<page-range>1309-28</page-range></nlm-citation>
</ref>
<ref id="B168">
<label>168</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[J Cardiovasc Magn Reson]]></source>
<year>2012</year>
<volume>14</volume>
<page-range>13</page-range></nlm-citation>
</ref>
<ref id="B169">
<label>169</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Olivotto]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Autore]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[JACC]]></source>
<year>2008</year>
<volume>52</volume>
<page-range>559-66</page-range></nlm-citation>
</ref>
<ref id="B170">
<label>170</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Rowin]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[How to image hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circ Cardiovasc Imaging]]></source>
<year>2017</year>
<volume>10</volume>
</nlm-citation>
</ref>
<ref id="B171">
<label>171</label><nlm-citation citation-type="book">
<source><![CDATA[European Reference Networks in the Field of Rare Diseases:state of the art and future directions (third report)]]></source>
<year>2008</year>
<publisher-loc><![CDATA[Brussels ]]></publisher-loc>
<publisher-name><![CDATA[Rare Diseases Task Force]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B172">
<label>172</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Elliott]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Lorenzini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Understanding the prognostic significance of left ventricular apical aneurysms in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[JACC Cardiovasc Imaging]]></source>
<year>2022</year>
<volume>15</volume>
<page-range>1712-4</page-range></nlm-citation>
</ref>
<ref id="B173">
<label>173</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Song]]></surname>
<given-names><![CDATA[YY]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[XY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Apical hypertrophic cardiomyopathy with left ventricular apical aneurysm:prevalence, cardiac magnetic resonance characteristics, and prognosis]]></article-title>
<source><![CDATA[Eur Heart J Cardiovasc Imaging]]></source>
<year>2020</year>
<volume>21</volume>
<page-range>1341-50</page-range></nlm-citation>
</ref>
<ref id="B174">
<label>174</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Xie]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Qian]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mitral valve in obstructive hypertrophic cardiomyopathy:abnormalities, management and controversies]]></article-title>
<source><![CDATA[Rev Cardiovasc Med]]></source>
<year>2023</year>
<volume>24</volume>
<page-range>246</page-range></nlm-citation>
</ref>
<ref id="B175">
<label>175</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seitler]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[De Zoysa Anthony]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Obianyo]]></surname>
<given-names><![CDATA[CCC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systolic anterior motion of the anterior mitral valve leaflet begins in subclinical hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Eur Heart J Cardiovasc Imaging]]></source>
<year>2023</year>
<volume>25</volume>
<page-range>86-94</page-range></nlm-citation>
</ref>
<ref id="B176">
<label>176</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moravsky]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ofek]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Rakowski]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Myocardial fibrosis in hypertrophic cardiomyopathy:accurate reflection of histopathological findings by CMR]]></article-title>
<source><![CDATA[JACC Cardiovasc Imaging]]></source>
<year>2013</year>
<volume>6</volume>
<page-range>587-96</page-range></nlm-citation>
</ref>
<ref id="B177">
<label>177</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Green]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Berger]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Kramer]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Salerno]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[JACC Cardiovasc Imaging]]></source>
<year>2012</year>
<volume>5</volume>
<page-range>370-7</page-range></nlm-citation>
</ref>
<ref id="B178">
<label>178</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Olivotto]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2014</year>
<volume>130</volume>
<page-range>484-95</page-range></nlm-citation>
</ref>
<ref id="B179">
<label>179</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mentias]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Raeisi-Giglou]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Smedira]]></surname>
<given-names><![CDATA[NG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Late gadolinium enhancement in patients with hypertrophic cardiomyopathy and preserved systolic function]]></article-title>
<source><![CDATA[JACC]]></source>
<year>2018</year>
<volume>72</volume>
<page-range>857-70</page-range></nlm-citation>
</ref>
<ref id="B180">
<label>180</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[YJ]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[EK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Semi-quantitative versus quantitative assessments of late gadolinium enhancement extent for predicting spontaneous ventricular tachyarrhythmia events in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Sci Rep]]></source>
<year>2020</year>
<volume>10</volume>
<page-range>2920</page-range></nlm-citation>
</ref>
<ref id="B181">
<label>181</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mitsutake]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Miura]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sako]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Nishikawa]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Saku]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Usefulness of multi-detector row computed tomography for the management of percutaneous transluminal septal myocardial ablation in patient with hypertrophic obstructive cardiomyopathy]]></article-title>
<source><![CDATA[Int J Cardiol]]></source>
<year>2008</year>
<volume>129</volume>
<page-range>61-3</page-range></nlm-citation>
</ref>
<ref id="B182">
<label>182</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Okayama]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Uemura]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Soeda]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Horii]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Saito]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of cardiac computed tomography in planning and evaluating percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy]]></article-title>
<source><![CDATA[J Cardiovasc Comput Tomogr]]></source>
<year>2010</year>
<volume>4</volume>
<page-range>62-5</page-range></nlm-citation>
</ref>
<ref id="B183">
<label>183</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shariat]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Thavendiranathan]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Utility of coronary CT angiography in outpatients with hypertrophic cardiomyopathy presenting with angina symptoms]]></article-title>
<source><![CDATA[J Cardiovasc Comput Tomogr]]></source>
<year>2014</year>
<volume>8</volume>
<page-range>429-37</page-range></nlm-citation>
</ref>
<ref id="B184">
<label>184</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cooper]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Binukrishnan]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Shahzad]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hasleton]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sigwart]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[-Stables]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Computed tomography angiography planning identifies the target vessel for optimum infarct location and improves clinical outcome in alcohol septal ablation for hypertrophic obstructive cardiomyopathy]]></article-title>
<source><![CDATA[EuroIntervention]]></source>
<year>2017</year>
<volume>12</volume>
<page-range>203</page-range></nlm-citation>
</ref>
<ref id="B185">
<label>185</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Edvardsen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Gerber]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Donal]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Maurovich-Horvat]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Maurer]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Popescu]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The year 2015-16 in the European Heart Journal-Cardiovascular Imaging. Part II]]></article-title>
<source><![CDATA[Eur Heart J Cardiovasc Imaging]]></source>
<year>2017</year>
<volume>18</volume>
<page-range>1322-30</page-range></nlm-citation>
</ref>
<ref id="B186">
<label>186</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shirani]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Dilsizian]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nuclear cardiac imaging in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[J Nucl Cardiol]]></source>
<year>2011</year>
<volume>18</volume>
<page-range>123-34</page-range></nlm-citation>
</ref>
<ref id="B187">
<label>187</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dilsizian]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Bonow]]></surname>
<given-names><![CDATA[RO]]></given-names>
</name>
<name>
<surname><![CDATA[Epstein]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Fananapazir]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[JACC]]></source>
<year>1993</year>
<volume>22</volume>
<page-range>796-804</page-range></nlm-citation>
</ref>
<ref id="B188">
<label>188</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sciagrà]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Calabretta]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Cipollini]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Myocardial blood flow and left ventricular functional reserve in hypertrophic cardiomyopathy:a 13NH3 gated PET study]]></article-title>
<source><![CDATA[Eur J Nucl Med Mol Imaging]]></source>
<year>2017</year>
<volume>44</volume>
<page-range>866-75</page-range></nlm-citation>
</ref>
<ref id="B189">
<label>189</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bravo]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
<name>
<surname><![CDATA[Tahari]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pozios]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Apparent left ventricular cavity dilatation during PET/CT in hypertrophic cardiomyopathy:clinical predictors and potential mechanisms]]></article-title>
<source><![CDATA[J Nucl Cardiol]]></source>
<year>2015</year>
<volume>23</volume>
<page-range>1304-14</page-range></nlm-citation>
</ref>
<ref id="B190">
<label>190</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bravo]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
<name>
<surname><![CDATA[Pinheiro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Higuchi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[PET/CT assessment of symptomatic individuals with obstructive and nonobstructive hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[J Nucl Med]]></source>
<year>2012</year>
<volume>53</volume>
<page-range>407-14</page-range></nlm-citation>
</ref>
<ref id="B191">
<label>191</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schindler]]></surname>
<given-names><![CDATA[TH]]></given-names>
</name>
<name>
<surname><![CDATA[Bateman]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Berman]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Appropriate use criteria for PET myocardial perfusion imaging]]></article-title>
<source><![CDATA[J Nucl Med]]></source>
<year>2020</year>
<volume>61</volume>
<page-range>1221-65</page-range></nlm-citation>
</ref>
<ref id="B192">
<label>192</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sciagrà]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Lubberink]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hyafil]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular Committee of the European Association of Nuclear Medicine (EANM). EANM procedural guidelines for PET/CT quantitative myocardial perfusion imaging]]></article-title>
<source><![CDATA[Eur J Nucl Med Mol Imaging]]></source>
<year>2020</year>
<volume>48</volume>
<page-range>1040-69</page-range></nlm-citation>
</ref>
<ref id="B193">
<label>193</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Monserrat]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Elliott]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Gimeno]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy:an independent marker of sudden death risk in young patients]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2003</year>
<volume>42</volume>
<page-range>873-9</page-range></nlm-citation>
</ref>
<ref id="B194">
<label>194</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Haghjoo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Faghfurian]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Taherpour]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Predictors of syncope in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Pacing Clin Electrophysiol]]></source>
<year>2009</year>
<volume>32</volume>
<page-range>642-7</page-range></nlm-citation>
</ref>
<ref id="B195">
<label>195</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shen]]></surname>
<given-names><![CDATA[W-K]]></given-names>
</name>
<name>
<surname><![CDATA[Sheldon]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Benditt]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope:a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2017</year>
<volume>136</volume>
<page-range>122</page-range></nlm-citation>
</ref>
<ref id="B196">
<label>196</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van Velzen]]></surname>
<given-names><![CDATA[HG]]></given-names>
</name>
<name>
<surname><![CDATA[Theuns]]></surname>
<given-names><![CDATA[DAMJ]]></given-names>
</name>
<name>
<surname><![CDATA[Yap]]></surname>
<given-names><![CDATA[S-C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence of device-detected atrial fibrillation and long-term outcomes in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2017</year>
<volume>119</volume>
<page-range>100-5</page-range></nlm-citation>
</ref>
<ref id="B197">
<label>197</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wilke]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Witzel]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Münch]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[High incidence of de novo and subclinical atrial fibrillation in patients with hypertrophic cardiomyopathy and cardiac rhythm management devices]]></article-title>
<source><![CDATA[J Cardiovasc Electrophysiol]]></source>
<year>2016</year>
<volume>27</volume>
<page-range>779-84</page-range></nlm-citation>
</ref>
<ref id="B198">
<label>198</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Siontis]]></surname>
<given-names><![CDATA[KC]]></given-names>
</name>
<name>
<surname><![CDATA[Geske]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Ong]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atrial fibrillation in hypertrophic cardiomyopathy:prevalence, clinical correlations, and mortality in a large high risk population]]></article-title>
<source><![CDATA[J Am Heart Assoc]]></source>
<year>2014</year>
<volume>3</volume>
</nlm-citation>
</ref>
<ref id="B199">
<label>199</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rowin]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hausvater]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Link]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical profile and consequences of atrial fibrillation in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2017</year>
<volume>136</volume>
<page-range>2420-36</page-range></nlm-citation>
</ref>
<ref id="B200">
<label>200</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rowin]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Orfanos]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Estes]]></surname>
<given-names><![CDATA[NAM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Occurrence and natural history of clinically silent episodes of atrial fibrillation in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2017</year>
<volume>119</volume>
<page-range>1862-5</page-range></nlm-citation>
</ref>
<ref id="B201">
<label>201</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cantor]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Yosefy]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Potekhin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ilia]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Keren]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The value of changes in QRS width and in ST-T segment during exercise test in hypertrophic cardiomyopathy for identification of associated coronary artery disease]]></article-title>
<source><![CDATA[Int J Cardiol]]></source>
<year>2006</year>
<volume>112</volume>
<page-range>99-104</page-range></nlm-citation>
</ref>
<ref id="B202">
<label>202</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bunch]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Chandrasekaran]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Ehrsam]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic significance of exercise induced arrhythmias and echocardiographic variables in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2007</year>
<volume>99</volume>
<page-range>835-8</page-range></nlm-citation>
</ref>
<ref id="B203">
<label>203</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gimeno]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Tomé-Esteban]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lofiego]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2009</year>
<volume>30</volume>
<page-range>2599-605</page-range></nlm-citation>
</ref>
<ref id="B204">
<label>204</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Magrì]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Santolamazza]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiopulmonary exercise test in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Ann Am Thorac Soc]]></source>
<year>2017</year>
<volume>14</volume>
<numero>Suppl 1</numero>
<issue>Suppl 1</issue>
<page-range>S102-9</page-range></nlm-citation>
</ref>
<ref id="B205">
<label>205</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Elliott]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Whyte]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Utility of metabolic exercise testing in distinguishing hypertrophic cardiomyopathy from physiologic left ventricular hypertrophy in athletes]]></article-title>
<source><![CDATA[JACC]]></source>
<year>2000</year>
<volume>36</volume>
<page-range>864-70</page-range></nlm-citation>
</ref>
<ref id="B206">
<label>206</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Efthimiadis]]></surname>
<given-names><![CDATA[GK]]></given-names>
</name>
<name>
<surname><![CDATA[Giannakoulas]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Parcharidou]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chronotropic incompetence and its relation to exercise intolerance in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Int J Cardiol]]></source>
<year>2011</year>
<volume>153</volume>
<page-range>179-84</page-range></nlm-citation>
</ref>
<ref id="B207">
<label>207</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Masri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pierson]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Smedira]]></surname>
<given-names><![CDATA[NG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Predictors of long-term outcomes in patients with hypertrophic cardiomyopathy undergoing cardiopulmonary stress testing and echocardiography]]></article-title>
<source><![CDATA[Am Heart J]]></source>
<year>2015</year>
<volume>169</volume>
<page-range>684-92.e1</page-range></nlm-citation>
</ref>
<ref id="B208">
<label>208</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Magri]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Re]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Limongelli]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Heart failure progression in hypertrophic cardiomyopathy-possible insights from cardiopulmonary exercise testing]]></article-title>
<source><![CDATA[Circ J]]></source>
<year>2016</year>
<volume>80</volume>
<page-range>2204-11</page-range></nlm-citation>
</ref>
<ref id="B209">
<label>209</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mehra]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Kobashigawa]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Starling]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Listing criteria for heart transplantation:International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates -]]></article-title>
<source><![CDATA[J Heart Lung Transplant]]></source>
<year>2006</year>
<volume>25</volume>
<page-range>1024-42</page-range></nlm-citation>
</ref>
<ref id="B210">
<label>210</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Olivotto]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Montereggi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mazzuoli]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Cecchi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical utility and safety of exercise testing in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[G Ital Cardiol]]></source>
<year>1999</year>
<volume>29</volume>
<page-range>11-9</page-range></nlm-citation>
</ref>
<ref id="B211">
<label>211</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Olivotto]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Montereggi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mazzuoli]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Dolara]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cecchi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>1999</year>
<volume>33</volume>
<page-range>2044-51</page-range></nlm-citation>
</ref>
<ref id="B212">
<label>212</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ciampi]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Betocchi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lombardi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hemodynamic determinants of exercise-induced abnormal blood pressure response in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2002</year>
<volume>40</volume>
<page-range>278-84</page-range></nlm-citation>
</ref>
<ref id="B213">
<label>213</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Coats]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Rantell]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Bartnik]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiopulmonary exercise testing and prognosis in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circ Heart Fail]]></source>
<year>2015</year>
<volume>8</volume>
<page-range>1022-31</page-range></nlm-citation>
</ref>
<ref id="B214">
<label>214</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Geske]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Sorajja]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Ommen]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Variability of left ventricular outflow tract gradient during cardiac catheterization in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[JACC Cardiovasc Interv]]></source>
<year>2011</year>
<volume>4</volume>
<page-range>704-9</page-range></nlm-citation>
</ref>
<ref id="B215">
<label>215</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brockenbrough]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
<name>
<surname><![CDATA[Braunwald]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Morrow]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A hemodynamic technique for the detection of hypertrophic subaortic stenosis]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1961</year>
<volume>23</volume>
<page-range>189-94</page-range></nlm-citation>
</ref>
<ref id="B216">
<label>216</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Dow]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Henkin]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Taub]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Complications of exercise and pharmacologic stress echocardiography]]></article-title>
<source><![CDATA[Front Cardiovasc Med]]></source>
<year>2023</year>
<volume>10</volume>
<page-range>1228613</page-range></nlm-citation>
</ref>
<ref id="B217">
<label>217</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marian]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Molecular genetic basis of hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circ Res]]></source>
<year>2021</year>
<volume>128</volume>
<page-range>1533-53</page-range></nlm-citation>
</ref>
<ref id="B218">
<label>218</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Landstrom]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Ackerman]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mutation type is not clinically useful in predicting prognosis in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2010</year>
<volume>122</volume>
<page-range>2441-9</page-range></nlm-citation>
</ref>
<ref id="B219">
<label>219</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ho]]></surname>
<given-names><![CDATA[CY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Genetics and clinical destiny:improving care in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2020</year>
<volume>122</volume>
<page-range>2430-40</page-range></nlm-citation>
</ref>
<ref id="B220">
<label>220</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Walsh]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mazzarotto]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Whiffin]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Quantitative approaches to variant classification increase the yield and precision of genetic testing in Mendelian diseases:the case of hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Genome Med]]></source>
<year>2019</year>
<volume>11</volume>
<page-range>5</page-range></nlm-citation>
</ref>
<ref id="B221">
<label>221</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Semsarian]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Genetics of hypertrophic cardiomyopathy after 20 years:clinical perspectives]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2012</year>
<volume>60</volume>
<page-range>705-15</page-range></nlm-citation>
</ref>
<ref id="B222">
<label>222</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[van Velzen]]></surname>
<given-names><![CDATA[HG]]></given-names>
</name>
<name>
<surname><![CDATA[Schinkel]]></surname>
<given-names><![CDATA[AFL]]></given-names>
</name>
<name>
<surname><![CDATA[Baart]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Outcomes of contemporary family screening in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circ Genom Precis Med]]></source>
<year>2018</year>
<volume>11</volume>
</nlm-citation>
</ref>
<ref id="B223">
<label>223</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alfares]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Kelly]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[McDermott]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Results of clinical genetic testing of 2 912 probands with hypertrophic cardiomyopathy:expanded panels offer limited additional sensitivity]]></article-title>
<source><![CDATA[Genet Med]]></source>
<year>2015</year>
<volume>17</volume>
<page-range>880-8</page-range></nlm-citation>
</ref>
<ref id="B224">
<label>224</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vigneault]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Jensen]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Left ventricular strain is abnormal in preclinical and overt hypertrophic cardiomyopathy:cardiac MR feature tracking]]></article-title>
<source><![CDATA[Radiology]]></source>
<year>2019</year>
<volume>290</volume>
<page-range>640-8</page-range></nlm-citation>
</ref>
<ref id="B225">
<label>225</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Desai]]></surname>
<given-names><![CDATA[MY]]></given-names>
</name>
<name>
<surname><![CDATA[Ommen]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[McKenna]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Imaging phenotype versus genotype in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circ Cardiovasc Imaging]]></source>
<year>2011</year>
<volume>4</volume>
<page-range>156-68</page-range></nlm-citation>
</ref>
<ref id="B226">
<label>226</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Das]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ingles]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bagnall]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Determining pathogenicity of genetic variants in hypertrophic cardiomyopathy:importance of periodic reassessment]]></article-title>
<source><![CDATA[Genet Med]]></source>
<year>2014</year>
<volume>16</volume>
<page-range>286-93</page-range></nlm-citation>
</ref>
<ref id="B227">
<label>227</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Christiaans]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Birnie]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bonsel]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Manifest disease, risk factors for sudden cardiac death, and cardiac events in a large nationwide cohort of predictively tested hypertrophic cardiomyopathy mutation carriers:determining the best cardiological screening strategy]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2011</year>
<volume>32</volume>
<page-range>1161-70</page-range></nlm-citation>
</ref>
<ref id="B228">
<label>228</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gray]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Ingles]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Semsarian]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Natural history of genotype positive&#8211;phenotype negative patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Int J Cardiol]]></source>
<year>2011</year>
<volume>152</volume>
<page-range>258-9</page-range></nlm-citation>
</ref>
<ref id="B229">
<label>229</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Teekakirikul]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Fung]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertrophic cardiomyopathy:an overview of genetics and management]]></article-title>
<source><![CDATA[Biomolecules]]></source>
<year>2019</year>
<volume>9</volume>
<page-range>878</page-range></nlm-citation>
</ref>
<ref id="B230">
<label>230</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Frustaci]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Russo]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Chimenti]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnostic contribution of left ventricular endomyocardial biopsy in patients with clinical phenotype of hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Hum Pathol]]></source>
<year>2013</year>
<volume>44</volume>
<page-range>133-41</page-range></nlm-citation>
</ref>
<ref id="B231">
<label>231</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seward]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Casaclang-Verzosa]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Infiltrative cardiovascular diseases:cardiomyopathies that look alike]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2010</year>
<volume>55</volume>
<page-range>1769-79</page-range></nlm-citation>
</ref>
<ref id="B232">
<label>232</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Davies]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[McKenna]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertrophic cardiomyopathy —pathology and pathogenesis]]></article-title>
<source><![CDATA[Histopathology]]></source>
<year>1995</year>
<volume>26</volume>
<page-range>493-500</page-range></nlm-citation>
</ref>
<ref id="B233">
<label>233</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hughes]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The pathology of hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Histopathology]]></source>
<year>2004</year>
<volume>44</volume>
<page-range>412-27</page-range></nlm-citation>
</ref>
<ref id="B234">
<label>234</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Elliott]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Poloniecki]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Dickie]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sudden death in hypertrophic cardiomyopathy:identification of high risk patients]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2000</year>
<volume>36</volume>
<page-range>2212-8</page-range></nlm-citation>
</ref>
<ref id="B235">
<label>235</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ostman-Smith]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Wettrell]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Keeton]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Age-and gender-specific mortality rates in childhood hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2008</year>
<volume>29</volume>
<page-range>1160-7</page-range></nlm-citation>
</ref>
<ref id="B236">
<label>236</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Rowin]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Casey]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2015</year>
<volume>65</volume>
<page-range>1915-28</page-range></nlm-citation>
</ref>
<ref id="B237">
<label>237</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Norrish]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ding]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Field]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development of a novel risk prediction model for sudden cardiac death in childhood hypertrophic cardiomyopathy (HCM Risk-Kids)]]></article-title>
<source><![CDATA[JAMA Cardiol]]></source>
<year>2019</year>
<volume>4</volume>
<page-range>918-27</page-range></nlm-citation>
</ref>
<ref id="B238">
<label>238</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Miron]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lafreniere-Roula]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fan]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A validated model for sudden cardiac death risk prediction in pediatric hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2020</year>
<volume>142</volume>
<page-range>217-29</page-range></nlm-citation>
</ref>
<ref id="B239">
<label>239</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[O'Mahony]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Jichi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Pavlou]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM riskSCD)]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2014</year>
<volume>35</volume>
<page-range>2010-20</page-range></nlm-citation>
</ref>
<ref id="B240">
<label>240</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[O'Mahony]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Jichi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ommen]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[International external validation study of the 2014 European Society of Cardiology guidelines on sudden cardiac death prevention in hypertrophic cardiomyopathy (EVIDENCEHCM)]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2018</year>
<volume>137</volume>
<page-range>1015-23</page-range></nlm-citation>
</ref>
<ref id="B241">
<label>241</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ismail]]></surname>
<given-names><![CDATA[TF]]></given-names>
</name>
<name>
<surname><![CDATA[Jabbour]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gulati]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Heart]]></source>
<year>2014</year>
<volume>100</volume>
<page-range>1851-8</page-range></nlm-citation>
</ref>
<ref id="B242">
<label>242</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rubinshtein]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Glockner]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Ommen]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circ Heart Fail]]></source>
<year>2010</year>
<volume>3</volume>
<page-range>51-8</page-range></nlm-citation>
</ref>
<ref id="B243">
<label>243</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weng]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Yao]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic value of LGE-CMR in HCM:a meta-analysis]]></article-title>
<source><![CDATA[J Am Coll Cardiol Imaging]]></source>
<year>2016</year>
<volume>9</volume>
<page-range>1392-402</page-range></nlm-citation>
</ref>
<ref id="B244">
<label>244</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Klopotowski]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kukula]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Malek]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[J Cardiol]]></source>
<year>2016</year>
<volume>68</volume>
<page-range>49-56</page-range></nlm-citation>
</ref>
<ref id="B245">
<label>245</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kaski]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Norrish]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ding]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development of a novel risk prediction model for sudden cardiac death in childhood hypertrophic cardiomyopathy (HCM Risk-Kids)]]></article-title>
<source><![CDATA[JAMA Cardiol]]></source>
<year>2019</year>
<volume>4</volume>
<page-range>918-27</page-range></nlm-citation>
</ref>
<ref id="B246">
<label>246</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2010</year>
<volume>121</volume>
<page-range>445-56</page-range></nlm-citation>
</ref>
<ref id="B247">
<label>247</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tower-Rader]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kramer]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Neubauer]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Nagueh]]></surname>
<given-names><![CDATA[SF]]></given-names>
</name>
<name>
<surname><![CDATA[Desai]]></surname>
<given-names><![CDATA[MY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multimodality imaging in hypertrophic cardiomyopathy for risk stratification]]></article-title>
<source><![CDATA[Circ Cardiovasc Imaging]]></source>
<year>2020</year>
<volume>13</volume>
</nlm-citation>
</ref>
<ref id="B248">
<label>248</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bos]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ackerman]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2010</year>
<volume>106</volume>
<page-range>1481-6</page-range></nlm-citation>
</ref>
<ref id="B249">
<label>249</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Efthimiadis]]></surname>
<given-names><![CDATA[GK]]></given-names>
</name>
<name>
<surname><![CDATA[Parcharidou]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
<name>
<surname><![CDATA[Giannakoulas]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Left ventricular outflow tract obstruction as a risk factor for sudden cardiac death in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2009</year>
<volume>104</volume>
<page-range>695-9</page-range></nlm-citation>
</ref>
<ref id="B250">
<label>250</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spirito]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Autore]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rapezzi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Syncope and risk of sudden death in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2009</year>
<volume>119</volume>
<page-range>1703-10</page-range></nlm-citation>
</ref>
<ref id="B251">
<label>251</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Christiaans]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Van Engelen]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Van Langen]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy:systematic review of clinical risk markers]]></article-title>
<source><![CDATA[Europace]]></source>
<year>2010</year>
<volume>12</volume>
<page-range>313-21</page-range></nlm-citation>
</ref>
<ref id="B252">
<label>252</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perillo]]></surname>
<given-names><![CDATA[EF]]></given-names>
</name>
<name>
<surname><![CDATA[Canciello]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Borrelli]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis and clinical implication of left ventricular aneurysm in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Diagnostics (Basel)]]></source>
<year>2023</year>
<volume>13</volume>
<page-range>1848</page-range></nlm-citation>
</ref>
<ref id="B253">
<label>253</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Briasoulis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mallikethi-Reddy]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Palla]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Alesh]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Afonso]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Myocardial fibrosis on cardiac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy:a meta-analysis]]></article-title>
<source><![CDATA[Heart]]></source>
<year>2015</year>
<volume>101</volume>
<page-range>1406-11</page-range></nlm-citation>
</ref>
<ref id="B254">
<label>254</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zamorano]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Anastasakis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Borger]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy:The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2014</year>
<volume>35</volume>
<page-range>2733-79</page-range></nlm-citation>
</ref>
<ref id="B255">
<label>255</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[O'Mahony]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Esteban]]></surname>
<given-names><![CDATA[MTT]]></given-names>
</name>
<name>
<surname><![CDATA[Lambiase]]></surname>
<given-names><![CDATA[PD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Heart]]></source>
<year>2013</year>
<volume>99</volume>
<page-range>534-41</page-range></nlm-citation>
</ref>
<ref id="B256">
<label>256</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Wan]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Variable and limited predictive value of the European Society of Cardiology hypertrophic cardiomyopathy sudden-death risk model:a meta-analysis]]></article-title>
<source><![CDATA[Can J Cardiol]]></source>
<year>2019</year>
<volume>35</volume>
<page-range>1791-9</page-range></nlm-citation>
</ref>
<ref id="B257">
<label>257</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Elliott]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Varnava]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Poloniecki]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rowland]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[McKenna]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>1999</year>
<volume>33</volume>
<page-range>1596-601</page-range></nlm-citation>
</ref>
<ref id="B258">
<label>258</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cecchi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Epstein]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>1989</year>
<volume>13</volume>
<page-range>1283-8</page-range></nlm-citation>
</ref>
<ref id="B259">
<label>259</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vriesendorp]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Schinkel]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Van Cleemput]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy:patient outcomes, rate of appropriate and inappropriate interventions, and complications]]></article-title>
<source><![CDATA[Am Heart J]]></source>
<year>2013</year>
<volume>166</volume>
<page-range>496-502</page-range></nlm-citation>
</ref>
<ref id="B260">
<label>260</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Spirito]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Shen]]></surname>
<given-names><![CDATA[W-K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2007</year>
<volume>298</volume>
<page-range>405-12</page-range></nlm-citation>
</ref>
<ref id="B261">
<label>261</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Rowin]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Wessler]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enhanced American College of Cardiology/American Heart Association strategy for prevention of sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[JAMA Cardiol]]></source>
<year>2019</year>
<volume>4</volume>
<page-range>644-57</page-range></nlm-citation>
</ref>
<ref id="B262">
<label>262</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iturralde]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Reyes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Manejo del paciente con miocardiopatía hipertrófica y sobreviviente de muerte súbita]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Llamas Esperón]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Cossío Arañada]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Alexanderson Rosas]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Miocardiopatía hipertrófica]]></source>
<year>2021</year>
<page-range>163-70</page-range><publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[PyDESA]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B263">
<label>263</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Al-Khatib]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Stevenson]]></surname>
<given-names><![CDATA[WG]]></given-names>
</name>
<name>
<surname><![CDATA[Ackerman]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2017 AHA/ACC/HR Guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death:executive summary]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2018</year>
<volume>138</volume>
<page-range>71</page-range></nlm-citation>
</ref>
<ref id="B264">
<label>264</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Elliott]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Gimeno]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Thaman]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Heart]]></source>
<year>2006</year>
<volume>92</volume>
<page-range>785-91</page-range></nlm-citation>
</ref>
<ref id="B265">
<label>265</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nicod]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Polikar]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Peterson]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertrophic cardiomyopathy and sudden death]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1988</year>
<volume>318</volume>
<page-range>1255-7</page-range></nlm-citation>
</ref>
<ref id="B266">
<label>266</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vriesendorp]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Schinkel]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Liebregts]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Validation of the 2014 ESC guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circ Arrhythm Electrophysiol]]></source>
<year>2015</year>
<volume>8</volume>
<page-range>829-35</page-range></nlm-citation>
</ref>
<ref id="B267">
<label>267</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Casey]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Garberich]]></surname>
<given-names><![CDATA[RF]]></given-names>
</name>
<name>
<surname><![CDATA[Rowin]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Independent assessment of the European Society of Cardiology sudden death risk model for hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2015</year>
<volume>116</volume>
<page-range>757-64</page-range></nlm-citation>
</ref>
<ref id="B268">
<label>268</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Quiroga]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ochoa]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Validation of the 2014 European Society of Cardiology sudden cardiac death risk prediction model in hypertrophic cardiomyopathy in a reference center in South America]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2016</year>
<volume>118</volume>
<page-range>121-6</page-range></nlm-citation>
</ref>
<ref id="B269">
<label>269</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stroumpoulis]]></surname>
<given-names><![CDATA[KI]]></given-names>
</name>
<name>
<surname><![CDATA[Pantazopoulos]]></surname>
<given-names><![CDATA[IN]]></given-names>
</name>
<name>
<surname><![CDATA[Xanthos]]></surname>
<given-names><![CDATA[TT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertrophic cardiomyopathy and sudden cardiac death]]></article-title>
<source><![CDATA[World J Cardiol]]></source>
<year>2010</year>
<volume>2</volume>
<page-range>289-98</page-range></nlm-citation>
</ref>
<ref id="B270">
<label>270</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marstrand]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Day]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertrophic cardiomyopathy with left ventricular systolic dysfunction:insights from the SHaRe registry]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2020</year>
<volume>141</volume>
<page-range>1371-83</page-range></nlm-citation>
</ref>
<ref id="B271">
<label>271</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Neubauer]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kolm]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Ho]]></surname>
<given-names><![CDATA[CY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM registry]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2019</year>
<volume>74</volume>
<page-range>2333-45</page-range></nlm-citation>
</ref>
<ref id="B272">
<label>272</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cui]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Tse]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mid-ventricular obstructive hypertrophic cardiomyopathy with apical aneurysm:an important subtype of arrhythmogenic cardiomyopathy]]></article-title>
<source><![CDATA[Ann Noninvasive Electrocardiol]]></source>
<year>2019</year>
<volume>24</volume>
</nlm-citation>
</ref>
<ref id="B273">
<label>273</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Minami]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Haruki]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hagiwara]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phenotypic overlap in hypertrophic cardiomyopathy:apical hypertrophy, midventricular obstruction, and apical aneurysm]]></article-title>
<source><![CDATA[J Cardiol]]></source>
<year>2014</year>
<volume>64</volume>
<page-range>463-9</page-range></nlm-citation>
</ref>
<ref id="B274">
<label>274</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Papanastasiou]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Zegkos]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kokkinidis]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
<name>
<surname><![CDATA[Parcharidou]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[-Karamitsos]]></surname>
<given-names><![CDATA[TD]]></given-names>
</name>
<name>
<surname><![CDATA[Efthimiadis]]></surname>
<given-names><![CDATA[GK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic role of left ventricular apical aneurysm in hypertrophic cardiomyopathy:a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Int J Cardiol]]></source>
<year>2021</year>
<volume>339</volume>
<page-range>108</page-range></nlm-citation>
</ref>
<ref id="B275">
<label>275</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kamp]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
<name>
<surname><![CDATA[Chery]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kosinski]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk stratification using late gadolinium enhancement on cardiac magnetic resonance imaging in patients with hypertrophic cardiomyopathy:a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Prog Cardiovasc Dis]]></source>
<year>2021</year>
<volume>66</volume>
<page-range>10-6</page-range></nlm-citation>
</ref>
<ref id="B276">
<label>276</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[ED]]></given-names>
</name>
<name>
<surname><![CDATA[Tome]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[McGrath]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Exercise hemodynamics in hypertrophic cardiomyopathy identify risk of incident heart failure but not ventricular arrhythmias or sudden cardiac death]]></article-title>
<source><![CDATA[Int J Cardiol]]></source>
<year>2019</year>
<volume>274</volume>
<page-range>226-31</page-range></nlm-citation>
</ref>
<ref id="B277">
<label>277</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sadoul]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Prasad]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Elliott]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Bannerjee]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Frenneaux]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[McKenna]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1997</year>
<volume>96</volume>
<page-range>2987-91</page-range></nlm-citation>
</ref>
<ref id="B278">
<label>278</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Frenneaux]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Counihan]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Caforio]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Chikamori]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[McKenna]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1990</year>
<volume>82</volume>
<page-range>1995-2002</page-range></nlm-citation>
</ref>
<ref id="B279">
<label>279</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Petersen]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Jerosch-Herold]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hudsmith]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evidence for microvascular dysfunction in hypertrophic cardiomyopathy:new insights from multiparametric magnetic resonance imaging]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2007</year>
<volume>115</volume>
<page-range>2418-25</page-range></nlm-citation>
</ref>
<ref id="B280">
<label>280</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[van Velzen]]></surname>
<given-names><![CDATA[HG]]></given-names>
</name>
<name>
<surname><![CDATA[Vriesendorp]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Oldenburg]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Value of genetic testing for the prediction of long-term outcome in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2016</year>
<volume>118</volume>
<page-range>881-7</page-range></nlm-citation>
</ref>
<ref id="B281">
<label>281</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vamos]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Healey]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Implantable cardioverter-defibrillator therapy in hypertrophic cardiomyopathy:a SIMPLE sub study]]></article-title>
<source><![CDATA[Heart Rhythm]]></source>
<year>2018</year>
<volume>15</volume>
<page-range>386-92</page-range></nlm-citation>
</ref>
<ref id="B282">
<label>282</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lambiase]]></surname>
<given-names><![CDATA[PD]]></given-names>
</name>
<name>
<surname><![CDATA[Barr]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Theuns]]></surname>
<given-names><![CDATA[DAMJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Worldwide experience with a totally subcutaneous implantable defibrillator:early results from the EFFORTLESS S-ICD Registry]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2014</year>
<volume>35</volume>
<page-range>1657-65</page-range></nlm-citation>
</ref>
<ref id="B283">
<label>283</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Providência]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kramer]]></surname>
<given-names><![CDATA[DB]]></given-names>
</name>
<name>
<surname><![CDATA[Pimenta]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Transvenous implantable cardioverter-defibrillator (ICD) lead performance:a meta-analysis of observational studies]]></article-title>
<source><![CDATA[J Am Heart Assoc]]></source>
<year>2015</year>
<volume>4</volume>
</nlm-citation>
</ref>
<ref id="B284">
<label>284</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Defaye]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Boveda]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Klug]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dual vs. single-chamber defibrillators for primary prevention of sudden cardiac death:long-term follow-up of the défibrillateur automatique implantable-prevention registry]]></article-title>
<source><![CDATA[Eur J Echocardiogr]]></source>
<year>2017</year>
<volume>19</volume>
<page-range>1478-84</page-range></nlm-citation>
</ref>
<ref id="B285">
<label>285</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Okamura]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Friedman]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Inoue]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Single-coil defibrillator leads yield satisfactory defibrillation safety margin in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circ J]]></source>
<year>2016</year>
<volume>80</volume>
<page-range>2199-203</page-range></nlm-citation>
</ref>
<ref id="B286">
<label>286</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[Z-Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[Z-T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficiencies and complications of dual chamber versus single chamber implantable cardioverter defibrillators in secondary sudden cardiac death prevention:a meta-analysis]]></article-title>
<source><![CDATA[Lung Cir]]></source>
<year>2016</year>
<volume>25</volume>
<page-range>148-54</page-range></nlm-citation>
</ref>
<ref id="B287">
<label>287</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kappenberger]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Linde]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Daubert]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study. PIC Study Group]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>1997</year>
<volume>18</volume>
<page-range>1249-56</page-range></nlm-citation>
</ref>
<ref id="B288">
<label>288</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mickelsen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bathina]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hsu]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Doppler evaluation of the descending aorta in patients with hypertrophic cardiomyopathy:potential for assessing the functional significance of outflow tract gradients and for optimizing pacemaker function]]></article-title>
<source><![CDATA[J Interv Card Electrophysiol]]></source>
<year>2004</year>
<volume>11</volume>
<page-range>47-53</page-range></nlm-citation>
</ref>
<ref id="B289">
<label>289</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Nishimura]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[McKenna]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY)]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1999</year>
<volume>99</volume>
<page-range>2927-33</page-range></nlm-citation>
</ref>
<ref id="B290">
<label>290</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hauser]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[Maisel]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
<name>
<surname><![CDATA[Friedman]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Longevity of Sprint Fidelis implantable cardioverter-defibrillator leads and risk factors for failure:implications for patient management]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2011</year>
<volume>123</volume>
<page-range>358-63</page-range></nlm-citation>
</ref>
<ref id="B291">
<label>291</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tascón]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Albarrán]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Miocardiopatía hipertrófica obstructiva y estimulación secuencial auriculoventricular. Resultados agudos y seguimiento a largo plazo. Siete años de experiencia]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2000</year>
<volume>53</volume>
<page-range>1028-39</page-range></nlm-citation>
</ref>
<ref id="B292">
<label>292</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yancy]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
<name>
<surname><![CDATA[Jessup]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bozkurt]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2013 ACCF/AHA guideline for the management of heart failure:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2013</year>
<volume>128</volume>
<page-range>327</page-range></nlm-citation>
</ref>
<ref id="B293">
<label>293</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rogers]]></surname>
<given-names><![CDATA[DPS]]></given-names>
</name>
<name>
<surname><![CDATA[Marazia]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chow]]></surname>
<given-names><![CDATA[AW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of biventricular pacing on symptoms and cardiac remodeling in patients with end-stage hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Eur J Heart Fail]]></source>
<year>2008</year>
<volume>10</volume>
<page-range>507-13</page-range></nlm-citation>
</ref>
<ref id="B294">
<label>294</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Jin]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Hua]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical outcome of cardiac resynchronization therapy in dilated-phase hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[J Geriatr Cardiol]]></source>
<year>2017</year>
<volume>14</volume>
<page-range>238-44</page-range></nlm-citation>
</ref>
<ref id="B295">
<label>295</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Killu]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[J-Y]]></given-names>
</name>
<name>
<surname><![CDATA[Sara]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiac resynchronization therapy in patients with end-stage hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Eur J Echocardiogr]]></source>
<year>2018</year>
<volume>20</volume>
<page-range>82-8</page-range></nlm-citation>
</ref>
<ref id="B296">
<label>296</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rowin]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Mohanty]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Madias]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Benefit of cardiac resynchronization therapy in end-stage nonobstructive hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[JACC Clin Electrophysiol]]></source>
<year>2019</year>
<volume>5</volume>
<page-range>131-3</page-range></nlm-citation>
</ref>
<ref id="B297">
<label>297</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cappelli]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Morini]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pieragnoli]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiac resynchronization therapy for end-stage hypertrophic cardiomyopathy:the need for disease-specific criteria]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2018</year>
<volume>71</volume>
<page-range>464-6</page-range></nlm-citation>
</ref>
<ref id="B298">
<label>298</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kusumoto]]></surname>
<given-names><![CDATA[FM]]></given-names>
</name>
<name>
<surname><![CDATA[Schoenfeld]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Barrett]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay:a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2019</year>
<volume>140</volume>
<page-range>482</page-range></nlm-citation>
</ref>
<ref id="B299">
<label>299</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ostman-Smith]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertrophic cardiomyopathy in childhood and adolescence —strategies to prevent sudden death]]></article-title>
<source><![CDATA[Fundam Clin Pharmacol]]></source>
<year>2010</year>
<volume>24</volume>
<page-range>637-52</page-range></nlm-citation>
</ref>
<ref id="B300">
<label>300</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lipshultz]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Orav]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Wilkinson]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk stratification at diagnosis for children with hypertrophic cardiomyopathy:an analysis of data from the Pediatric Cardiomyopathy Registry]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2013</year>
<volume>382</volume>
<page-range>1889-97</page-range></nlm-citation>
</ref>
<ref id="B301">
<label>301</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bharucha]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Daubeney]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[NACCS (National Australian Childhood Cardiomyopathy Study) Investigators. Sudden death in childhood cardiomyopathy:results from a long-term national population-based study]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2015</year>
<volume>65</volume>
<page-range>2302-10</page-range></nlm-citation>
</ref>
<ref id="B302">
<label>302</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Norrish]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Qu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Field]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[External validation of the HCM Risk-Kids model for predicting sudden cardiac death in childhood hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Eur J Prev Cardiol]]></source>
<year>2022</year>
<volume>29</volume>
<page-range>678-86</page-range></nlm-citation>
</ref>
<ref id="B303">
<label>303</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Norrish]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cantarutti]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Pissaridou]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy:a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Eur J Prev Cardiol]]></source>
<year>2017</year>
<volume>24</volume>
<page-range>1220-30</page-range></nlm-citation>
</ref>
<ref id="B304">
<label>304</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Raja]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Farhad]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Valente]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence and progression of late gadolinium enhancement in children and adolescents with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2018</year>
<volume>138</volume>
<page-range>782-92</page-range></nlm-citation>
</ref>
<ref id="B305">
<label>305</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Petryka-Mazurkiewicz]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ziolkowska]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Kowalczyk-Domagala]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[LGE for risk stratification in primary prevention in children with HCM]]></article-title>
<source><![CDATA[JACC Cardiovasc Imaging]]></source>
<year>2020</year>
<volume>13</volume>
<page-range>2684-6</page-range></nlm-citation>
</ref>
<ref id="B306">
<label>306</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kansal]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Mookadam]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Tajik]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drink more, and eat less:advice in obstructive hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2010</year>
<volume>106</volume>
<page-range>1313-6</page-range></nlm-citation>
</ref>
<ref id="B307">
<label>307</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gilligan]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Marsonis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Joshi]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular and hormonal responses to a meal in hypertrophic cardiomyopathy:a comparison of patients with and without postprandial exacerbation of symptoms]]></article-title>
<source><![CDATA[Clin Cardiol]]></source>
<year>1996</year>
<volume>19</volume>
<page-range>129-35</page-range></nlm-citation>
</ref>
<ref id="B308">
<label>308</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Feiner]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Arabadjian]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Winson]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Chaudhry]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Sherrid]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Post-prandial upright exercise echocardiography in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[JACC]]></source>
<year>2013</year>
<volume>61</volume>
<page-range>2487-8</page-range></nlm-citation>
</ref>
<ref id="B309">
<label>309</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zuchinali]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Souza]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
<name>
<surname><![CDATA[Pimentel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Short-term effects of high-dose caffeine on cardiac arrhythmias in patients with heart failure:a randomized clinical trial]]></article-title>
<source><![CDATA[JAMA Intern Med]]></source>
<year>2016</year>
<volume>176</volume>
<page-range>1752-9</page-range></nlm-citation>
</ref>
<ref id="B310">
<label>310</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caldeira]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Martins]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Alves]]></surname>
<given-names><![CDATA[LB]]></given-names>
</name>
<name>
<surname><![CDATA[Pereira]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Caffeine does not increase the risk of auricular fibrillation:a systematic review and meta-analysis of observational studies]]></article-title>
<source><![CDATA[Heart]]></source>
<year>2013</year>
<volume>99</volume>
<page-range>1383-9</page-range></nlm-citation>
</ref>
<ref id="B311">
<label>311</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Enriquez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Frankel]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Arrhythmogenic effects of energy drinks]]></article-title>
<source><![CDATA[J Cardiovasc Electrophysiol]]></source>
<year>2017</year>
<volume>28</volume>
<page-range>711-7</page-range></nlm-citation>
</ref>
<ref id="B312">
<label>312</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Paz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Jortner]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Tunick]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effect of the ingestion of ethanol on obstruction of the left ventricular outflow tract in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1996</year>
<volume>335</volume>
<page-range>938-41</page-range></nlm-citation>
</ref>
<ref id="B313">
<label>313</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ettinger]]></surname>
<given-names><![CDATA[PO]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[CF]]></given-names>
</name>
<name>
<surname><![CDATA[De La Cruz Jr]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Weisse]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Ahmed]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Regan]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Arrhythmias and the “holiday heart”:alcohol-associated cardiac rhythm disorders]]></article-title>
<source><![CDATA[Am Heart J]]></source>
<year>1978</year>
<volume>95</volume>
<page-range>555-62</page-range></nlm-citation>
</ref>
<ref id="B314">
<label>314</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kodama]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Saito]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Tanaka]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alcohol consumption and risk of auricular fibrillation:a meta-analysis]]></article-title>
<source><![CDATA[JACC]]></source>
<year>2011</year>
<volume>57</volume>
<page-range>427-36</page-range></nlm-citation>
</ref>
<ref id="B315">
<label>315</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leigh]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Kaplan]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Swett]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Smoking intensity and duration is associated with cardiac structure and function:the ECHOcardiographic Study of Hispanics/Latinos]]></article-title>
<source><![CDATA[Open Heart]]></source>
<year>2017</year>
<volume>4</volume>
</nlm-citation>
</ref>
<ref id="B316">
<label>316</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jouanjus]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Lapeyre-Mestre]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Micallef]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[French Association of the Regional Abuse and Dependence Monitoring Centres (CEIP-A) Working Group on Cannabis Complications. Cannabis use:signal of increasing risk of serious cardiovascular disorders]]></article-title>
<source><![CDATA[J Am Heart Assoc]]></source>
<year>2014</year>
<volume>3</volume>
</nlm-citation>
</ref>
<ref id="B317">
<label>317</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pelliccia]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fagard]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bjornstad]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recommendations for competitive sports participation in athletes with cardiovascular disease:a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2005</year>
<volume>26</volume>
<page-range>1422-45</page-range></nlm-citation>
</ref>
<ref id="B318">
<label>318</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Levine]]></surname>
<given-names><![CDATA[GN]]></given-names>
</name>
<name>
<surname><![CDATA[Steinke]]></surname>
<given-names><![CDATA[EE]]></given-names>
</name>
<name>
<surname><![CDATA[Bakaeen]]></surname>
<given-names><![CDATA[FG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sexual activity and cardiovascular disease:a scientific statement from the American Heart Association]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2012</year>
<volume>125</volume>
<page-range>1058-72</page-range></nlm-citation>
</ref>
<ref id="B319">
<label>319</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ko]]></surname>
<given-names><![CDATA[DT]]></given-names>
</name>
<name>
<surname><![CDATA[Hebert]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
<name>
<surname><![CDATA[Coffey]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Sedrakyan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Curtis]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Krumholz]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2002</year>
<volume>288</volume>
<page-range>351-7</page-range></nlm-citation>
</ref>
<ref id="B320">
<label>320</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spirito]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Seidman]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[McKenna]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The management of hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1997</year>
<volume>336</volume>
<page-range>775-85</page-range></nlm-citation>
</ref>
<ref id="B321">
<label>321</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Adelman]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Gramiak]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term propranolol therapy in muscular subaortic stenosis]]></article-title>
<source><![CDATA[Br Heart J]]></source>
<year>1970</year>
<volume>32</volume>
<page-range>804-11</page-range></nlm-citation>
</ref>
<ref id="B322">
<label>322</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sherrid]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Pearle]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Gunsburg]]></surname>
<given-names><![CDATA[DZ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mechanism of benefit of negative inotropes in obstructive hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1998</year>
<volume>97</volume>
<page-range>41-7</page-range></nlm-citation>
</ref>
<ref id="B323">
<label>323</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harrison]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Braunwald]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Glick]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Mason]]></surname>
<given-names><![CDATA[DT]]></given-names>
</name>
<name>
<surname><![CDATA[Chidsey]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Ross Jr]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of beta-adrenergic blockade on the circulation with particular reference to observations in patients with hypertrophic subaortic stenosis]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1964</year>
<volume>29</volume>
<page-range>84-98</page-range></nlm-citation>
</ref>
<ref id="B324">
<label>324</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stenson]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
<name>
<surname><![CDATA[Flamm Jr]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Harrison]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Hancock]]></surname>
<given-names><![CDATA[EW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertrophic subaortic stenosis. Clinical and hemodynamic effects of long-term propranolol therapy]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>1973</year>
<volume>31</volume>
<page-range>763-73</page-range></nlm-citation>
</ref>
<ref id="B325">
<label>325</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Flamm]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Harrison]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Hancock]]></surname>
<given-names><![CDATA[EW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Muscular subaortic stenosis. Prevention of outflow obstruction with propranolol]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1968</year>
<volume>38</volume>
<page-range>846-58</page-range></nlm-citation>
</ref>
<ref id="B326">
<label>326</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tendera]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wycisk]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Schneeweiss]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Polonski]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Wodnieck]]></surname>
<given-names><![CDATA[IJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of sotalol on arrhythmias and exercise tolerance in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Cardiology]]></source>
<year>1993</year>
<volume>82</volume>
<page-range>335-42</page-range></nlm-citation>
</ref>
<ref id="B327">
<label>327</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cabrera-Bueno]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Beta-blocker therapy for dynamic LVOT obstruction induced by exercise]]></article-title>
<source><![CDATA[Int J Cardiol]]></source>
<year>2009</year>
<volume>117</volume>
<page-range>222-6</page-range></nlm-citation>
</ref>
<ref id="B328">
<label>328</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gilligan]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[WL]]></given-names>
</name>
<name>
<surname><![CDATA[Joshi]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A double-blind, placebo controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[JACC]]></source>
<year>1993</year>
<volume>21</volume>
<page-range>1672-9</page-range></nlm-citation>
</ref>
<ref id="B329">
<label>329</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Braunwald]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1967</year>
<volume>35</volume>
<page-range>847-51</page-range></nlm-citation>
</ref>
<ref id="B330">
<label>330</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fifer]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Vlahakes]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of symptoms in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2008</year>
<volume>117</volume>
<page-range>429-39</page-range></nlm-citation>
</ref>
<ref id="B331">
<label>331</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bonow]]></surname>
<given-names><![CDATA[RO]]></given-names>
</name>
<name>
<surname><![CDATA[Frederick]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Bacharach]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atrial systole and left ventricular filling in hypertrophic cardiomyopathy:effect of verapamil]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>1983</year>
<volume>51</volume>
<page-range>1386-91</page-range></nlm-citation>
</ref>
<ref id="B332">
<label>332</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bonow]]></surname>
<given-names><![CDATA[RO]]></given-names>
</name>
<name>
<surname><![CDATA[Dilsizian]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Rosing]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bacharach]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Green]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy:short- and long-term effects]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1985</year>
<volume>72</volume>
<page-range>853-64</page-range></nlm-citation>
</ref>
<ref id="B333">
<label>333</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bonow]]></surname>
<given-names><![CDATA[RO]]></given-names>
</name>
<name>
<surname><![CDATA[Rosing]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Bacharach]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1981</year>
<volume>64</volume>
<page-range>787-96</page-range></nlm-citation>
</ref>
<ref id="B334">
<label>334</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hess]]></surname>
<given-names><![CDATA[OM]]></given-names>
</name>
<name>
<surname><![CDATA[Murakami]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Krayenbuehl]]></surname>
<given-names><![CDATA[HP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Does verapamil improve left ventricular relaxation in patients with myocardial hypertrophy?]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1986</year>
<volume>74</volume>
<page-range>530-43</page-range></nlm-citation>
</ref>
<ref id="B335">
<label>335</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Udelson]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Bonow]]></surname>
<given-names><![CDATA[RO]]></given-names>
</name>
<name>
<surname><![CDATA[O'Gara]]></surname>
<given-names><![CDATA[PT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1989</year>
<volume>79</volume>
<page-range>1052-60</page-range></nlm-citation>
</ref>
<ref id="B336">
<label>336</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gistri]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Cecchi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Choudhury]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of verapamil on absolute myocardial blood flow in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>1994</year>
<volume>74</volume>
<page-range>363-8</page-range></nlm-citation>
</ref>
<ref id="B337">
<label>337</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Epstein]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Rosing]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Verapamil:its potential for causing serious complications in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1981</year>
<volume>64</volume>
<page-range>437-41</page-range></nlm-citation>
</ref>
<ref id="B338">
<label>338</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Petkow Dimitrow]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Krzanowski]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Nizankowski]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Szczeklik]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Dubiel]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of verapamil on systolic and diastolic coronary blood flow velocity in asymptomatic and mildly symptomatic patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Heart]]></source>
<year>2000</year>
<volume>83</volume>
<page-range>262-6</page-range></nlm-citation>
</ref>
<ref id="B339">
<label>339</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosing]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Kent]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Epstein]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Verapamil therapy:a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy II. Effects on exercise capacity and symptomatic status]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1979</year>
<volume>60</volume>
<page-range>1208-13</page-range></nlm-citation>
</ref>
<ref id="B340">
<label>340</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chatterjee]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Raff]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Parmley]]></surname>
<given-names><![CDATA[WW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertrophic cardiomyopathy —therapy with slow channel inhibiting agents]]></article-title>
<source><![CDATA[Prog Cardiovasc Dis]]></source>
<year>1982</year>
<volume>25</volume>
<page-range>193-210</page-range></nlm-citation>
</ref>
<ref id="B341">
<label>341</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosing]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Kent]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Borer]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Verapamil therapy:a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy, I:hemodynamic effects]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1979</year>
<volume>60</volume>
<page-range>1201-7</page-range></nlm-citation>
</ref>
<ref id="B342">
<label>342</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosing]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Condit]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Verapamil therapy:a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy, III:effects of long-term administration]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>1981</year>
<volume>48</volume>
<page-range>545-53</page-range></nlm-citation>
</ref>
<ref id="B343">
<label>343</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sherrid]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Barac]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[McKenna]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[JACC]]></source>
<year>2005</year>
<volume>45</volume>
<page-range>1251-8</page-range></nlm-citation>
</ref>
<ref id="B344">
<label>344</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sherrid]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Shetty]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Winson]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with beta-blockade or verapamil]]></article-title>
<source><![CDATA[Circ Heart Fail]]></source>
<year>2013</year>
<volume>6</volume>
<page-range>694-702</page-range></nlm-citation>
</ref>
<ref id="B345">
<label>345</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kajimoto]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Imai]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Minami]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Kasanuki]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of acute reduction in left ventricular outflow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus cibenzoline]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2010</year>
<volume>106</volume>
<page-range>1307-12</page-range></nlm-citation>
</ref>
<ref id="B346">
<label>346</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sherrid]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Arabadjian]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A primer of disopyramide treatment of obstructive hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Prog Cardiovasc Dis]]></source>
<year>2012</year>
<volume>6</volume>
<page-range>483-92</page-range></nlm-citation>
</ref>
<ref id="B347">
<label>347</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Verlinden]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
<name>
<surname><![CDATA[Coons]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Disopyramide for hypertrophic cardiomyopathy:a pragmatic reappraisal of an old drug]]></article-title>
<source><![CDATA[Pharmacotherapy]]></source>
<year>2015</year>
<volume>35</volume>
<page-range>1164-72</page-range></nlm-citation>
</ref>
<ref id="B348">
<label>348</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Minami]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Kajimoto]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kawana]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Synergistic effect of dual chamber pacing and disopyramide in obstructive hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Int J Cardiol]]></source>
<year>2010</year>
<volume>141</volume>
<page-range>195-7</page-range></nlm-citation>
</ref>
<ref id="B349">
<label>349</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Adler]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fourey]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Weissler-Snir]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety of outpatient initiation of disopyramide for obstructive hypertrophic cardiomyopathy patients]]></article-title>
<source><![CDATA[J Am Heart Assoc]]></source>
<year>2017</year>
<volume>6</volume>
</nlm-citation>
</ref>
<ref id="B350">
<label>350</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Teichman]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrick]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
<name>
<surname><![CDATA[Matos]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Waspe]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Fisher]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Disopyramide-pyridostigmine interaction:selective reversal of anticholinergic symptoms with preservation of antiarrhythmic effect]]></article-title>
<source><![CDATA[JACC]]></source>
<year>1987</year>
<volume>3</volume>
<page-range>633-41</page-range></nlm-citation>
</ref>
<ref id="B351">
<label>351</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grillo]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Erve]]></surname>
<given-names><![CDATA[JCL]]></given-names>
</name>
<name>
<surname><![CDATA[Dick]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin]]></article-title>
<source><![CDATA[Xenobiotica]]></source>
<year>2019</year>
<volume>49</volume>
<page-range>718-33</page-range></nlm-citation>
</ref>
<ref id="B352">
<label>352</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heitner]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
<name>
<surname><![CDATA[Jacoby]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Lester]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mavacamten treatment for obstructive hypertrophic cardiomyopathy:a clinical trial]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2019</year>
<volume>170</volume>
<page-range>741-8</page-range></nlm-citation>
</ref>
<ref id="B353">
<label>353</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heitner]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Jacoby]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Lester]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Sehnert]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term safety and effectiveness of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy patients, PIONEER-open label extension study (PIONEER-OLE)]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2019</year>
<volume>73</volume>
<numero>9 Suppl 1</numero>
<issue>9 Suppl 1</issue>
<page-range>951</page-range></nlm-citation>
</ref>
<ref id="B354">
<label>354</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Heitner]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
<name>
<surname><![CDATA[Jacoby]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term safety and effectiveness of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients (pts):update from PIONEER open-label extension (PIONEER-OLE) study]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2019</year>
<volume>40</volume>
<numero>Suppl 1</numero>
<issue>Suppl 1</issue>
</nlm-citation>
</ref>
<ref id="B355">
<label>355</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Olivotto]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Oreziak]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Barriales-Villa]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[EXPLORER-HCM Study Investigators. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM):a randomized, double-blind, placebo-controlled, phase 3 trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2020</year>
<volume>396</volume>
<page-range>759-69</page-range></nlm-citation>
</ref>
<ref id="B356">
<label>356</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zaiser]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Sehnert]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Duenas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patient experiences with hypertrophic cardiomyopathy:a conceptual model of symptoms and impacts on quality of life]]></article-title>
<source><![CDATA[J Patient Rep Outcomes]]></source>
<year>2020</year>
<volume>4</volume>
<page-range>102</page-range></nlm-citation>
</ref>
<ref id="B357">
<label>357</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reaney]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Allen]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Sehnert]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ):a new patient-reported outcome (PRO) instrument]]></article-title>
<source><![CDATA[Pharmacoecon Open]]></source>
<year>2022</year>
<volume>6</volume>
<page-range>563-74</page-range></nlm-citation>
</ref>
<ref id="B358">
<label>358</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spertus]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Fine]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Elliott]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM):health status analysis of a randomized, double-blind, placebo-controlled, phase 3 trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2021</year>
<volume>397</volume>
<page-range>2467-75</page-range></nlm-citation>
</ref>
<ref id="B359">
<label>359</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hegde]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Lester]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Solomon]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2021</year>
<volume>78</volume>
<page-range>2518-32</page-range></nlm-citation>
</ref>
<ref id="B360">
<label>360</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ullah]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Tayyaba Rehan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of mavacamten for symptomatic hypertrophic cardiomyopathy —an updated meta-analysis of randomized controlled trials]]></article-title>
<source><![CDATA[Int J Cardiol Heart Vasc]]></source>
<year>2024</year>
<volume>53</volume>
<page-range>101467</page-range></nlm-citation>
</ref>
<ref id="B361">
<label>361</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vyas]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Panchal]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Jain]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluating the efficacy and safety of mavacamten in hypertrophic cardiomyopathy:a systematic review and meta-analysis focusing on qualitative assessment, biomarkers, and cardiac imaging]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2024</year>
<volume>19</volume>
</nlm-citation>
</ref>
<ref id="B362">
<label>362</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Geske]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[McKie]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Ommen]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Sorajja]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[B-type natriuretic peptide and survival in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2013</year>
<volume>61</volume>
<page-range>2456-60</page-range></nlm-citation>
</ref>
<ref id="B363">
<label>363</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Matthia]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[Setteducato]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Elzeneini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Circulating biomarkers in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[J Am Heart Assoc]]></source>
<year>2022</year>
<volume>11</volume>
</nlm-citation>
</ref>
<ref id="B364">
<label>364</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rader]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Choudhury]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Saberi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term safety of mavacamten in patients with obstructive hypertrophic cardiomyopathy:interim results of the MAVA-LONG Term Extension (LTE) study]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2021</year>
<volume>77</volume>
<numero>18 Suppl 1</numero>
<issue>18 Suppl 1</issue>
<page-range>532</page-range></nlm-citation>
</ref>
<ref id="B365">
<label>365</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Desai Milind]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Owens]]></surname>
<given-names><![CDATA[Anjali]]></given-names>
</name>
<name>
<surname><![CDATA[Geske Jeffrey]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2022</year>
<volume>80</volume>
<page-range>95-108</page-range></nlm-citation>
</ref>
<ref id="B366">
<label>366</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fermin]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Saberi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Abraham]]></surname>
<given-names><![CDATA[TP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mavacamten treatment in patients with obstructive and nonobstructive hypertrophic cardiomyopathy:a pooled safety analysis of 5 clinicals trials]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2022</year>
<volume>146</volume>
<page-range>A12690</page-range></nlm-citation>
</ref>
<ref id="B367">
<label>367</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Desai]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Xie]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Projecting the long-term clinical value of mavacamten for the treatment of obstructive hypertrophic cardiomyopathy in the United States:an assessment of net health benefit]]></article-title>
<source><![CDATA[Clin Ther]]></source>
<year>2022</year>
<volume>44</volume>
<page-range>52-66</page-range></nlm-citation>
</ref>
<ref id="B368">
<label>368</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Masri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Choudhury]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2023</year>
<volume>81</volume>
<page-range>34-45</page-range></nlm-citation>
</ref>
<ref id="B369">
<label>369</label><nlm-citation citation-type="">
<article-title xml:lang=""><![CDATA[A phase 3, multi-center, randomized, , double-blind, placebo-controlled trial to evaluate the efficacy and safety of CK-3773274 in adults with symptomatic hypertrophic cardiomyopathy and left ventricular outflow tract obstruction (SEQUOIA-HCM)]]></article-title>
<source><![CDATA[ClinicalTrials.gov]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B370">
<label>370</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cecchi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Olivotto]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Montereggi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Squillatini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Dolara]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy:assessment in an unselected non referral-based patient population]]></article-title>
<source><![CDATA[Heart]]></source>
<year>1998</year>
<volume>79</volume>
<page-range>331-6</page-range></nlm-citation>
</ref>
<ref id="B371">
<label>371</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Robinson]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Frenneaux]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Stockins]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atrial fibrillation in hypertrophic cardiomyopathy:a longitudinal study]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>1990</year>
<volume>15</volume>
<page-range>1279-85</page-range></nlm-citation>
</ref>
<ref id="B372">
<label>372</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oliveri]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Pepe]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bongiorno]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertrophic cardiomyopathy and atrial fibrillation:a systematic review and meta-analysis of anticoagulation strategy]]></article-title>
<source><![CDATA[Am J Cardiovasc Drugs]]></source>
<year>2023</year>
<volume>23</volume>
<page-range>269-76</page-range></nlm-citation>
</ref>
<ref id="B373">
<label>373</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sigwart]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1995</year>
<volume>346</volume>
<page-range>211-4</page-range></nlm-citation>
</ref>
<ref id="B374">
<label>374</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jensen]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Prinz]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Horstkotte]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy:low incidence of sudden cardiac death and reduced risk profile]]></article-title>
<source><![CDATA[Heart]]></source>
<year>2013</year>
<volume>99</volume>
<page-range>1012-7</page-range></nlm-citation>
</ref>
<ref id="B375">
<label>375</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nishimura]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Seggewiss]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Schaff]]></surname>
<given-names><![CDATA[HV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertrophic obstructive cardiomyopathy. Surgical myomectomy and septal ablation]]></article-title>
<source><![CDATA[Circ Res]]></source>
<year>2017</year>
<volume>121</volume>
<page-range>771-83</page-range></nlm-citation>
</ref>
<ref id="B376">
<label>376</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sorajja]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alcohol septal ablation for obstructive hypertrophic cardiomyopathy. A word of balance]]></article-title>
<source><![CDATA[JACC]]></source>
<year>2017</year>
<volume>70</volume>
<page-range>489-94</page-range></nlm-citation>
</ref>
<ref id="B377">
<label>377</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oktay]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Arslan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gecit]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Bulat]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Gokce]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Short- and mid-term outcomes of early alcohol septal ablation therapy for patients with mildly symptomatic hypertrophic obstructive cardiomyopathy:a tertiary center experience]]></article-title>
<source><![CDATA[J Clin Med]]></source>
<year>2024</year>
<volume>13</volume>
<page-range>1444</page-range></nlm-citation>
</ref>
<ref id="B378">
<label>378</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fifer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Septal reduction therapy for hypertrophic obstructive cardiomyopathy]]></article-title>
<source><![CDATA[JACC]]></source>
<year>2018</year>
<volume>72</volume>
<page-range>3095-7</page-range></nlm-citation>
</ref>
<ref id="B379">
<label>379</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Douglas Jr]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current state of the roles of alcohol septal ablation and surgical myomectomy in the treatment of hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Cardiovasc Diagn Ther]]></source>
<year>2020</year>
<volume>10</volume>
<page-range>36-44</page-range></nlm-citation>
</ref>
<ref id="B380">
<label>380</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Veselka]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Faber]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Jensen]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of institutional experience on outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy]]></article-title>
<source><![CDATA[Can J Cardiol]]></source>
<year>2018</year>
<volume>34</volume>
<page-range>16-22</page-range></nlm-citation>
</ref>
<ref id="B381">
<label>381</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rigopoulos]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Seggewiss]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Twenty years of alcohol septal ablation in hypertrophic obstructive cardiomyopathy]]></article-title>
<source><![CDATA[Curr Cardiol Rev]]></source>
<year>2016</year>
<volume>12</volume>
<page-range>285-96</page-range></nlm-citation>
</ref>
<ref id="B382">
<label>382</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[LK]]></given-names>
</name>
<name>
<surname><![CDATA[Swaminathan]]></surname>
<given-names><![CDATA[RV]]></given-names>
</name>
<name>
<surname><![CDATA[Looser]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy:US nationwide inpatient database, 2003-2011]]></article-title>
<source><![CDATA[JAMA Cardiol]]></source>
<year>2016</year>
<volume>1</volume>
<page-range>324-32</page-range></nlm-citation>
</ref>
<ref id="B383">
<label>383</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kashtanov]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Rzhannikova]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Chernyshev]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Outcomes of hypertrophic obstructive cardiomyopathy patients undergoing septal ablation with a standard 3 ml dose of ethanol:focus on long term safety]]></article-title>
<source><![CDATA[Catheter Cardiovasc Interv]]></source>
<year>2020</year>
<volume>95</volume>
<page-range>1212-8</page-range></nlm-citation>
</ref>
<ref id="B384">
<label>384</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chiang]]></surname>
<given-names><![CDATA[YP]]></given-names>
</name>
<name>
<surname><![CDATA[Shimada]]></surname>
<given-names><![CDATA[YJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ginns]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Weiner]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Takayama]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Septal myectomy for hypertrophic cardiomyopathy:important surgical knowledge and technical tips in the era of increasing alcohol septal ablation]]></article-title>
<source><![CDATA[Gen Thorac Cardiovasc Surg]]></source>
<year>2018</year>
<volume>66</volume>
<page-range>192-200</page-range></nlm-citation>
</ref>
<ref id="B385">
<label>385</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Osman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kheiri]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Osman]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alcohol septal ablation vs myectomy for symptomatic hypertrophic obstructive cardiomyopathy:Systematic review and meta-analysis]]></article-title>
<source><![CDATA[Clin Cardiol]]></source>
<year>2019</year>
<volume>42</volume>
<page-range>190-7</page-range></nlm-citation>
</ref>
<ref id="B386">
<label>386</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bytyçi]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Nistri]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mörner]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Henein]]></surname>
<given-names><![CDATA[MY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alcohol septal ablation versus septal myectomy treatment of obstructive hypertrophic cardiomyopathy:a systematic review and meta-analysis]]></article-title>
<source><![CDATA[J Clin Med]]></source>
<year>2020</year>
<volume>9</volume>
<page-range>3062</page-range></nlm-citation>
</ref>
<ref id="B387">
<label>387</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liebregts]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Faber]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Jensen]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Outcomes of alcohol septal ablation in younger patients with obstructive hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[JACC Interv]]></source>
<year>2017</year>
<volume>10</volume>
<page-range>1134-43</page-range></nlm-citation>
</ref>
<ref id="B388">
<label>388</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Veselka]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Faber]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Liebregts]]></surname>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Outcome of alcohol septal ablation in mildly symptomatic patients with hypertrophic obstructive cardiomyopathy:a long-term follow-up study based on Euro-Alcohol Septal Ablation registry]]></article-title>
<source><![CDATA[J Am Heart Assoc]]></source>
<year>2017</year>
<volume>6</volume>
</nlm-citation>
</ref>
<ref id="B389">
<label>389</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Batzner]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pfeiffer]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Neugebauer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Survival after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2018</year>
<volume>72</volume>
<page-range>3087-94</page-range></nlm-citation>
</ref>
<ref id="B390">
<label>390</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kimmelstiel]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Zisa]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Kuttab]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guideline-based referral for septal reduction therapy in obstructive hypertrophic cardiomyopathy is associated with excellent clinical outcomes]]></article-title>
<source><![CDATA[Circ Cardiovasc Interv]]></source>
<year>2019</year>
<volume>12</volume>
</nlm-citation>
</ref>
<ref id="B391">
<label>391</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Schaff]]></surname>
<given-names><![CDATA[HV]]></given-names>
</name>
<name>
<surname><![CDATA[Hang]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy:a propensity score matched cohort]]></article-title>
<source><![CDATA[J Thorac Cardiovasc Surg]]></source>
<year>2019</year>
<volume>157</volume>
<page-range>306-15.e3</page-range></nlm-citation>
</ref>
<ref id="B392">
<label>392</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Agarwal]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Tuzcu]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Desai]]></surname>
<given-names><![CDATA[MY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2010</year>
<volume>55</volume>
<page-range>823-34</page-range></nlm-citation>
</ref>
<ref id="B393">
<label>393</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Qutub]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Carson]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A meta-analysis of current status of alcohol septal ablation and surgical myectomy for obstructive hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Catheter Cardiovasc Interv]]></source>
<year>2016</year>
<volume>88</volume>
<page-range>107-15</page-range></nlm-citation>
</ref>
<ref id="B394">
<label>394</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[van der Velde]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Huurman]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Yamasaki]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Frequency and significance of coronary artery disease and myocardial bridging in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2020</year>
<volume>125</volume>
<page-range>1404-12</page-range></nlm-citation>
</ref>
<ref id="B395">
<label>395</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morrow]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Reitz]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Epstein]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Operative treatment in hypertrophic subaortic stenosis. Techniques and the results of pre and postoperative assessments in 83 patients]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1975</year>
<volume>52</volume>
<page-range>88-102</page-range></nlm-citation>
</ref>
<ref id="B396">
<label>396</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McCully]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Nishimura]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Tajik]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Schaff]]></surname>
<given-names><![CDATA[HV]]></given-names>
</name>
<name>
<surname><![CDATA[Danielson]]></surname>
<given-names><![CDATA[GK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Extent of clinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1996</year>
<volume>94</volume>
<page-range>467-71</page-range></nlm-citation>
</ref>
<ref id="B397">
<label>397</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ten Berg]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Suttorp]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Knaepen]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ernst]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Vermeulen]]></surname>
<given-names><![CDATA[FE]]></given-names>
</name>
<name>
<surname><![CDATA[-Jaarsma]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertrophic obstructive cardiomyopathy. Initial results and long-term follow-up after Morrow septal myectomy]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1994</year>
<volume>90</volume>
<page-range>1781-5</page-range></nlm-citation>
</ref>
<ref id="B398">
<label>398</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heric]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Lytle]]></surname>
<given-names><![CDATA[BW]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenkranz]]></surname>
<given-names><![CDATA[ER]]></given-names>
</name>
<name>
<surname><![CDATA[Lever]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Cosgrove]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Surgical management of hypertrophic obstructive cardiomyopathy. Early and late results]]></article-title>
<source><![CDATA[J Thorac Cardiovasc Surg]]></source>
<year>1995</year>
<volume>110</volume>
<page-range>195-206</page-range></nlm-citation>
</ref>
<ref id="B399">
<label>399</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Robbins]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Stinson]]></surname>
<given-names><![CDATA[EB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[J Thorac Cardiovasc Surg]]></source>
<year>1996</year>
<volume>111</volume>
<page-range>586-94</page-range></nlm-citation>
</ref>
<ref id="B400">
<label>400</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schulte]]></surname>
<given-names><![CDATA[HD]]></given-names>
</name>
<name>
<surname><![CDATA[Borisov]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Gams]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Gramsch-Zabel]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Lösse]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Schwartzkopff]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of symptomatic hypertrophic obstructive cardiomyopathy —long-term results after surgical therapy]]></article-title>
<source><![CDATA[Thorac Cardiovasc Surg]]></source>
<year>1999</year>
<volume>47</volume>
<page-range>213-8</page-range></nlm-citation>
</ref>
<ref id="B401">
<label>401</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ommen]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Olivotto]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2005</year>
<volume>46</volume>
<page-range>470-6</page-range></nlm-citation>
</ref>
<ref id="B402">
<label>402</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McIntosh]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Greenberg]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Leon]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Cannon 3rd]]></surname>
<given-names><![CDATA[RO]]></given-names>
</name>
<name>
<surname><![CDATA[Clark]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical and hemodynamic results after mitral valve replacement in patients with obstructive hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Ann Thorac Surg]]></source>
<year>1989</year>
<volume>47</volume>
<page-range>236-46</page-range></nlm-citation>
</ref>
<ref id="B403">
<label>403</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Krajcer]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Leachman]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Cooley]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Ostojic]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Coronado]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mitral valve replacement and septal myomectomy in hypertrophic cardiomyopathy. Ten-year follow-up in 80 patients]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1988</year>
<volume>78</volume>
<page-range>I35-43</page-range></nlm-citation>
</ref>
<ref id="B404">
<label>404</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Teo]]></surname>
<given-names><![CDATA[EP]]></given-names>
</name>
<name>
<surname><![CDATA[Teoh]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Hung]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mitral valve and papillary muscle abnormalities in hypertrophic obstructive cardiomyopathy]]></article-title>
<source><![CDATA[Curr Opin Cardiol]]></source>
<year>2015</year>
<volume>30</volume>
<page-range>475-82</page-range></nlm-citation>
</ref>
<ref id="B405">
<label>405</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kayalar]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Schaff]]></surname>
<given-names><![CDATA[HV]]></given-names>
</name>
<name>
<surname><![CDATA[Daly]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Concomitant septal myectomy at the time of aortic valve replacement for severe aortic stenosis]]></article-title>
<source><![CDATA[Ann Thorac Surg]]></source>
<year>2010</year>
<volume>89</volume>
<page-range>459-64</page-range></nlm-citation>
</ref>
<ref id="B406">
<label>406</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Minakata]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Dearani]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Nishimura]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Extended septal myectomy for hypertrophic obstructive cardiomyopathy with anomalous mitral papillary muscles or chordae]]></article-title>
<source><![CDATA[J Thorac Cardiovasc Surg]]></source>
<year>2004</year>
<volume>127</volume>
<page-range>481-9</page-range></nlm-citation>
</ref>
<ref id="B407">
<label>407</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cui]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The surgical management of hypertrophic obstructive cardiomyopathy with the concomitant mitral valve abnormalities]]></article-title>
<source><![CDATA[Interact Cardiovasc Thorac Surg]]></source>
<year>2015</year>
<volume>21</volume>
<page-range>722-6</page-range></nlm-citation>
</ref>
<ref id="B408">
<label>408</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Panaich]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Chothani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Badheka]]></surname>
<given-names><![CDATA[AO]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Procedural volume and outcomes of septal reduction therapies in patients with hypertrophic obstructive cardiomyopathy]]></article-title>
<source><![CDATA[JAMA. Cardiol]]></source>
<year>2017</year>
<volume>2</volume>
<page-range>110-1</page-range></nlm-citation>
</ref>
<ref id="B409">
<label>409</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hodges]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Rivas]]></surname>
<given-names><![CDATA[CG]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilera]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Surgical management of left ventricular outflow tract obstruction in a specialized hypertrophic obstructive cardiomyopathy center]]></article-title>
<source><![CDATA[J Thorac Cardiovasc Surg]]></source>
<year>2019</year>
<volume>157</volume>
<page-range>2289-99</page-range></nlm-citation>
</ref>
<ref id="B410">
<label>410</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ralph-Edwards]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Woo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[McCrindle]]></surname>
<given-names><![CDATA[BW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertrophic obstructive cardiomyopathy:comparison of outcomes after myectomy or alcohol ablation adjusted by propensity score]]></article-title>
<source><![CDATA[J Thorac Cardiovasc Surg]]></source>
<year>2005</year>
<volume>129</volume>
<page-range>351-8</page-range></nlm-citation>
</ref>
<ref id="B411">
<label>411</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kaple]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
<name>
<surname><![CDATA[Murphy]]></surname>
<given-names><![CDATA[RT]]></given-names>
</name>
<name>
<surname><![CDATA[DiPaola]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mitral valve abnormalities in hypertrophic cardiomyopathy:echocardiographic features and surgical outcomes]]></article-title>
<source><![CDATA[Ann Thorac Surg]]></source>
<year>2008</year>
<volume>85</volume>
<page-range>1527-35</page-range></nlm-citation>
</ref>
<ref id="B412">
<label>412</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ommen]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Semsarian]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Spirito]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Olivotto]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertrophic cardiomyopathy present and future with translation into contemporary cardiovascular medicine]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2014</year>
<volume>64</volume>
<page-range>83-99</page-range></nlm-citation>
</ref>
<ref id="B413">
<label>413</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schaff]]></surname>
<given-names><![CDATA[HV]]></given-names>
</name>
<name>
<surname><![CDATA[Dearani]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Ommen]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Sorajja]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Nishimura]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Expanding the indications for septal myectomy in patients with hypertrophic cardiomyopathy:results of operation in patients with latent obstruction]]></article-title>
<source><![CDATA[J Thorac Cardiovasc Surg]]></source>
<year>2012</year>
<volume>143</volume>
<page-range>303-9</page-range></nlm-citation>
</ref>
<ref id="B414">
<label>414</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dearani]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Ommen]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Gersh]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Schaff]]></surname>
<given-names><![CDATA[HV]]></given-names>
</name>
<name>
<surname><![CDATA[Danielson]]></surname>
<given-names><![CDATA[GK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Surgery insight:septal myectomy for obstructive hypertrophic cardiomyopathy —the Mayo Clinic experience]]></article-title>
<source><![CDATA[Nat Clin Pract Cardiovasc Med]]></source>
<year>2007</year>
<volume>4</volume>
<page-range>503-12</page-range></nlm-citation>
</ref>
<ref id="B415">
<label>415</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schulte]]></surname>
<given-names><![CDATA[HD]]></given-names>
</name>
<name>
<surname><![CDATA[Bircks]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Korfer]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kuhn]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Surgical aspects of typical subaortic and atypical midventricular hypertrophic cardiomyopathy (HOCM)]]></article-title>
<source><![CDATA[Thorac Cardiovasc Surg]]></source>
<year>1981</year>
<volume>29</volume>
<page-range>375-80</page-range></nlm-citation>
</ref>
<ref id="B416">
<label>416</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kirklin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Barratt-Boyes]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertrophic obstructive cardiomyopathy]]></article-title>
<source><![CDATA[En:Cardiac Surgery]]></source>
<year>1992</year>
<edition>2nd ed</edition>
<page-range>1239-62</page-range><publisher-loc><![CDATA[New York ]]></publisher-loc>
<publisher-name><![CDATA[Churchill-Livingston]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B417">
<label>417</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schaff]]></surname>
<given-names><![CDATA[HV]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Dearani]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Apical myectomy:a new surgical technique for management of severely symptomatic patients with apical hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[J Thorac Cardiovasc Surg]]></source>
<year>2010</year>
<volume>139</volume>
<page-range>634-40</page-range></nlm-citation>
</ref>
<ref id="B418">
<label>418</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Keane]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Hynes]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[King]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Shiels]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Feasibility study of percutaneous transvalvular endomyocardial cryoablation for the treatment of hypertrophic obstructive cardiomyopathy]]></article-title>
<source><![CDATA[J Invasive Cardiol]]></source>
<year>2007</year>
<volume>19</volume>
<page-range>247-51</page-range></nlm-citation>
</ref>
<ref id="B419">
<label>419</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lawrenz]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Borchert]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Leuner]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bartelsmeier]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Reinhardt]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Strunk-Mueller]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Endocardial radiofrequency ablation for hypertrophic obstructive cardiomyopathy:acute results and 6 months'follow-up in 19 patients]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2011</year>
<volume>57</volume>
<page-range>572-6</page-range></nlm-citation>
</ref>
<ref id="B420">
<label>420</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nishimura]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Hayes]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Ilstrup]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Holmes Jr]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Tajik]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of dual-chamber pacing on systolic and diastolic function in patients with hypertrophic cardiomyopathy. Acute Doppler echocardiographic and catheterization hemodynamic study]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>1996</year>
<volume>27</volume>
<page-range>421-30</page-range></nlm-citation>
</ref>
<ref id="B421">
<label>421</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Slade]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Sadoul]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Shapiro]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[DDD pacing in hypertrophic cardiomyopathy:a multicenter clinical experience]]></article-title>
<source><![CDATA[Heart]]></source>
<year>1996</year>
<volume>75</volume>
<page-range>44-9</page-range></nlm-citation>
</ref>
<ref id="B422">
<label>422</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Betocchi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Losi]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Piscione]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of dual-chamber pacing in hypertrophic cardiomyopathy on left ventricular outflow tract obstruction and on diastolic function]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>1996</year>
<volume>77</volume>
<page-range>498-502</page-range></nlm-citation>
</ref>
<ref id="B423">
<label>423</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McDonald]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[McWilliams]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[O'Keeffe]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Maurer]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Functional assessment of patients treated with permanent dual chamber pacing as a primary treatment for hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>1988</year>
<volume>9</volume>
<page-range>893-8</page-range></nlm-citation>
</ref>
<ref id="B424">
<label>424</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fananapazir]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Cannon 3rd]]></surname>
<given-names><![CDATA[RO]]></given-names>
</name>
<name>
<surname><![CDATA[Tripodi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Panza]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of dual-chamber permanent pacing in patients with obstructive hypertrophic cardiomyopathy with symptoms refractory to verapamil and beta-adrenergic blocker therapy]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1992</year>
<volume>85</volume>
<page-range>2149-61</page-range></nlm-citation>
</ref>
<ref id="B425">
<label>425</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fananapazir]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Epstein]]></surname>
<given-names><![CDATA[ND]]></given-names>
</name>
<name>
<surname><![CDATA[Curiel]]></surname>
<given-names><![CDATA[RV]]></given-names>
</name>
<name>
<surname><![CDATA[Panza]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Tripodi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Mc-Areavey]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1994</year>
<volume>90</volume>
<page-range>2731-42</page-range></nlm-citation>
</ref>
<ref id="B426">
<label>426</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Radu]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Cojocaru]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Onciul]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiac resynchronization therapy and hypertrophic cardiomyopathy:a comprehensive review]]></article-title>
<source><![CDATA[Biomedicines]]></source>
<year>2023</year>
<volume>11</volume>
<page-range>350</page-range></nlm-citation>
</ref>
<ref id="B427">
<label>427</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jeanrenaud]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Goy]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kappenberger]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of dual chamber pacing in hypertrophic obstructive cardiomyopathy]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1992</year>
<volume>339</volume>
<page-range>1318-23</page-range></nlm-citation>
</ref>
<ref id="B428">
<label>428</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Qintar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Morad]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Alhawasli]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2012</year>
<volume>5</volume>
<page-range>CD008523</page-range></nlm-citation>
</ref>
<ref id="B429">
<label>429</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nishimura]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Trusty]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Hayes]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dual chamber pacing for hypertrophic cardiomyopathy:a randomized, double-blind, crossover trial]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>1997</year>
<volume>29</volume>
<page-range>435-41</page-range></nlm-citation>
</ref>
<ref id="B430">
<label>430</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Galve]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Sambola]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Saldana]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Late benefits of dual-chamber pacing in obstructive hypertrophic cardiomyopathy:a 10-year follow-up study]]></article-title>
<source><![CDATA[Heart]]></source>
<year>2010</year>
<volume>96</volume>
<page-range>352-6</page-range></nlm-citation>
</ref>
<ref id="B431">
<label>431</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kappenberger]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Linde]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Jeanrenaud]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical progress after randomized on/off pacemaker treatment for hypertrophic obstructive cardiomyopathy. Pacing in Cardiomyopathy (PIC) Study Group]]></article-title>
<source><![CDATA[Europace]]></source>
<year>1999</year>
<volume>1</volume>
<page-range>77-84</page-range></nlm-citation>
</ref>
<ref id="B432">
<label>432</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ommen]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Nishimura]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Squires]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
<name>
<surname><![CDATA[Schaff]]></surname>
<given-names><![CDATA[HV]]></given-names>
</name>
<name>
<surname><![CDATA[Danielson]]></surname>
<given-names><![CDATA[GK]]></given-names>
</name>
<name>
<surname><![CDATA[-Tajik]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of dual chamber pacing versus septal myectomy for the treatment of patients with hypertrophic obstructive cardiomyopathy. A comparison of objective hemodynamic and exercise end points]]></article-title>
<source><![CDATA[JACC]]></source>
<year>1999</year>
<volume>34</volume>
<page-range>191-6</page-range></nlm-citation>
</ref>
<ref id="B433">
<label>433</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Linde]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gadler]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Kappenberger]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Rydén]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. PIC Study Group. Pacing In Cardiomyopathy]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>1999</year>
<volume>83</volume>
<page-range>903-7</page-range></nlm-citation>
</ref>
<ref id="B434">
<label>434</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gadler]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Linde]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Daubert]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Significant improvement of quality of life following atrioventricular synchronous pacing in patients with hypertrophic obstructive cardiomyopathy:data from 1 year of follow-up]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>1999</year>
<volume>20</volume>
<page-range>1044-50</page-range></nlm-citation>
</ref>
<ref id="B435">
<label>435</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Erwin 3rd]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Nishimura]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Lloyd]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Tajik]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dual chamber pacing for patients with hypertrophic obstructive cardiomyopathy:a clinical perspective in 2000]]></article-title>
<source><![CDATA[Mayo Clin Proc]]></source>
<year>2000</year>
<volume>75</volume>
<page-range>173-80</page-range></nlm-citation>
</ref>
<ref id="B436">
<label>436</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gao]]></surname>
<given-names><![CDATA[YC]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[ZH]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[XL]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[TY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Transcoronary ablation of septal hypertrophy versus dual-chamber cardiac pacing for the treatment of aged patients with hypertrophic obstructive cardiomyopathy]]></article-title>
<source><![CDATA[Zhonghua Xin Xue Guan Bing Za Zhi]]></source>
<year>2007</year>
<volume>35</volume>
<page-range>333-6</page-range></nlm-citation>
</ref>
<ref id="B437">
<label>437</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Casey]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Poliac]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Gohman]]></surname>
<given-names><![CDATA[TE]]></given-names>
</name>
<name>
<surname><![CDATA[Almquist]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Aeppli]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical course of hypertrophic cardiomyopathy in a regional United States cohort]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>1999</year>
<volume>281</volume>
<page-range>650-5</page-range></nlm-citation>
</ref>
<ref id="B438">
<label>438</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jurado]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Montero]]></surname>
<given-names><![CDATA[CJM]]></given-names>
</name>
<name>
<surname><![CDATA[Rubio]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estimulación auriculoventricular secuencial en pacientes con miocardiopatía hipertrófica:18 años de experiencia]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2016</year>
<volume>69</volume>
<page-range>377-83</page-range></nlm-citation>
</ref>
<ref id="B439">
<label>439</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Berruezo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Vatasescu]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mont]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biventricular pacing in hypertrophic obstructive cardiomyopathy:a pilot study]]></article-title>
<source><![CDATA[Heart Rhythm]]></source>
<year>2011</year>
<volume>8</volume>
<page-range>221-7</page-range></nlm-citation>
</ref>
<ref id="B440">
<label>440</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Berruezo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Linhart]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Auricchio]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rationale and design of the TRICHAMPION trial:triple chamber pacing in hypertrophic obstructive cardiomyopathy patients]]></article-title>
<source><![CDATA[J Interv Cardiac Electrophysiol]]></source>
<year>2018</year>
<volume>51</volume>
<page-range>117-24</page-range></nlm-citation>
</ref>
<ref id="B441">
<label>441</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vatasescu]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Evertz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mont]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Sitges]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Brugada]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Berruezo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biventricular/left ventricular pacing in hypertrophic obstructive cardiomyopathy:an overview]]></article-title>
<source><![CDATA[Indian Pacing Electrophysiol J]]></source>
<year>2012</year>
<volume>12</volume>
<page-range>114-23</page-range></nlm-citation>
</ref>
<ref id="B442">
<label>442</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jan]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Todaro]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Oreto]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Tajik]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Apical hypertrophic cardiomyopathy:present status]]></article-title>
<source><![CDATA[Int J Cardiol]]></source>
<year>2016</year>
<volume>222</volume>
<page-range>745-59</page-range></nlm-citation>
</ref>
<ref id="B443">
<label>443</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Schaff]]></surname>
<given-names><![CDATA[HV]]></given-names>
</name>
<name>
<surname><![CDATA[Nishimura]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Dearani]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Ommen]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Early outcomes of repair of left ventricular apical aneurysms in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2017</year>
<volume>136</volume>
<page-range>1979-81</page-range></nlm-citation>
</ref>
<ref id="B444">
<label>444</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Olivotto]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Camici]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
<name>
<surname><![CDATA[Merlini]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of ranolazine in patients with symptomatic hypertrophic cardiomyopathy:the RESTYLE-HCM randomized, double-blind, placebo-controlled study]]></article-title>
<source><![CDATA[Circ Heart Fail]]></source>
<year>2018</year>
<volume>11</volume>
</nlm-citation>
</ref>
<ref id="B445">
<label>445</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Axelsson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Iversen]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Vejlstrup]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy:the INHERIT randomized, double-blind, placebo-controlled trial]]></article-title>
<source><![CDATA[Lancet Diabetes Endocrinol]]></source>
<year>2015</year>
<volume>3</volume>
<page-range>123-31</page-range></nlm-citation>
</ref>
<ref id="B446">
<label>446</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Olivotto]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Cecchi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Casey]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Dolara]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Traverse]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2001</year>
<volume>104</volume>
<page-range>2517-24</page-range></nlm-citation>
</ref>
<ref id="B447">
<label>447</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nair]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fischer]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atrial fibrillation in hypertrophic cardiomyopathy:mechanisms, embolic risk and prognosis]]></article-title>
<source><![CDATA[Anadolu Kardiyol Derg]]></source>
<year>2006</year>
<volume>6</volume>
<numero>Suppl 2</numero>
<issue>Suppl 2</issue>
<page-range>40-3</page-range></nlm-citation>
</ref>
<ref id="B448">
<label>448</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Noseworthy]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Yao]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[ND]]></given-names>
</name>
<name>
<surname><![CDATA[Gersh]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stroke and bleeding risks in NOAC- and warfarin-treated patients with hypertrophic cardiomyopathy and atrial fibrillation]]></article-title>
<source><![CDATA[JACC]]></source>
<year>2016</year>
<volume>67</volume>
<page-range>3020-1</page-range></nlm-citation>
</ref>
<ref id="B449">
<label>449</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Doi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Kitaoka]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertrophic cardiomyopathy in the elderly:significance of atrial fibrillation]]></article-title>
<source><![CDATA[J Cardiol]]></source>
<year>2001</year>
<volume>37</volume>
<numero>Suppl 1</numero>
<issue>Suppl 1</issue>
<page-range>133-8</page-range></nlm-citation>
</ref>
<ref id="B450">
<label>450</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Joglar]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Armbruster]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2023 ACC/AHA/ACCP/HRS Guideline for the diagnosis and management of atrial fibrillation:a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2024</year>
<volume>149</volume>
<page-range>e156</page-range></nlm-citation>
</ref>
<ref id="B451">
<label>451</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Camm]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kirchhof]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Lip]]></surname>
<given-names><![CDATA[GY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guidelines for the management of atrial fibrillation:the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)]]></article-title>
<source><![CDATA[Europace]]></source>
<year>2010</year>
<volume>12</volume>
<page-range>1360-420</page-range></nlm-citation>
</ref>
<ref id="B452">
<label>452</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Klopotowski]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kwapiszewska]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kukula]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical and echocardiographic parameter as risk factors for auricular fibrillation in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Clin Cardiol]]></source>
<year>2018</year>
<volume>41</volume>
<page-range>1336-40</page-range></nlm-citation>
</ref>
<ref id="B453">
<label>453</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Losi]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Betocchi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Aversa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Determinants of atrial fibrillation development in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2004</year>
<volume>94</volume>
<page-range>895-900</page-range></nlm-citation>
</ref>
<ref id="B454">
<label>454</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boriani]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Glotzer]]></surname>
<given-names><![CDATA[TV]]></given-names>
</name>
<name>
<surname><![CDATA[Santini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Device-detected atrial fibrillation and risk for stroke:an analysis of &gt;10000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices)]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2014</year>
<volume>35</volume>
<page-range>508-16</page-range></nlm-citation>
</ref>
<ref id="B455">
<label>455</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crijns]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Weijs]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Fairley]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Contemporary real-life cardioversion of atrial fibrillation:results from the multinational RHYTHM-AF study]]></article-title>
<source><![CDATA[Int J Cardiol]]></source>
<year>2014</year>
<volume>172</volume>
<page-range>588-94</page-range></nlm-citation>
</ref>
<ref id="B456">
<label>456</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernández-Madrid]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Svendsen]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Lip]]></surname>
<given-names><![CDATA[GY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardioversion for atrial fibrillation in current European practice:results of the European Heart Rhythm Association survey]]></article-title>
<source><![CDATA[Europace]]></source>
<year>2013</year>
<volume>15</volume>
<page-range>915-8</page-range></nlm-citation>
</ref>
<ref id="B457">
<label>457</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pisters]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Nieuwlaat]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Prins]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation:the Euro Heart Survey]]></article-title>
<source><![CDATA[Europace]]></source>
<year>2012</year>
<volume>14</volume>
<page-range>666-74</page-range></nlm-citation>
</ref>
<ref id="B458">
<label>458</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dankner]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Shahar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Novikov]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of stable atrial fibrillation in the emergency department:a population-based comparison of electrical direct-current versus pharmacological cardioversion or conservative management]]></article-title>
<source><![CDATA[Cardiology]]></source>
<year>2009</year>
<volume>112</volume>
<page-range>270-8</page-range></nlm-citation>
</ref>
<ref id="B459">
<label>459</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lip]]></surname>
<given-names><![CDATA[GY]]></given-names>
</name>
<name>
<surname><![CDATA[Gitt]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Le Heuzey]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Overtreatment and undertreatment with anticoagulation in relation to cardioversion of atrial fibrillation (the RHYTHM-AF study)]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2014</year>
<volume>113</volume>
<page-range>480-4</page-range></nlm-citation>
</ref>
<ref id="B460">
<label>460</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Airaksinen]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
<name>
<surname><![CDATA[Grönberg]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Nuotio]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Thromboembolic complications after cardioversion of acute atrial fibrillation:the FinCV (Finnish CardioVersion) study]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2013</year>
<volume>62</volume>
<page-range>1187-92</page-range></nlm-citation>
</ref>
<ref id="B461">
<label>461</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fatkin]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Kuchar]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Thorburn]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation:evidence for “atrial stunning”as a mechanism of thromboembolic complications]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>1994</year>
<volume>23</volume>
<page-range>307-16</page-range></nlm-citation>
</ref>
<ref id="B462">
<label>462</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Klein]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Grimm]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Murray]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2001</year>
<volume>344</volume>
<page-range>1411-20</page-range></nlm-citation>
</ref>
<ref id="B463">
<label>463</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lip]]></surname>
<given-names><![CDATA[GY]]></given-names>
</name>
<name>
<surname><![CDATA[Hammerstingl]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Marin]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Left atrial thrombus resolution in atrial fibrillation or flutter:results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF)]]></article-title>
<source><![CDATA[Am Heart J]]></source>
<year>2016</year>
<volume>178</volume>
<page-range>126-34</page-range></nlm-citation>
</ref>
<ref id="B464">
<label>464</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pathan]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Hecht]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Narula]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Roles of transesophageal echocardiography and cardiac computed tomography for evaluation of left atrial thrombus and associated pathology:a review and critical analysis]]></article-title>
<source><![CDATA[JACC Cardiovasc Imaging]]></source>
<year>2018</year>
<volume>11</volume>
<page-range>616-27</page-range></nlm-citation>
</ref>
<ref id="B465">
<label>465</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Romero]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Husain]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Kelesidis]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Detection of left atrial appendage thrombus by cardiac computed tomography in patients with atrial fibrillation:a meta-analysis]]></article-title>
<source><![CDATA[Circ Cardiovasc Imaging]]></source>
<year>2013</year>
<volume>6</volume>
<page-range>185-94</page-range></nlm-citation>
</ref>
<ref id="B466">
<label>466</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spagnolo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Giglio]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Di Marco]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis of left atrial appendage thrombus in patients with atrial fibrillation:delayed contrast-enhanced cardiac CT]]></article-title>
<source><![CDATA[Eur Radiol]]></source>
<year>2021</year>
<volume>31</volume>
<page-range>1236-44</page-range></nlm-citation>
</ref>
<ref id="B467">
<label>467</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tieleman]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[Van Gelder]]></surname>
<given-names><![CDATA[IC]]></given-names>
</name>
<name>
<surname><![CDATA[Crijns]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Early recurrences of atrial fibrillation after electrical cardioversion:a result of fibrillation-induced electrical remodeling of the atria?]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>1998</year>
<volume>31</volume>
<page-range>167-73</page-range></nlm-citation>
</ref>
<ref id="B468">
<label>468</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spoladore]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[D'Amato]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Camici]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
<name>
<surname><![CDATA[Olivotto]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacological treatment options for hypertrophic cardiomyopathy:high time for evidence]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2012</year>
<volume>33</volume>
<page-range>1724-33</page-range></nlm-citation>
</ref>
<ref id="B469">
<label>469</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bassiouny]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lindsay]]></surname>
<given-names><![CDATA[BD]]></given-names>
</name>
<name>
<surname><![CDATA[Lever]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Outcomes of nonpharmacologic treatment of atrial fibrillation in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Heart Rhythm]]></source>
<year>2015</year>
<volume>12</volume>
<page-range>1438-47</page-range></nlm-citation>
</ref>
<ref id="B470">
<label>470</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moore]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Trager]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Anzia]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dofetilide for suppression of atrial fibrillation in hypertrophic cardiomyopathy:a case series and literature review]]></article-title>
<source><![CDATA[Pacing Clin Electrophysiol]]></source>
<year>2018</year>
<volume>41</volume>
<page-range>396-401</page-range></nlm-citation>
</ref>
<ref id="B471">
<label>471</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tanel]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
<name>
<surname><![CDATA[Walsh]]></surname>
<given-names><![CDATA[EP]]></given-names>
</name>
<name>
<surname><![CDATA[Lulu]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sotalol for refractory arrhythmias in pediatric and young adult patients:initial efficacy and long-term outcome]]></article-title>
<source><![CDATA[Am Heart J]]></source>
<year>1995</year>
<volume>130</volume>
<page-range>791-7</page-range></nlm-citation>
</ref>
<ref id="B472">
<label>472</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Valdés]]></surname>
<given-names><![CDATA[SO]]></given-names>
</name>
<name>
<surname><![CDATA[Miyake]]></surname>
<given-names><![CDATA[CY]]></given-names>
</name>
<name>
<surname><![CDATA[Niu]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Early experience with intravenous sotalol in children with and without congenital heart disease]]></article-title>
<source><![CDATA[Heart Rhythm]]></source>
<year>2018</year>
<volume>15</volume>
<page-range>1862-9</page-range></nlm-citation>
</ref>
<ref id="B473">
<label>473</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rahimi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Otto]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Heartbeat:is atrial fibrillation ablation effective in patients with hypertrophic cardiomyopathy?]]></article-title>
<source><![CDATA[Heart]]></source>
<year>2016</year>
<volume>102</volume>
<page-range>1511-2</page-range></nlm-citation>
</ref>
<ref id="B474">
<label>474</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Prutkin]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Owens]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Heart]]></source>
<year>2016</year>
<volume>102</volume>
<page-range>1513-4</page-range></nlm-citation>
</ref>
<ref id="B475">
<label>475</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yan]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Dong]]></surname>
<given-names><![CDATA[JZ]]></given-names>
</name>
<name>
<surname><![CDATA[Long]]></surname>
<given-names><![CDATA[DY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effectiveness of catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Chin J Cardiac Arrhyth]]></source>
<year>2013</year>
<volume>3</volume>
<page-range>167-71</page-range></nlm-citation>
</ref>
<ref id="B476">
<label>476</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Shen]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Outcomes of catheter ablation of auricular fibrillation in patients with hypertrophic cardiomyopathy:a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Europace]]></source>
<year>2016</year>
<volume>18</volume>
<page-range>508-20</page-range></nlm-citation>
</ref>
<ref id="B477">
<label>477</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Providencia]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Elliott]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy:a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Heart]]></source>
<year>2016</year>
<volume>102</volume>
<page-range>1533-43</page-range></nlm-citation>
</ref>
<ref id="B478">
<label>478</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[McCarthy]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Lever]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Smedira]]></surname>
<given-names><![CDATA[NG]]></given-names>
</name>
<name>
<surname><![CDATA[Lytle]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effectiveness of atrial fibrillation surgery in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2004</year>
<volume>93</volume>
<page-range>373-5</page-range></nlm-citation>
</ref>
<ref id="B479">
<label>479</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lapenna]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Pozzoli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[De Bonis]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mid-term outcomes of concomitant surgical ablation of atrial fibrillation in patients undergoing cardiac surgery for hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Eur J Cardiothorac Surg]]></source>
<year>2017</year>
<volume>51</volume>
<page-range>1112-8</page-range></nlm-citation>
</ref>
<ref id="B480">
<label>480</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scheuermeyer]]></surname>
<given-names><![CDATA[FX]]></given-names>
</name>
<name>
<surname><![CDATA[Grafstein]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Stenstrom]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety and efficiency of calcium channel blockers versus beta-blockers for rate control in patients with atrial fibrillation and no acute underlying medical illness]]></article-title>
<source><![CDATA[Acad Emerg Med]]></source>
<year>2013</year>
<volume>20</volume>
<page-range>222-30</page-range></nlm-citation>
</ref>
<ref id="B481">
<label>481</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zaman]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Naccarelli]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Foy]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A comparison of rate control agents for the treatment of atrial fibrillation:follow-up investigation of the AFFIRM study]]></article-title>
<source><![CDATA[J Cardiovasc Pharmacol Ther]]></source>
<year>2021</year>
<volume>26</volume>
<page-range>328-34</page-range></nlm-citation>
</ref>
<ref id="B482">
<label>482</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lopes]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Rordorf]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[De Ferrari]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Digoxin and mortality in patients with atrial fibrillation]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2018</year>
<volume>71</volume>
<page-range>1063-74</page-range></nlm-citation>
</ref>
<ref id="B483">
<label>483</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wood]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Brown-Mahoney]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kay]]></surname>
<given-names><![CDATA[GN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical outcomes after ablation and pacing therapy for atrial fibrillation:a meta-analysis]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2000</year>
<volume>101</volume>
<page-range>1138-44</page-range></nlm-citation>
</ref>
<ref id="B484">
<label>484</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lim]]></surname>
<given-names><![CDATA[KT]]></given-names>
</name>
<name>
<surname><![CDATA[Davis]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Powell]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ablate and pace strategy for atrial fibrillation:long-term outcome of AIRCRAFT trial]]></article-title>
<source><![CDATA[Europace]]></source>
<year>2007</year>
<volume>9</volume>
<page-range>498-505</page-range></nlm-citation>
</ref>
<ref id="B485">
<label>485</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Takahashi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Yoshito]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Takahashi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[AV nodal ablation and pacemaker implantation improves hemodynamic function in atrial fibrillation]]></article-title>
<source><![CDATA[Pacing Clin Electrophysiol]]></source>
<year>2003</year>
<volume>26</volume>
<page-range>1212-7</page-range></nlm-citation>
</ref>
<ref id="B486">
<label>486</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Haruki]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Minami]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Hagiwara]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stroke and embolic events in hypertrophic cardiomyopathy:risk stratification in patients without atrial fibrillation]]></article-title>
<source><![CDATA[Stroke]]></source>
<year>2016</year>
<volume>47</volume>
<page-range>936-42</page-range></nlm-citation>
</ref>
<ref id="B487">
<label>487</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guttmann]]></surname>
<given-names><![CDATA[OP]]></given-names>
</name>
<name>
<surname><![CDATA[Pavlou]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[O'Mahony]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA)]]></article-title>
<source><![CDATA[Eur J Heart Fail]]></source>
<year>2015</year>
<volume>17</volume>
<page-range>837-45</page-range></nlm-citation>
</ref>
<ref id="B488">
<label>488</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cam]]></surname>
<given-names><![CDATA[CF]]></given-names>
</name>
<name>
<surname><![CDATA[Camm]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Auricular fibrillation and anticoagulation in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Arrhythm Electrophysiol Rev]]></source>
<year>2017</year>
<volume>6</volume>
<page-range>63-8</page-range></nlm-citation>
</ref>
<ref id="B489">
<label>489</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gómez-Outes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Terleira-Fernández]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
<name>
<surname><![CDATA[Calvo-Rojas]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Suárez-Gea]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Vargas-Castrillón]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation:a systematic review and meta-analysis of subgroups]]></article-title>
<source><![CDATA[Thrombosis]]></source>
<year>2013</year>
<volume>2013</volume>
<page-range>640723</page-range></nlm-citation>
</ref>
<ref id="B490">
<label>490</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Connolly]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ezekowitz]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Yusuf]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dabigatran versus warfarin in patients with atrial fibrillation]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2009</year>
<volume>361</volume>
<page-range>1139-51</page-range></nlm-citation>
</ref>
<ref id="B491">
<label>491</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McIntyre]]></surname>
<given-names><![CDATA[WF]]></given-names>
</name>
<name>
<surname><![CDATA[Benz]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Becher]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Direct oral anticoagulants for stroke prevention in patients with device-detected atrial fibrillation:a study-level meta-analysis of the NOAH-AFNET 6 and ARTESiA trials]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2024</year>
<volume>149</volume>
<page-range>981-8</page-range></nlm-citation>
</ref>
<ref id="B492">
<label>492</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Palyam]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Azam]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[Odeyinka]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertrophic cardiomyopathy and atrial fibrillation:a review]]></article-title>
<source><![CDATA[Cureus]]></source>
<year>2022</year>
<volume>14</volume>
</nlm-citation>
</ref>
<ref id="B493">
<label>493</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van Gelder]]></surname>
<given-names><![CDATA[IC]]></given-names>
</name>
<name>
<surname><![CDATA[Healey]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Crijns]]></surname>
<given-names><![CDATA[HJGM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2017</year>
<volume>38</volume>
<page-range>1339-44</page-range></nlm-citation>
</ref>
<ref id="B494">
<label>494</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Swiryn]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Orlov]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Bendit]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical implications of brief device detected atrial tachyarrhythmias in a cardiac rhythm management device population:results from the registry of atrial tachycardia and atrial fibrillation episodes]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2016</year>
<volume>134</volume>
<page-range>1130-40</page-range></nlm-citation>
</ref>
<ref id="B495">
<label>495</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Frontera]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
<name>
<surname><![CDATA[Sekhon]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Duncan]]></surname>
<given-names><![CDATA[ER]]></given-names>
</name>
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atrial fibrillation and hypertrophic cardiomyopathy:who to anticoagulated?]]></article-title>
<source><![CDATA[Clin Res Cardiol]]></source>
<year>2015</year>
<volume>104</volume>
<page-range>799-802</page-range></nlm-citation>
</ref>
<ref id="B496">
<label>496</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Connolly]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Dorian]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators:the OPTIC Study:a randomized trial]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2006</year>
<volume>295</volume>
<page-range>165-71</page-range></nlm-citation>
</ref>
<ref id="B497">
<label>497</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Echt]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Liebson]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
<name>
<surname><![CDATA[Mitchell]]></surname>
<given-names><![CDATA[LB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1991</year>
<volume>324</volume>
<page-range>781-8</page-range></nlm-citation>
</ref>
<ref id="B498">
<label>498</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wilkoff]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
<name>
<surname><![CDATA[Fauchier]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Stiles]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing]]></article-title>
<source><![CDATA[Europace]]></source>
<year>2016</year>
<volume>18</volume>
<page-range>159-83</page-range></nlm-citation>
</ref>
<ref id="B499">
<label>499</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baquero]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Banchs]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Depalma]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies]]></article-title>
<source><![CDATA[J Cardiovasc Electrophysiol]]></source>
<year>2012</year>
<volume>23</volume>
<page-range>296-301</page-range></nlm-citation>
</ref>
<ref id="B500">
<label>500</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Igarashi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Nogami]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kurosaki]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Radiofrequency catheter ablation of ventricular tachycardia in patients with hypertrophic cardiomyopathy and apical aneurysm]]></article-title>
<source><![CDATA[JACC Clin Electrophysiol]]></source>
<year>2018</year>
<volume>4</volume>
<page-range>339-50</page-range></nlm-citation>
</ref>
<ref id="B501">
<label>501</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Charron]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Elliott]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Gimeno]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[EORP Cardiomyopathy Registry Investigators. The Cardiomyopathy Registry of the EURObservational Research Programme of the European Society of Cardiology:baseline data and contemporary management of adult patients with cardiomyopathies]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2018</year>
<volume>39</volume>
<page-range>1784-93</page-range></nlm-citation>
</ref>
<ref id="B502">
<label>502</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Du]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Yi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic effect of atrial fibrillation on survival in patients with hypertrophic cardiomyopathy:a meta-analysis]]></article-title>
<source><![CDATA[J Cardiothorac Surg]]></source>
<year>2023</year>
<volume>18</volume>
<page-range>196</page-range></nlm-citation>
</ref>
<ref id="B503">
<label>503</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Rowin]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Udelson]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical spectrum and management of heart failure in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[JACC Heart Fail]]></source>
<year>2018</year>
<volume>6</volume>
<page-range>353-63</page-range></nlm-citation>
</ref>
<ref id="B504">
<label>504</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pamplona]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insuficiencia cardiaca, características y sus consecuencias en miocardiopatía hipertrófica]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Llamas-Esperón]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[Miocardiopatía hipertrófica. Cómo tratarla y entenderla mejor]]></source>
<year>2022</year>
<page-range>124-38</page-range><publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[PyDESA]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B505">
<label>505</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hong]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Su]]></surname>
<given-names><![CDATA[WW]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk factors of sudden cardiac death in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Curr Opin Cardiol]]></source>
<year>2022</year>
<volume>37</volume>
<page-range>15-21</page-range></nlm-citation>
</ref>
<ref id="B506">
<label>506</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Desai]]></surname>
<given-names><![CDATA[MY]]></given-names>
</name>
<name>
<surname><![CDATA[Nishimura]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of hypertrophic cardiomyopathy:JACC State-of-the-Art Review]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2022</year>
<volume>79</volume>
<page-range>390-414</page-range></nlm-citation>
</ref>
<ref id="B507">
<label>507</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ommen]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Ho]]></surname>
<given-names><![CDATA[CY]]></given-names>
</name>
<name>
<surname><![CDATA[Asif]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the management of hypertrophic cardiomyopathy:a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2024</year>
<volume>149</volume>
<page-range>311</page-range></nlm-citation>
</ref>
<ref id="B508">
<label>508</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seferovi&#263;]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Polovina]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bauersachs]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Heart failure in cardiomyopathies:a position paper from the Heart Failure Association of the European Society of Cardiology]]></article-title>
<source><![CDATA[Eur J Heart Fail]]></source>
<year>2019</year>
<volume>21</volume>
<page-range>553-76</page-range></nlm-citation>
</ref>
<ref id="B509">
<label>509</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McDonagh]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Metra]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Adamo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2021</year>
<volume>42</volume>
<page-range>3599-726</page-range></nlm-citation>
</ref>
<ref id="B510">
<label>510</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kittleson]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Panjrath]]></surname>
<given-names><![CDATA[GS]]></given-names>
</name>
<name>
<surname><![CDATA[Amancherla]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction:a report of the American College of Cardiology Solution Set Oversight Committee]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2023</year>
<volume>81</volume>
<page-range>1835-78</page-range></nlm-citation>
</ref>
<ref id="B511">
<label>511</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pasqualucci]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Fornaro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Castelli]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical spectrum, therapeutic options, and outcome of advanced heart failure in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circ Heart Fail]]></source>
<year>2015</year>
<volume>8</volume>
<page-range>1014-21</page-range></nlm-citation>
</ref>
<ref id="B512">
<label>512</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grupper]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Pereira]]></surname>
<given-names><![CDATA[NL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of ventricular assist therapy for patients with heart failure and restrictive physiology:improving outcomes for a lethal disease]]></article-title>
<source><![CDATA[J Heart Lung Transplant]]></source>
<year>2015</year>
<volume>34</volume>
<page-range>1042-9</page-range></nlm-citation>
</ref>
<ref id="B513">
<label>513</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muthiah]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Phan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Robson]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Centrifugal continuous-flow left ventricular assist device in patients with hypertrophic cardiomyopathy:a case series]]></article-title>
<source><![CDATA[ASAIO J]]></source>
<year>2013</year>
<volume>59</volume>
<page-range>183-7</page-range></nlm-citation>
</ref>
<ref id="B514">
<label>514</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kato]]></surname>
<given-names><![CDATA[TS]]></given-names>
</name>
<name>
<surname><![CDATA[Takayama]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Yoshizawa]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiac transplantation in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2012</year>
<volume>110</volume>
<page-range>568-74</page-range></nlm-citation>
</ref>
<ref id="B515">
<label>515</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Zimmer]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kobashigawa]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term outcomes of orthotopic heart transplantation for hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Transplant Proc]]></source>
<year>2014</year>
<volume>46</volume>
<page-range>1502-5</page-range></nlm-citation>
</ref>
<ref id="B516">
<label>516</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rowin]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Abt]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of advanced therapies for improving survival to heart transplant in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2018</year>
<volume>121</volume>
<page-range>986-96</page-range></nlm-citation>
</ref>
<ref id="B517">
<label>517</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rowin]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kiernan]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Advanced heart failure with preserved systolic function in nonobstructive hypertrophic cardiomyopathy:under-recognized subset of candidates for heart transplant]]></article-title>
<source><![CDATA[Circ Heart Fail]]></source>
<year>2014</year>
<volume>7</volume>
<page-range>967-75</page-range></nlm-citation>
</ref>
<ref id="B518">
<label>518</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Hauser]]></surname>
<given-names><![CDATA[TH]]></given-names>
</name>
<name>
<surname><![CDATA[Dubrow]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Right ventricular involvement in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2007</year>
<volume>100</volume>
<page-range>1293-8</page-range></nlm-citation>
</ref>
<ref id="B519">
<label>519</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Keeling]]></surname>
<given-names><![CDATA[AN]]></given-names>
</name>
<name>
<surname><![CDATA[Carr]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Choudhury]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Right ventricular hypertrophy and scarring in mutation positive hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2010</year>
<volume>31</volume>
<page-range>381</page-range></nlm-citation>
</ref>
<ref id="B520">
<label>520</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Olivotto]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Cecchi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Camici]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Coronary microvascular dysfunction and ischemia in hypertrophic cardiomyopathy. Mechanisms and clinical consequences]]></article-title>
<source><![CDATA[Ital Heart J]]></source>
<year>2004</year>
<volume>5</volume>
<page-range>572-80</page-range></nlm-citation>
</ref>
<ref id="B521">
<label>521</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rubin]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Morrison]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Padnick]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Idiopathic hypertrophic subaortic stenosis:evaluation of anginal symptoms with thallium-201 myocardial imaging]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>1979</year>
<volume>44</volume>
<page-range>1040-5</page-range></nlm-citation>
</ref>
<ref id="B522">
<label>522</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yalçin]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Valenta]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Yalçin]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of diffuse subendocardial hypoperfusion on left ventricular cavity size by 13N-ammonia perfusion PET in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2016</year>
<volume>118</volume>
<page-range>1908-15</page-range></nlm-citation>
</ref>
<ref id="B523">
<label>523</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Gui]]></surname>
<given-names><![CDATA[FD]]></given-names>
</name>
<name>
<surname><![CDATA[Xue]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Focal ischemic myocardial fibrosis assessed by late gadolinium enhancement cardiovascular magnetic resonance in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[BMC Cardiovasc Disord]]></source>
<year>2024</year>
<volume>24</volume>
<page-range>203</page-range></nlm-citation>
</ref>
<ref id="B524">
<label>524</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Galo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Feroze]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ischemic myocardial positron emission tomography perfusion without epicardial coronary disease in hypertrophic obstructive cardiomyopathy]]></article-title>
<source><![CDATA[Cureus]]></source>
<year>2024</year>
<volume>16</volume>
</nlm-citation>
</ref>
<ref id="B525">
<label>525</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cecchi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Sgalambro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Baldi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Microvascular dysfunction, myocardial ischemia, and progression to heart failure in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[J Cardiovasc Transl Res]]></source>
<year>2009</year>
<volume>2</volume>
<page-range>452-61</page-range></nlm-citation>
</ref>
<ref id="B526">
<label>526</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Olivotto]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Girolami]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Sciagrà]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2011</year>
<volume>58</volume>
<page-range>839-48</page-range></nlm-citation>
</ref>
<ref id="B527">
<label>527</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[TL]]></given-names>
</name>
<name>
<surname><![CDATA[Hao]]></surname>
<given-names><![CDATA[WR]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Myocardial bridging increases the risk of adverse cardiovascular events in patients without coronary atherosclerosis]]></article-title>
<source><![CDATA[Life (Basel)]]></source>
<year>2024</year>
<volume>14</volume>
<page-range>811</page-range></nlm-citation>
</ref>
<ref id="B528">
<label>528</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gow]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Myocardial bridging:does it cause sudden death?]]></article-title>
<source><![CDATA[Card Electrophysiol Rev]]></source>
<year>2002</year>
<volume>6</volume>
<page-range>112-4</page-range></nlm-citation>
</ref>
<ref id="B529">
<label>529</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Celenk]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Celenk]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Myocardial bridging in adult with hypertrophic cardiomyopathy:imaging findings with coronary computed tomography angiography]]></article-title>
<source><![CDATA[Radiol Case Rep]]></source>
<year>2022</year>
<volume>17</volume>
<page-range>4627-31</page-range></nlm-citation>
</ref>
<ref id="B530">
<label>530</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mohiddin]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Fananapazir]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systolic compression of epicardial coronary and intramural arteries in children with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Tex Heart Inst J]]></source>
<year>2002</year>
<volume>29</volume>
<page-range>290-8</page-range></nlm-citation>
</ref>
<ref id="B531">
<label>531</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Basso]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Thiene]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Mackey-Bojack]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Frigo]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Corrado]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Myocardial bridging, a frequent component of the hypertrophic cardiomyopathy phenotype, lacks systematic association with sudden cardiac death]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2009</year>
<volume>30</volume>
<page-range>1627-34</page-range></nlm-citation>
</ref>
<ref id="B532">
<label>532</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jaber]]></surname>
<given-names><![CDATA[WA]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[EH]]></given-names>
</name>
<name>
<surname><![CDATA[Nishimura]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immediate improvement in coronary flow reserve after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy]]></article-title>
<source><![CDATA[Heart]]></source>
<year>2009</year>
<volume>95</volume>
<page-range>564-9</page-range></nlm-citation>
</ref>
<ref id="B533">
<label>533</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cannon]]></surname>
<given-names><![CDATA[RO]]></given-names>
</name>
<name>
<surname><![CDATA[Dilsizian]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[O'Gara]]></surname>
<given-names><![CDATA[PT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of surgical relief of outflow obstruction on thallium perfusion abnormalities in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1992</year>
<volume>85</volume>
<page-range>1039-45</page-range></nlm-citation>
</ref>
<ref id="B534">
<label>534</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sugihara]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Taniguchi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ito]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of diltiazem on myocardial perfusion abnormalities during exercise in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Ann Nucl Med]]></source>
<year>1998</year>
<volume>12</volume>
<page-range>349-54</page-range></nlm-citation>
</ref>
<ref id="B535">
<label>535</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Taniguchi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Sugihara]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ohtsuki]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[[Effect of verapamil on myocardial ischemia in patients with hypertrophic cardiomyopathy:evaluation by exercise thallium-201 SPECT]]></article-title>
<source><![CDATA[J Cardiol]]></source>
<year>1994</year>
<volume>24</volume>
<page-range>45-51</page-range></nlm-citation>
</ref>
<ref id="B536">
<label>536</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pollick]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Muscular subaortic stenosis:hemodynamic and clinical improvement after disopyramide]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1982</year>
<volume>307</volume>
<page-range>997-9</page-range></nlm-citation>
</ref>
<ref id="B537">
<label>537</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cui]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mid-term outcomes of simultaneous coronary artery bypass graft surgery and septal myectomy in patients with hypertrophic obstructive cardiomyopathy:a case-controlled study]]></article-title>
<source><![CDATA[J Card Surg]]></source>
<year>2019</year>
<volume>34</volume>
<page-range>103-9</page-range></nlm-citation>
</ref>
<ref id="B538">
<label>538</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Schaff]]></surname>
<given-names><![CDATA[HV]]></given-names>
</name>
<name>
<surname><![CDATA[Sedeek]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Septal myectomy and concomitant coronary artery bypass grafting for patients with hypertrophic cardiomyopathy and coronary artery disease]]></article-title>
<source><![CDATA[Mayo Clin Proc]]></source>
<year>2020</year>
<volume>95</volume>
<page-range>521-5</page-range></nlm-citation>
</ref>
<ref id="B539">
<label>539</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mathew]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Nishimura]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Septal myectomy in patients with previous coronary revascularization —hypertrophic cardiomyopathy masquerading as ischemic heart disease]]></article-title>
<source><![CDATA[Int J Cardiol]]></source>
<year>2020</year>
<volume>319</volume>
<page-range>97-100</page-range></nlm-citation>
</ref>
<ref id="B540">
<label>540</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[VC]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[TH]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Outcomes of patients with hypertrophic cardiomyopathy and acute myocardial infarction:a propensity score-matched, 15-year nationwide population-based study in Asia]]></article-title>
<source><![CDATA[BMJ Open]]></source>
<year>2018</year>
<volume>8</volume>
</nlm-citation>
</ref>
<ref id="B541">
<label>541</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gupta]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Harikrishnan]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Kolte]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Outcomes of acute myocardial infarction in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Am J Med]]></source>
<year>2015</year>
<volume>128</volume>
<page-range>879-87</page-range></nlm-citation>
</ref>
<ref id="B542">
<label>542</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[YJ]]></given-names>
</name>
<name>
<surname><![CDATA[Fan]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Yuan]]></surname>
<given-names><![CDATA[JQ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term survival after acute myocardial infarction in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Clin Cardiol]]></source>
<year>2017</year>
<volume>40</volume>
<page-range>26-31</page-range></nlm-citation>
</ref>
<ref id="B543">
<label>543</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weissler]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Adler]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevention of sudden death in hypertrophic cardiomyopathy:bridging the gaps in knowledge]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2017</year>
<volume>38</volume>
<page-range>1728-37</page-range></nlm-citation>
</ref>
<ref id="B544">
<label>544</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peterson]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
<name>
<surname><![CDATA[Kucera]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aetiology and incidence of sudden cardiac arrest and death in young competitive athletes in the USA:a 4-year prospective study]]></article-title>
<source><![CDATA[Br J Sports Med]]></source>
<year>2021</year>
<volume>55</volume>
<page-range>1196-203</page-range></nlm-citation>
</ref>
<ref id="B545">
<label>545</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lo]]></surname>
<given-names><![CDATA[AKC]]></given-names>
</name>
<name>
<surname><![CDATA[Mew]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Mew]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Exaggerated myocardial torsion may contribute to dynamic left ventricular outflow tract obstruction in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Eur Heart J Open]]></source>
<year>2023</year>
<volume>3</volume>
<page-range>oead043</page-range></nlm-citation>
</ref>
<ref id="B546">
<label>546</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[XY]]></given-names>
</name>
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[XG]]></given-names>
</name>
<name>
<surname><![CDATA[Qiao]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[[Two types of exercise-induced abnormal blood pressure response in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Zhongguo Ying Yong Sheng Li Xue Za Zhi]]></source>
<year>2021</year>
<volume>37</volume>
<page-range>27-33</page-range></nlm-citation>
</ref>
<ref id="B547">
<label>547</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thomson]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
<name>
<surname><![CDATA[Morris-Thurgood]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Atherton]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Frenneaux]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reduced cardiopulmonary baroreflex sensitivity in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[JACC]]></source>
<year>1998</year>
<volume>31</volume>
<page-range>1377-82</page-range></nlm-citation>
</ref>
<ref id="B548">
<label>548</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gilligan]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Nihoyannopoulos]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[WL]]></given-names>
</name>
<name>
<surname><![CDATA[Oakley]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Investigation of a hemodynamic basis for syncope in hypertrophic cardiomyopathy:use of a head-up tilt test]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1992</year>
<volume>85</volume>
<page-range>2140-8</page-range></nlm-citation>
</ref>
<ref id="B549">
<label>549</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Manganelli]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Betocchi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ciampi]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of hemodynamic adaptation to orthostatic stress in patients with hypertrophic cardiomyopathy with or without syncope and in vasovagal syncope]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2002</year>
<volume>89</volume>
<page-range>1405-10</page-range></nlm-citation>
</ref>
<ref id="B550">
<label>550</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Prasad]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Campbell]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Elliott]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[McKenna]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[-Frenneaux]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Episodic syncope in hypertrophic cardiomyopathy:evidence for inappropriate vasodilation]]></article-title>
<source><![CDATA[Heart]]></source>
<year>2008</year>
<volume>94</volume>
<page-range>1312-7</page-range></nlm-citation>
</ref>
<ref id="B551">
<label>551</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Llamas-Esperón]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Secuencia de evaluación diagnóstica inicial, del tratamiento y del seguimiento del paciente con miocardiopatía hipertrófica]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Llamas-Esperón]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cossio-Aranda]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Alexánderson-Rosas]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Miocardiopatía hipertrófica. Cómo tratarla y entenderla mejor]]></source>
<year>2021</year>
<publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[Planeación y Desarrollo Editorial SA de CV]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B552">
<label>552</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Udelson]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Bonow]]></surname>
<given-names><![CDATA[RO]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities:task force 3:hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis:a scientific statement from the American Heart Association and American College of Cardiology]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2015</year>
<volume>132</volume>
<page-range>80</page-range></nlm-citation>
</ref>
<ref id="B553">
<label>553</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Regitz-Zagrosek]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Blomstrom]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Borghi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ESC Guidelines on the management of cardiovascular diseases during pregnancy:the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC)]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2011</year>
<volume>32</volume>
<page-range>3147-97</page-range></nlm-citation>
</ref>
<ref id="B554">
<label>554</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thaman]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Varnava]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hamid]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pregnancy related complications in women with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Heart]]></source>
<year>2003</year>
<volume>89</volume>
<page-range>752-6</page-range></nlm-citation>
</ref>
<ref id="B555">
<label>555</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Autore]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Conte]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Piccininno]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk associated with pregnancy in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2002</year>
<volume>40</volume>
<page-range>1864-9</page-range></nlm-citation>
</ref>
<ref id="B556">
<label>556</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Avila]]></surname>
<given-names><![CDATA[WS]]></given-names>
</name>
<name>
<surname><![CDATA[Amaral]]></surname>
<given-names><![CDATA[FM]]></given-names>
</name>
<name>
<surname><![CDATA[Ramires]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Influence of pregnancy on clinical course and fetal outcome of women with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Arq Bras Cardiol]]></source>
<year>2007</year>
<volume>88</volume>
<page-range>480-5</page-range></nlm-citation>
</ref>
<ref id="B557">
<label>557</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goland]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[van Hagen]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
<name>
<surname><![CDATA[Elbaz-Greener]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pregnancy in women with hypertrophic cardiomyopathy:data from the European Society of Cardiology initiated registry of pregnancy and cardiac disease (ROPAC)]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2017</year>
<volume>38</volume>
<page-range>2683-90</page-range></nlm-citation>
</ref>
<ref id="B558">
<label>558</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pieper]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
<name>
<surname><![CDATA[Walker]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pregnancy in women with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Neth Heart J]]></source>
<year>2013</year>
<volume>21</volume>
<page-range>14-8</page-range></nlm-citation>
</ref>
<ref id="B559">
<label>559</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[WY]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[KT]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pregnancy related complications in women with hypertrophic cardiomyopathy:a nationwide population-based cohort study]]></article-title>
<source><![CDATA[BMC Cardiovasc Disord]]></source>
<year>2024</year>
<volume>24</volume>
<page-range>268</page-range></nlm-citation>
</ref>
<ref id="B560">
<label>560</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vitale]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[De Feo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[De Santo]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>1999</year>
<volume>33</volume>
<page-range>1637-41</page-range></nlm-citation>
</ref>
<ref id="B561">
<label>561</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[van Driel]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Wesseling]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sauer]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Teratogen update:fetal effects after in utero exposure to coumarins overview of cases, follow-up findings, and pathogenesis]]></article-title>
<source><![CDATA[Teratology]]></source>
<year>2002</year>
<volume>66</volume>
<page-range>127-40</page-range></nlm-citation>
</ref>
<ref id="B562">
<label>562</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Plasencia]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Eguiluz]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Barber]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Miocardiopatía hipertrófica. Manejo durante el embarazo y el parto]]></article-title>
<source><![CDATA[Clin Invest Gin Obst]]></source>
<year>2004</year>
<volume>31</volume>
<page-range>169-75</page-range></nlm-citation>
</ref>
<ref id="B563">
<label>563</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schaefer]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hannemann]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Meister]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vitamin K antagonists and pregnancy outcome. A multi-center prospective study]]></article-title>
<source><![CDATA[Thromb Haemost]]></source>
<year>2006</year>
<volume>95</volume>
<page-range>949-57</page-range></nlm-citation>
</ref>
<ref id="B564">
<label>564</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Owens]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pregnancy in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2017</year>
<volume>38</volume>
<page-range>2691-2</page-range></nlm-citation>
</ref>
<ref id="B565">
<label>565</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sahoo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Dash]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rant]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Badole]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Upasani]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Perioperative anesthetic management of patients with hypertrophic cardiomyopathy for non-cardiac surgery:a case series]]></article-title>
<source><![CDATA[Ann Card Anaesth]]></source>
<year>2010</year>
<volume>13</volume>
<page-range>253-6</page-range></nlm-citation>
</ref>
<ref id="B566">
<label>566</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[LF]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sociedad Española de Cardiología. Clinical practice guidelines of the Spanish Society of Cardiology for surgical risk assessment in cardiac patients treated with non-cardiac surgery]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2001</year>
<volume>54</volume>
<page-range>186-93</page-range></nlm-citation>
</ref>
<ref id="B567">
<label>567</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dhillon]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Khanna]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Randhawa]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Perioperative outcomes of patients with hypertrophic cardiomyopathy undergoing non-cardiac surgery]]></article-title>
<source><![CDATA[Heart]]></source>
<year>2016</year>
<volume>102</volume>
<page-range>1627-32</page-range></nlm-citation>
</ref>
<ref id="B568">
<label>568</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[TO]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiac risk of noncardiac surgery in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Int J Cardiol]]></source>
<year>2008</year>
<volume>129</volume>
<page-range>307-8</page-range></nlm-citation>
</ref>
<ref id="B569">
<label>569</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xuan]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Zeng]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Xuan]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Zeng]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[WL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk of patients with hypertrophic cardiomyopathy undergoing noncardiac surgery]]></article-title>
<source><![CDATA[Chin Med Sci J]]></source>
<year>2007</year>
<volume>22</volume>
<page-range>211-5</page-range></nlm-citation>
</ref>
<ref id="B570">
<label>570</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hreybe]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Zahid]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sonel]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Good]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
<name>
<surname><![CDATA[Shaver]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Saba]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Noncardiac surgery and the risk of death and other cardiovascular events in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Clin Cardiol]]></source>
<year>2006</year>
<volume>29</volume>
<page-range>65-8</page-range></nlm-citation>
</ref>
<ref id="B571">
<label>571</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Robertson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intraoperative management of liver transplantation in patients with hypertrophic cardiomyopathy:a review]]></article-title>
<source><![CDATA[Transplant Proc]]></source>
<year>2010</year>
<volume>42</volume>
<page-range>1721-3</page-range></nlm-citation>
</ref>
<ref id="B572">
<label>572</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Haering]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Comunale]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Parker]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiac risk of noncardiac surgery in patients with asymmetric septal hypertrophy]]></article-title>
<source><![CDATA[Anesthesiology]]></source>
<year>1996</year>
<volume>85</volume>
<page-range>254-9</page-range></nlm-citation>
</ref>
<ref id="B573">
<label>573</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
<name>
<surname><![CDATA[Sano]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Saitoh]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Hanaoka]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[[Anesthetic management of patients with hypertrophic obstructive cardiomyopathy undergoing non-cardiac surgery]]]></article-title>
<source><![CDATA[Masui]]></source>
<year>2004</year>
<volume>53</volume>
<page-range>934-42</page-range></nlm-citation>
</ref>
<ref id="B574">
<label>574</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Liberthson]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
<name>
<surname><![CDATA[Lowestein]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Perioperative anesthetic risk of noncardiac surgery in hypertrophic obstructive cardiomyopathy]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>1985</year>
<volume>254</volume>
<page-range>2419-21</page-range></nlm-citation>
</ref>
<ref id="B575">
<label>575</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bruno]]></surname>
<given-names><![CDATA[PH]]></given-names>
</name>
<name>
<surname><![CDATA[Giordano]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiomyopathies. Causes, effects and treatments]]></article-title>
<source><![CDATA[Cardiology Research and Clinical Developments Series]]></source>
<year>2009</year>
<publisher-loc><![CDATA[Hauppauge, NY ]]></publisher-loc>
<publisher-name><![CDATA[Nova Biomedical]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B576">
<label>576</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[PD]]></given-names>
</name>
<name>
<surname><![CDATA[Puffer]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular participation screening of competitive athletes. A statement for health professionals from the Sudden Death Committee (Clinical Cardiology) and Congenital Cardiac Defects Committee (Cardiovascular Disease in the Young), American Heart Association]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1996</year>
<volume>94</volume>
<page-range>850-6</page-range></nlm-citation>
</ref>
<ref id="B577">
<label>577</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yán~ez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Síndrome corazón de atleta:historia, manifestaciones morfológicas e implicancias clínicas]]></article-title>
<source><![CDATA[Rev Chil Cardiol]]></source>
<year>2012</year>
<volume>31</volume>
<page-range>215-25</page-range></nlm-citation>
</ref>
<ref id="B578">
<label>578</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wheeler]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Heidenreich]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Froelicher]]></surname>
<given-names><![CDATA[VF]]></given-names>
</name>
<name>
<surname><![CDATA[Hlatky]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-effectiveness of preparticipation screening for prevention of sudden cardiac death in young athletes]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2010</year>
<volume>152</volume>
<page-range>276-86</page-range></nlm-citation>
</ref>
<ref id="B579">
<label>579</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zorzi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Perazzolo Marra]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Corado]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Differential diagnosis between athlete's heart and hypertrophic cardiomyopathy:New pieces of the puzzle]]></article-title>
<source><![CDATA[Int J Cardiol]]></source>
<year>2022</year>
<volume>353</volume>
<page-range>77-9</page-range></nlm-citation>
</ref>
<ref id="B580">
<label>580</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Carro]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Enrique Del Valle]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The “athlete's Heart”:structure, function and differential diagnosis]]></article-title>
<source><![CDATA[Med Clin]]></source>
<year>2011</year>
<volume>137</volume>
<page-range>509-12</page-range></nlm-citation>
</ref>
<ref id="B581">
<label>581</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Pelliccia]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The heart of trained athletes:cardiac remodeling and the risks of sports, including sudden death]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2006</year>
<volume>114</volume>
<page-range>1633-44</page-range></nlm-citation>
</ref>
<ref id="B582">
<label>582</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stecker]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
<name>
<surname><![CDATA[Reinier]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Marijon]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Public health burden of sudden cardiac death in the United States]]></article-title>
<source><![CDATA[Circ Arrhythm Electrophysiol]]></source>
<year>2014</year>
<volume>7</volume>
<page-range>212-7</page-range></nlm-citation>
</ref>
<ref id="B583">
<label>583</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Distinguishing hypertrophic cardiomyopathy from athlete's heart:a clinical problem of increasing magnitude and significance]]></article-title>
<source><![CDATA[Heart]]></source>
<year>2005</year>
<volume>91</volume>
<page-range>1380-2</page-range></nlm-citation>
</ref>
<ref id="B584">
<label>584</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sudden death in young athletes]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2000</year>
<volume>349</volume>
<page-range>1064-75</page-range></nlm-citation>
</ref>
<ref id="B585">
<label>585</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Durakovic]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Misigoj-Durakovic]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Medved]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sudden death due to physical exercise in the elderly]]></article-title>
<source><![CDATA[Coll Antropol]]></source>
<year>2002</year>
<volume>26</volume>
<page-range>239-43</page-range></nlm-citation>
</ref>
<ref id="B586">
<label>586</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kohl]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Powell]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Gordon]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Physical activity, physical fitness and sudden cardiac death]]></article-title>
<source><![CDATA[Epidemiol Rev]]></source>
<year>1992</year>
<volume>14</volume>
<page-range>37-58</page-range></nlm-citation>
</ref>
<ref id="B587">
<label>587</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Corrado]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Basso]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rizzoli]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Schiavon]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Thiene]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Does sports activity enhance the risk of sudden death in adolescents and young adults?]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2003</year>
<volume>42</volume>
<page-range>1959-63</page-range></nlm-citation>
</ref>
<ref id="B588">
<label>588</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morganroth]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Henry]]></surname>
<given-names><![CDATA[WL]]></given-names>
</name>
<name>
<surname><![CDATA[Epstein]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparative left ventricular dimensions in trained athletes]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>1975</year>
<volume>82</volume>
<page-range>521-4</page-range></nlm-citation>
</ref>
<ref id="B589">
<label>589</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Naylor]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[George]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[O'Driscoll]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Green]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The athlete's heart:a contemporary appraisal of the Morganroth hypotheses]]></article-title>
<source><![CDATA[Sports Med]]></source>
<year>2008</year>
<volume>38</volume>
<page-range>69-90</page-range></nlm-citation>
</ref>
<ref id="B590">
<label>590</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Haykowsky]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Samuel]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Nelson]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Gerche]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Athlete's heart:is the Morganroth hypothesis obsolete?]]></article-title>
<source><![CDATA[Heart Lung Circ]]></source>
<year>2018</year>
<volume>27</volume>
<page-range>1037-41</page-range></nlm-citation>
</ref>
<ref id="B591">
<label>591</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Structural features of the athlete heart as defined by echocardiography]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>1986</year>
<volume>7</volume>
<page-range>190-203</page-range></nlm-citation>
</ref>
<ref id="B592">
<label>592</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dickhuth]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
<name>
<surname><![CDATA[Röcker]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Niess]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The echocardiographic determination of volume and muscle mass of the heart]]></article-title>
<source><![CDATA[Int J Sports Med]]></source>
<year>1996</year>
<volume>17</volume>
<numero>Suppl 3</numero>
<issue>Suppl 3</issue>
<page-range>132-9</page-range></nlm-citation>
</ref>
<ref id="B593">
<label>593</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pluim]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
<name>
<surname><![CDATA[Zwinderman]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Van der Laarse]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The athlete's heart:a meta-analysis of cardiac structure and function]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1999</year>
<volume>100</volume>
<page-range>336-44</page-range></nlm-citation>
</ref>
<ref id="B594">
<label>594</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pelliccia]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Culasso]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Di Paolo]]></surname>
<given-names><![CDATA[FM]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Physiologic left ventricular cavity dilatation in elite athletes]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>1999</year>
<volume>130</volume>
<page-range>23-31</page-range></nlm-citation>
</ref>
<ref id="B595">
<label>595</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scharhag]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Schneider]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Urhausen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Athlete's heart:right and left ventricular mass and function in male endurance athletes and untrained individuals determined by magnetic resonance imaging]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2002</year>
<volume>10</volume>
<page-range>1856-63</page-range></nlm-citation>
</ref>
<ref id="B596">
<label>596</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mackie]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Screening of competitive athletes to prevent sudden death:think twice]]></article-title>
<source><![CDATA[Heart]]></source>
<year>2013</year>
<volume>99</volume>
<page-range>306-7</page-range></nlm-citation>
</ref>
<ref id="B597">
<label>597</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Estes 3rd]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Vetter]]></surname>
<given-names><![CDATA[VL]]></given-names>
</name>
<name>
<surname><![CDATA[Corrado]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical decisions. Cardiac screening before participation in sports]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2013</year>
<volume>369</volume>
<page-range>2049-53</page-range></nlm-citation>
</ref>
<ref id="B598">
<label>598</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Corrado]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Pelliccia]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Heidbuchel]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recommendations for interpretation of 12-lead electrocardiogram in the athlete]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2010</year>
<volume>31</volume>
<page-range>243-59</page-range></nlm-citation>
</ref>
<ref id="B599">
<label>599</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Drezner]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Ackerman]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Electrocardiographic interpretation in athletes:the 'Seattle criteria']]></article-title>
<source><![CDATA[Br J Sports Med]]></source>
<year>2013</year>
<volume>47</volume>
<page-range>122-4</page-range></nlm-citation>
</ref>
<ref id="B600">
<label>600</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Drezner]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Ashley]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Baggish]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Abnormal electrocardiographic findings in athletes:recognizing changes suggestive of cardiomyopathy]]></article-title>
<source><![CDATA[Br J Sports Med]]></source>
<year>2013</year>
<volume>47</volume>
<page-range>137-52</page-range></nlm-citation>
</ref>
<ref id="B601">
<label>601</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rahman]]></surname>
<given-names><![CDATA[QA]]></given-names>
</name>
<name>
<surname><![CDATA[Tereshchenko]]></surname>
<given-names><![CDATA[LG]]></given-names>
</name>
<name>
<surname><![CDATA[Kongkatong]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Abraham]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Abraham]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Shatkay]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Utilizing ECG-based heartbeat classification for hypertrophic cardiomyopathy identification]]></article-title>
<source><![CDATA[IEEE Trans Nanobioscience]]></source>
<year>2015</year>
<volume>14</volume>
<page-range>505-12</page-range></nlm-citation>
</ref>
<ref id="B602">
<label>602</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dumont]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Monserrat]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Soler]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Interpretation of electrocardiographic abnormalities in hypertrophic cardiomyopathy with cardiac magnetic resonance]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2006</year>
<volume>27</volume>
<page-range>1725-31</page-range></nlm-citation>
</ref>
<ref id="B603">
<label>603</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ryan]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Cleland]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[French]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The standard electrocardiogram as a screening test for hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>1995</year>
<volume>76</volume>
<page-range>689-94</page-range></nlm-citation>
</ref>
<ref id="B604">
<label>604</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Pelliccia]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Spirito]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiac disease in young trained athletes]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1995</year>
<volume>91</volume>
<page-range>1596-601</page-range></nlm-citation>
</ref>
<ref id="B605">
<label>605</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lewis]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Spirito]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Pelliccia]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Usefulness of Doppler echocardiographic assessment of diastolic filling in distinguishing “athlete's heart”from hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Br Heart J]]></source>
<year>1992</year>
<volume>68</volume>
<page-range>296-300</page-range></nlm-citation>
</ref>
<ref id="B606">
<label>606</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[D'Andrea]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sperlongano]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Russo]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The role of multimodality imaging in athlete's heart diagnosis:current status and future directions]]></article-title>
<source><![CDATA[J Clin Med]]></source>
<year>2021</year>
<volume>10</volume>
<page-range>5126</page-range></nlm-citation>
</ref>
<ref id="B607">
<label>607</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mikic]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ristic]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Markovic Nikolic]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The role of cardiopulmonary exercise testing in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Medicina (Kaunas)]]></source>
<year>2023</year>
<volume>59</volume>
<page-range>1296</page-range></nlm-citation>
</ref>
<ref id="B608">
<label>608</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Pelliccia]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Spataro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Granata]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reduction in left ventricular wall thickness after deconditioning in highly trained Olympic athletes]]></article-title>
<source><![CDATA[Br Heart J]]></source>
<year>1993</year>
<volume>69</volume>
<page-range>125-8</page-range></nlm-citation>
</ref>
<ref id="B609">
<label>609</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lauschke]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Maisch]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Athlete's heart or hypertrophic cardiomyopathy?]]></article-title>
<source><![CDATA[Clin Res Cardiol]]></source>
<year>2009</year>
<volume>98</volume>
<page-range>80-8</page-range></nlm-citation>
</ref>
<ref id="B610">
<label>610</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pelliccia]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Solberg]]></surname>
<given-names><![CDATA[EE]]></given-names>
</name>
<name>
<surname><![CDATA[Papadakis]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis:position statement of the sport cardiology section of the European Association of Preventive Cardiology (EAPC)]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2019</year>
<volume>40</volume>
<page-range>19-33</page-range></nlm-citation>
</ref>
<ref id="B611">
<label>611</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sheikh]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Papadakis]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Schnell]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical profile of athletes with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circ Cardiovasc Imaging]]></source>
<year>2015</year>
<volume>8</volume>
</nlm-citation>
</ref>
<ref id="B612">
<label>612</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caselli]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Urbano-Moral]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Pandian]]></surname>
<given-names><![CDATA[NG]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[-Pelliccia]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Differentiating left ventricular hypertrophy in athletes from that in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2014</year>
<volume>114</volume>
<page-range>1383-9</page-range></nlm-citation>
</ref>
<ref id="B613">
<label>613</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anastasakis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kotsiopoulou]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rigopoulos]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Similarities in the profile of cardiopulmonary exercise testing between patients with hypertrophic cardiomyopathy and strength athletes]]></article-title>
<source><![CDATA[Heart]]></source>
<year>2005</year>
<volume>91</volume>
<page-range>1477-8</page-range></nlm-citation>
</ref>
<ref id="B614">
<label>614</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pelliccia]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lemme]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Maestrini]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Does sport participation worsen the clinical course of hypertrophic cardiomyopathy?Clinical outcome of hypertrophic cardiomyopathy in athletes]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2018</year>
<volume>137</volume>
<page-range>531-3</page-range></nlm-citation>
</ref>
<ref id="B615">
<label>615</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Konhilas]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Watson]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Maass]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Exercise can prevent and reverse the severity of hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circ Res]]></source>
<year>2006</year>
<volume>98</volume>
<page-range>540-8</page-range></nlm-citation>
</ref>
<ref id="B616">
<label>616</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Klempfner]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kamerman]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Schwammenthal]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of exercise training in symptomatic patients with hypertrophic cardiomyopathy:results of a structured exercise training program in a cardiac rehabilitation center]]></article-title>
<source><![CDATA[Eur J Prev Cardiol]]></source>
<year>2015</year>
<volume>22</volume>
<page-range>13-9</page-range></nlm-citation>
</ref>
<ref id="B617">
<label>617</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saberi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wheeler]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bragg-Gresham]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of moderate intensity exercise training on peak oxygen consumption in patients with hypertrophic cardiomyopathy:a randomized clinical trial]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2017</year>
<volume>317</volume>
<page-range>1349-57</page-range></nlm-citation>
</ref>
<ref id="B618">
<label>618</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[PD]]></given-names>
</name>
<name>
<surname><![CDATA[Ackerman]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes:2007 update:a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism:endorsed by the American College of Cardiology Foundation]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2007</year>
<volume>115</volume>
<page-range>1643-55</page-range></nlm-citation>
</ref>
<ref id="B619">
<label>619</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Corrado]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Pelliccia]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bjørnstad]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death:proposal for a common European protocol:consensus statement of the Study Group of Sport Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2005</year>
<volume>26</volume>
<page-range>516-24</page-range></nlm-citation>
</ref>
<ref id="B620">
<label>620</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Azarbal]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Finocchiaro]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Exercise capacity and paroxysmal atrial fibrillation in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Heart]]></source>
<year>2014</year>
<volume>100</volume>
<page-range>624-30</page-range></nlm-citation>
</ref>
<ref id="B621">
<label>621</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Le]]></surname>
<given-names><![CDATA[V-V]]></given-names>
</name>
<name>
<surname><![CDATA[Perez]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Wheeler]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Myers]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Schnittger]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Ashley]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mechanisms of exercise intolerance in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Am Heart J]]></source>
<year>2009</year>
<volume>158</volume>
<page-range>34</page-range></nlm-citation>
</ref>
<ref id="B622">
<label>622</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MacNamara]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Dias]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Hearon Jr]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Randomized controlled trial of moderate- and high-intensity exercise training in patients with hypertrophic cardiomyopathy:effects on fitness and cardiovascular response to exercise]]></article-title>
<source><![CDATA[J Am Heart Assoc]]></source>
<year>2023</year>
<volume>12</volume>
</nlm-citation>
</ref>
<ref id="B623">
<label>623</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dias]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Link]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Levine]]></surname>
<given-names><![CDATA[BD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Exercise training for patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2018</year>
<volume>72</volume>
<page-range>1157-65</page-range></nlm-citation>
</ref>
<ref id="B624">
<label>624</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Hong]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rediscovering the value of exercise in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Zhejiang Da Xue Xue Bao Yi Xue Ban]]></source>
<year>2022</year>
<volume>51</volume>
<page-range>758-64</page-range></nlm-citation>
</ref>
<ref id="B625">
<label>625</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mueller]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Winzer]]></surname>
<given-names><![CDATA[EB]]></given-names>
</name>
<name>
<surname><![CDATA[Duvinage]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[OptimEx-Clin Study Group. Effect of high-intensity interval training, moderate continuous training, or guideline-based physical activity advice on peak oxygen consumption in patients with heart failure with preserved ejection fraction:a randomized clinical trial]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2021</year>
<volume>325</volume>
<page-range>542-51</page-range></nlm-citation>
</ref>
<ref id="B626">
<label>626</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saberi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Day]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Exercise and hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2018</year>
<volume>137</volume>
<page-range>419-21</page-range></nlm-citation>
</ref>
<ref id="B627">
<label>627</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gielen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Schuler]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Adams]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular effects of exercise training]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2010</year>
<volume>122</volume>
<page-range>1221-38</page-range></nlm-citation>
</ref>
<ref id="B628">
<label>628</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wasserstrum]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Barbarova]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Lotan]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of exercise rehabilitation in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[J Cardiol]]></source>
<year>2019</year>
<volume>74</volume>
<page-range>466-72</page-range></nlm-citation>
</ref>
<ref id="B629">
<label>629</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Monda]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Rubino]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lioncino]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertrophic cardiomyopathy in children:pathophysiology, diagnosis, and treatment of non-sarcomeric causes]]></article-title>
<source><![CDATA[Front Pediatr]]></source>
<year>2021</year>
<volume>9</volume>
<page-range>632293</page-range></nlm-citation>
</ref>
<ref id="B630">
<label>630</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lawley]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Kaski]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical and genetic screening for hypertrophic cardiomyopathy in pediatric relatives:changing paradigms in clinical practice]]></article-title>
<source><![CDATA[J Clin Med]]></source>
<year>2023</year>
<volume>12</volume>
<page-range>2788</page-range></nlm-citation>
</ref>
<ref id="B631">
<label>631</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bonaventura]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Berul]]></surname>
<given-names><![CDATA[CI]]></given-names>
</name>
<name>
<surname><![CDATA[Rowin]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Analysis of risk stratification and prevention of sudden death in pediatric patients with hypertrophic cardiomyopathy:dilemmas and clarity]]></article-title>
<source><![CDATA[Heart Rhythm O2]]></source>
<year>2023</year>
<volume>4</volume>
<page-range>506-16</page-range></nlm-citation>
</ref>
<ref id="B632">
<label>632</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Santoro]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Mango]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Mallardi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Arrhythmic risk stratification among patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[J Clin Med]]></source>
<year>2023</year>
<volume>12</volume>
<page-range>3397</page-range></nlm-citation>
</ref>
<ref id="B633">
<label>633</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ali]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Marrone]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Martins]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic factors in hypertrophic cardiomyopathy in children:an MRI based study]]></article-title>
<source><![CDATA[Int J Cardiol]]></source>
<year>2022</year>
<volume>364</volume>
<page-range>141-7</page-range></nlm-citation>
</ref>
<ref id="B634">
<label>634</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tsatsopoulou]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Protonotarios]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Xylouri]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiomyopathies in children:an overview]]></article-title>
<source><![CDATA[Hellenic J Cardiol]]></source>
<year>2023</year>
<volume>72</volume>
<page-range>43-56</page-range></nlm-citation>
</ref>
<ref id="B635">
<label>635</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trasca]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Popescu]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Popescu]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Balanescu]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Echocardiography in the diagnosis of cardiomyopathies:current status and future directions]]></article-title>
<source><![CDATA[Rev Cardiovasc Med]]></source>
<year>2022</year>
<volume>23</volume>
<page-range>1-19</page-range></nlm-citation>
</ref>
<ref id="B636">
<label>636</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Yin]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MRI characteristics, prevalence, and outcomes of hypertrophic cardiomyopathy with restrictive phenotype]]></article-title>
<source><![CDATA[Radiol Cardiothoracic Imaging]]></source>
<year>2020</year>
<volume>2</volume>
</nlm-citation>
</ref>
<ref id="B637">
<label>637</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[J Cardiovasc Magn Reson]]></source>
<year>2012</year>
<volume>14</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>7</page-range></nlm-citation>
</ref>
<ref id="B638">
<label>638</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nakano]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Menon]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk stratification in pediatric hypertrophic cardiomyopathy:insights for bridging the evidence gap?]]></article-title>
<source><![CDATA[Prog Pediatr Cardiol]]></source>
<year>2018</year>
<volume>49</volume>
<page-range>31-7</page-range></nlm-citation>
</ref>
<ref id="B639">
<label>639</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[DZJ]]></given-names>
</name>
<name>
<surname><![CDATA[Montazeri]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bataiosu]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical characteristics and prognostic importance of left ventricular apical aneurysms in hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[JACC Cardiovasc Imaging]]></source>
<year>2022</year>
<volume>15</volume>
<page-range>1696-711</page-range></nlm-citation>
</ref>
<ref id="B640">
<label>640</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Keramida]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Lazaros]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Nihoyannopoulos]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Right ventricular involvement in hypertrophic cardiomyopathy:patterns and implications]]></article-title>
<source><![CDATA[Hellenic J Cardiol]]></source>
<year>2020</year>
<volume>61</volume>
<page-range>3-8</page-range></nlm-citation>
</ref>
<ref id="B641">
<label>641</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chaowu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Shihua]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Jian]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Wei]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular magnetic resonance characteristics in children with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circ Heart Fail]]></source>
<year>2013</year>
<volume>6</volume>
<page-range>1013-20</page-range></nlm-citation>
</ref>
<ref id="B642">
<label>642</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Habib]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Adler]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hoss]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Temporal changes in cardiac morphology and its relationship with clinical characteristics and outcomes in patients with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2022</year>
<volume>176</volume>
<page-range>125-31</page-range></nlm-citation>
</ref>
<ref id="B643">
<label>643</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parekh]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Markl]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Deng]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[de Freitas]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Rigsby]]></surname>
<given-names><![CDATA[CK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[T1 mapping in children and young adults with hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Int J Cardiovasc Imaging]]></source>
<year>2017</year>
<volume>33</volume>
<page-range>109-17</page-range></nlm-citation>
</ref>
<ref id="B644">
<label>644</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maldonado]]></surname>
<given-names><![CDATA[TB]]></given-names>
</name>
<name>
<surname><![CDATA[Calderón]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Micheli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aspectos electrocardiográficos y ecocardiográficos de la miocardiopatía hipertrófica en edad pediátrica]]></article-title>
<source><![CDATA[Arch Cardiol Mex]]></source>
<year>2000</year>
<volume>70</volume>
<page-range>247-60</page-range></nlm-citation>
</ref>
<ref id="B645">
<label>645</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mathew]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zahavich]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Lafreniere-Roula]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Utility of genetics for risk stratification in pediatric hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Clin Genet]]></source>
<year>2018</year>
<volume>93</volume>
<page-range>310-9</page-range></nlm-citation>
</ref>
<ref id="B646">
<label>646</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Herrera-Rodríguez]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Totomoch-Serra]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rosas-Madrigal]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Genes frecuentemente asociados con muerte súbita en miocardiopatía hipertrófica primaria]]></article-title>
<source><![CDATA[Arch Cardiol Mex]]></source>
<year>2020</year>
<volume>90</volume>
<page-range>58-68</page-range></nlm-citation>
</ref>
<ref id="B647">
<label>647</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Márquez-Murillo]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Chávez-Gutiérrez]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz-Tostado]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bustillos-García]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez-Flores]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Nava-Townsend]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of subcutaneous cardioverter-defibrillator. First cases reported from National Institute of Cardiology Ignacio Chávez-Mexico]]></article-title>
<source><![CDATA[Arch Cardiol Mex]]></source>
<year>2023</year>
<volume>93</volume>
<page-range>276-83</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
